tag:blogger.com,1999:blog-47383313780482753072024-03-18T02:55:45.747-07:00Drug Patents InternationalAll about Patents and Intellectual property by DR ANTHONY MELVIN CRASTO, Worldpeaceambassdor, worlddrugtracker, Ph.D ( ICT, Mumbai) , INDIA 30+Yrs Exp. in the feld of Organic Chemistry, Serving chemists around the world. THE VIEWS EXPRESSED ARE MY PERSONAL AND IN NO-WAY SUGGEST THE VIEWS OF THE PROFESSIONAL BODY OR THE COMPANY THAT I REPRESENT, amcrasto@gmail.com, +91 9323115463 IndiaDRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.comBlogger252125tag:blogger.com,1999:blog-4738331378048275307.post-14528952715754154822022-02-27T18:47:00.001-08:002022-02-27T18:47:09.723-08:00UNITED ARAB EMIRATES UNIVERSITY NEW PATENT WO/2022/038578<p> </p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/a/AVvXsEhdn4XtPFCGp8SYlbyfAvCwjCpbIYmEFkLwenOt5agy0-o_WNS02JQ0My9yEQA2vF67p1DZPeSPAXAICxxlPKqbdIu2TBLJgcPApWldIDlBBACv_Gt7Jvx1xyQvFKRnIFCuW532qnP_Wc0KcUDoBciDHNFyk5b4Rfc_c_5p-CYSkkxXmmYAPeF-xHXmsw=s398" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="398" data-original-width="387" height="320" src="https://blogger.googleusercontent.com/img/a/AVvXsEhdn4XtPFCGp8SYlbyfAvCwjCpbIYmEFkLwenOt5agy0-o_WNS02JQ0My9yEQA2vF67p1DZPeSPAXAICxxlPKqbdIu2TBLJgcPApWldIDlBBACv_Gt7Jvx1xyQvFKRnIFCuW532qnP_Wc0KcUDoBciDHNFyk5b4Rfc_c_5p-CYSkkxXmmYAPeF-xHXmsw=s320" width="311" /></a></div><div class="separator" style="clear: both; text-align: center;"><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/a/AVvXsEgTLmcefenxL_MBWT8Ze_s5f9Vvj8U75m734wt-kzQ8axo_Q4o3pPZ1vBHLArNd0C6A--QolrzYi3d5YGRAJcbWcU8aMkjjIauFi5A5wsSuO7JUEXSRJqKAKowP0EH827fPUrd4houHfEnZ7dq38Ht-VqKGDvhg-nUzyYaGH-tP57TD7ANtYi_RXt2OOA" style="margin-left: 1em; margin-right: 1em;"><img alt="" data-original-height="159" data-original-width="318" height="160" src="https://blogger.googleusercontent.com/img/a/AVvXsEgTLmcefenxL_MBWT8Ze_s5f9Vvj8U75m734wt-kzQ8axo_Q4o3pPZ1vBHLArNd0C6A--QolrzYi3d5YGRAJcbWcU8aMkjjIauFi5A5wsSuO7JUEXSRJqKAKowP0EH827fPUrd4houHfEnZ7dq38Ht-VqKGDvhg-nUzyYaGH-tP57TD7ANtYi_RXt2OOA" width="320" /></a></div><br /><br /></div><br /><p></p><p><br /></p><p><a class="detail-link" href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022038578&_gid=202208" id="weeklyPublicationForm:resultTable:2714:woLink" name="weeklyPublicationForm:resultTable:2714:woLink" style="background-color: #f7f7f7; box-sizing: inherit; color: #1a1a1a; cursor: pointer; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px; margin: 0px 0.25em;">WO/2022/038578</a></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">BIODEGRADGRADABLE DEVICES, AND METHODS OF MAKING THE SAME</span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">UNITED ARAB EMIRATES UNIVERSITY</span></p><p><span style="background-color: #f7f7f7;"><span style="color: grey; font-family: simplon, arial, meiryo, sans-serif;"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022038578&_gid=202208">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022038578&_gid=202208</a></span></span></p><div class="ps-field ps-biblio-field " id="detailMainForm:MyTabViewId:j_idt1478:j_idt1834" style="background-color: white; box-sizing: inherit; color: #1a1a1a; display: flex; flex-direction: column; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; line-height: 1.0625rem;"><span class="ps-field--label ps-biblio-field--label" style="box-sizing: inherit; margin-right: 0.1875rem;">Applicants</span><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;">UNITED ARAB EMIRATES UNIVERSITY </span></span></div><div class="ps-field ps-biblio-field " id="detailMainForm:MyTabViewId:j_idt1478:j_idt1904" style="background-color: white; box-sizing: inherit; color: #1a1a1a; display: flex; flex-direction: column; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; line-height: 1.0625rem;"><span class="ps-field--label ps-biblio-field--label" style="box-sizing: inherit; margin-right: 0.1875rem;">Inventors</span><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;">GALIWANGO, Emmanuel</span></span><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;">AL MARZOUQI, Ali</span></span><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;">ABU-JDAYIL, Basim</span></span><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;">CAIRES, Yousuf</span></span><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;">MOuSA noran</span></span><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;">HARIS, Sabeera</span></span></div><div class="ps-field ps-biblio-field " id="detailMainForm:MyTabViewId:j_idt1478:j_idt1959" style="background-color: white; box-sizing: inherit; color: #1a1a1a; display: flex; flex-direction: column; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; line-height: 1.0625rem;"><span class="ps-field--label ps-biblio-field--label" style="box-sizing: inherit; margin-right: 0.1875rem;">Agents</span><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;">AL TAMIMI & COMPANY </span></span><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;"><span style="text-align: justify;"> bioplastic blend is disclosed. The bioplastic blend may comprise a polylactic acid polymer and a lignocellulosic biomass. The lignocellulosic biomass may be a particulate and have an average particle size that is less than or equal to 60 micrometers, or less than or equal to 50 micrometers. The lignocellulosic biomass may be a particulate and comprise greater than or equal to 50 percent by weight of the bioplastic blend, or greater than or equal to 60 percent by weight of the bioplastic blend. In addition, the bioplastic blend may comprise a plasticizer.</span></span></span><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;"><span style="text-align: justify;"><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/a/AVvXsEhhTWhrVIR4aRNAU8Sj4sjeXO7CTdsA7jmxoZJi6spD3fnztkW3WKP2Z6UX8SUEeXibZa42K5FKTDrTUdmi0FTPSAQIz7QijwleDZfpI46qJWWglFQuJAQUsDis2x6WOHXGXIXhbvPz9o8TYZoTkCaHk9s4wRzALFpsaWtxEw7XlY1a4dYJmGUNjMN3gQ" style="margin-left: 1em; margin-right: 1em;"><img alt="" data-original-height="200" data-original-width="200" height="240" src="https://blogger.googleusercontent.com/img/a/AVvXsEhhTWhrVIR4aRNAU8Sj4sjeXO7CTdsA7jmxoZJi6spD3fnztkW3WKP2Z6UX8SUEeXibZa42K5FKTDrTUdmi0FTPSAQIz7QijwleDZfpI46qJWWglFQuJAQUsDis2x6WOHXGXIXhbvPz9o8TYZoTkCaHk9s4wRzALFpsaWtxEw7XlY1a4dYJmGUNjMN3gQ" width="240" /></a></div><br /><br /></span></span></span><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;"><span style="text-align: justify;"><br /></span></span></span><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;"><table class="infobox vcard" style="background-color: #f8f9fa; border-spacing: 3px; border: 1px solid rgb(162, 169, 177); clear: right; color: black; font-family: sans-serif; font-size: 12.32px; line-height: 1.5em; margin: 0.5em 0px 0.5em 1em; padding: 0.2em; width: 22em;"><caption class="infobox-title fn org" style="font-size: 15.4px; font-weight: bold; padding: 0.2em;">United Arab Emirates University</caption><tbody><tr><td class="infobox-subheader" colspan="2" style="text-align: center; vertical-align: top;"><div class="nickname" lang="ar">جامعة الإمارات العربية المتحدة</div></td></tr><tr><td class="infobox-image" colspan="2" style="text-align: center; vertical-align: top;"><a class="image" href="https://en.wikipedia.org/wiki/File:UAEU_logo.png" style="background: none; color: #0645ad; text-decoration-line: none;"><img alt="UAEU logo.png" data-file-height="360" data-file-width="2048" decoding="async" height="39" src="https://upload.wikimedia.org/wikipedia/commons/thumb/f/f2/UAEU_logo.png/220px-UAEU_logo.png" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/f/f2/UAEU_logo.png/330px-UAEU_logo.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/f/f2/UAEU_logo.png/440px-UAEU_logo.png 2x" style="border: 0px; vertical-align: middle;" width="220" /></a></td></tr><tr><th class="infobox-label" scope="row" style="padding-right: 0.65em; text-align: left; vertical-align: top;">Type</th><td class="infobox-data" style="vertical-align: top;"><a class="mw-redirect" href="https://en.wikipedia.org/wiki/Public_research_university" style="background: none; color: #0645ad; text-decoration-line: none;" title="Public research university">Public</a></td></tr><tr><th class="infobox-label" scope="row" style="padding-right: 0.65em; text-align: left; vertical-align: top;">Established</th><td class="infobox-data" style="vertical-align: top;">1976<span class="noprint">; 46 years ago</span></td></tr><tr><th class="infobox-label" scope="row" style="padding-right: 0.65em; text-align: left; vertical-align: top;"><a href="https://en.wikipedia.org/wiki/Chancellor_(education)" style="background: none; color: #0645ad; text-decoration-line: none;" title="Chancellor (education)">Chancellor</a></th><td class="infobox-data" style="vertical-align: top;"><a href="https://en.wikipedia.org/wiki/Zaki_Nusseibeh" style="background: none; color: #0645ad; text-decoration-line: none;" title="Zaki Nusseibeh">Zaki Nusseibeh</a></td></tr><tr><th class="infobox-label" scope="row" style="padding-right: 0.65em; text-align: left; vertical-align: top;"><span class="nowrap" style="white-space: nowrap;"><a class="mw-redirect" href="https://en.wikipedia.org/wiki/Vice-Chancellor" style="background: none; color: #0645ad; text-decoration-line: none;" title="Vice-Chancellor">Vice-Chancellor</a></span></th><td class="infobox-data" style="vertical-align: top;">Ghaleb Ali Al Hadrami Al Breiki</td></tr><tr><th class="infobox-label" scope="row" style="padding-right: 0.65em; text-align: left; vertical-align: top;"><a href="https://en.wikipedia.org/wiki/Provost_(education)" style="background: none; color: #0645ad; text-decoration-line: none;" title="Provost (education)">Provost</a></th><td class="infobox-data" style="vertical-align: top;">Mohammed Hassan Ali</td></tr><tr><th class="infobox-label" scope="row" style="padding-right: 0.65em; text-align: left; vertical-align: top;"><a href="https://en.wikipedia.org/wiki/Undergraduate_education" style="background: none; color: #0645ad; text-decoration-line: none;" title="Undergraduate education">Undergraduates</a></th><td class="infobox-data" style="vertical-align: top;">15,019</td></tr><tr><th class="infobox-label" scope="row" style="padding-right: 0.65em; text-align: left; vertical-align: top;"><a href="https://en.wikipedia.org/wiki/Postgraduate_education" style="background: none; color: #0645ad; text-decoration-line: none;" title="Postgraduate education">Postgraduates</a></th><td class="infobox-data" style="vertical-align: top;">676</td></tr><tr><th class="infobox-label" scope="row" style="padding-right: 0.65em; text-align: left; vertical-align: top;">Location</th><td class="infobox-data adr" style="vertical-align: top;"><div class="locality" style="display: inline;"><a href="https://en.wikipedia.org/wiki/Al_Ain" style="background: none; color: #0645ad; text-decoration-line: none;" title="Al Ain">Al Ain</a></div>, <div class="country-name" style="display: inline;"><a href="https://en.wikipedia.org/wiki/United_Arab_Emirates" style="background: none; color: #0645ad; text-decoration-line: none;" title="United Arab Emirates">United Arab Emirates</a></div></td></tr><tr><th class="infobox-label" scope="row" style="padding-right: 0.65em; text-align: left; vertical-align: top;">Campus</th><td class="infobox-data" style="vertical-align: top;"><a href="https://en.wikipedia.org/wiki/Urban_area" style="background: none; color: #0645ad; text-decoration-line: none;" title="Urban area">Urban</a></td></tr><tr><th class="infobox-label" scope="row" style="padding-right: 0.65em; text-align: left; vertical-align: top;"><a href="https://en.wikipedia.org/wiki/Athletic_nickname" style="background: none; color: #0645ad; text-decoration-line: none;" title="Athletic nickname">Nickname</a></th><td class="infobox-data" style="vertical-align: top;">UAEU</td></tr><tr><th class="infobox-label" scope="row" style="padding-right: 0.65em; text-align: left; vertical-align: top;">Website</th><td class="infobox-data" style="vertical-align: top;"><span class="url"><a class="external text" href="http://uaeu.ac.ae/" rel="nofollow" style="background: url("/w/skins/Vector/resources/common/images/external-link-ltr-icon.svg?48e54") right center no-repeat; color: #3366bb; padding-right: 13px; text-decoration-line: none;">uaeu<wbr></wbr>.ac<wbr></wbr>.ae</a></span></td></tr></tbody></table>link <a href="https://en.wikipedia.org/wiki/United_Arab_Emirates_University">https://en.wikipedia.org/wiki/United_Arab_Emirates_University</a><br /><b style="color: #202122; font-family: sans-serif;">United Arab Emirates University</b><span style="color: #202122; font-family: sans-serif;"> (</span><b style="color: #202122; font-family: sans-serif;">UAEU</b><span style="color: #202122; font-family: sans-serif;">; </span><a class="mw-redirect" href="https://en.wikipedia.org/wiki/Arabic_language" style="background-attachment: initial; background-clip: initial; background-image: none; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #0645ad; font-family: sans-serif; text-decoration-line: none;" title="Arabic language">Arabic</a><span style="color: #202122; font-family: sans-serif;">: </span><span dir="rtl" lang="ar" style="color: #202122; font-family: sans-serif; text-align: start;">جامعة الإمارات العربية المتحدة</span><span style="color: #202122; font-family: sans-serif;">) is a </span><a href="https://en.wikipedia.org/wiki/Public_university" style="background-attachment: initial; background-clip: initial; background-image: none; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #0645ad; font-family: sans-serif; text-decoration-line: none;" title="Public university">public</a><span style="color: #202122; font-family: sans-serif;"> </span><a href="https://en.wikipedia.org/wiki/Research_university" style="background-attachment: initial; background-clip: initial; background-image: none; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #0645ad; font-family: sans-serif; text-decoration-line: none;" title="Research university">research university</a><span style="color: #202122; font-family: sans-serif;"> located in </span><a href="https://en.wikipedia.org/wiki/Al_Ain" style="background-attachment: initial; background-clip: initial; background-image: none; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #0645ad; font-family: sans-serif; text-decoration-line: none;" title="Al Ain">Al Ain</a><span style="color: #202122; font-family: sans-serif;">, </span><a href="https://en.wikipedia.org/wiki/United_Arab_Emirates" style="background-attachment: initial; background-clip: initial; background-image: none; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #0645ad; font-family: sans-serif; text-decoration-line: none;" title="United Arab Emirates">United Arab Emirates</a><span style="color: #202122; font-family: sans-serif;">. It is the oldest university in the United Arab Emirates. It was established in 1976 after independence from Britain by the founding father of the UAE, the late </span><a href="https://en.wikipedia.org/wiki/Zayed_bin_Sultan_Al_Nahyan" style="background-attachment: initial; background-clip: initial; background-image: none; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #0645ad; font-family: sans-serif; text-decoration-line: none;" title="Zayed bin Sultan Al Nahyan">Sheikh Zayed bin Sultan Al Nahyan</a><span style="color: #202122; font-family: sans-serif;">.</span></span></span><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;"><span style="color: #202122; font-family: sans-serif;"><br /></span></span></span><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;"><span style="color: #202122; font-family: sans-serif;"><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/a/AVvXsEiEWMJ26dNZQb8yCZqAtI5TVKv1ufwMVdPiICZRViwHLDaH3ab_90HxAFFX7lVS7M3DB09_LpjyP29oLz5fSMjGeX20ghIpu1lUSg5_O1rsLMEQSjej8l5zYdDqyC0G4OIg9D7sJiPZqdVFpjA7a9V3Xc3NebSsbpZqC2VWXi8rVLui-_rXRBRKxXkWQQ" style="margin-left: 1em; margin-right: 1em;"><img alt="" data-original-height="334" data-original-width="592" height="181" src="https://blogger.googleusercontent.com/img/a/AVvXsEiEWMJ26dNZQb8yCZqAtI5TVKv1ufwMVdPiICZRViwHLDaH3ab_90HxAFFX7lVS7M3DB09_LpjyP29oLz5fSMjGeX20ghIpu1lUSg5_O1rsLMEQSjej8l5zYdDqyC0G4OIg9D7sJiPZqdVFpjA7a9V3Xc3NebSsbpZqC2VWXi8rVLui-_rXRBRKxXkWQQ" width="320" /></a></div><div class="separator" style="clear: both; text-align: center;"><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/a/AVvXsEhuhOkgD7Hezeh2_5g4yHk_6nDcPP78iJltuqKRCtvXTEpxZPwXNaGD_YqbrFN0QCXCHm9mtwV7ZlBa_rZUcEOJL6ZiqzvN9S88fdNxAn_Wc6ScojUuD804Cw70piqBzbN9VTn41UY-aO9k-iDsUe8yfc_wniyBQ8rLBZmvjOcAaezadEfBricbHQpJ1A" style="margin-left: 1em; margin-right: 1em;"><img alt="" data-original-height="700" data-original-width="1200" height="187" src="https://blogger.googleusercontent.com/img/a/AVvXsEhuhOkgD7Hezeh2_5g4yHk_6nDcPP78iJltuqKRCtvXTEpxZPwXNaGD_YqbrFN0QCXCHm9mtwV7ZlBa_rZUcEOJL6ZiqzvN9S88fdNxAn_Wc6ScojUuD804Cw70piqBzbN9VTn41UY-aO9k-iDsUe8yfc_wniyBQ8rLBZmvjOcAaezadEfBricbHQpJ1A" width="320" /></a></div><br /><br /></div><br /><br /></span></span></span></div>DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com1tag:blogger.com,1999:blog-4738331378048275307.post-84596302978852165242022-02-12T02:44:00.001-08:002022-02-12T02:44:07.080-08:00WO/2021/205354 NOVEL NATURE-INSPIRED ANTICANCER AND ANTIBACTERIAL ... UNIV SHARJAH<p> </p><p><span style="background-color: #f7f7f7; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 32px; font-weight: 700; letter-spacing: 2px; text-transform: uppercase;">WO2021205354 - NOVEL NATURE-INSPIRED ANTICANCER AND ANTIBACTERIAL MOTIFS AND PHARMACEUTICAL COMPOSITION THEREOF</span></p><p><br /></p><p><a class="detail-link" href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021205354&_gid=202206" id="weeklyPublicationForm:resultTable:3784:woLink" name="weeklyPublicationForm:resultTable:3784:woLink" style="background-color: #f7f7f7; box-sizing: inherit; color: #1a1a1a; cursor: pointer; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px; margin: 0px 0.25em;">WO/2021/205354</a></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">NOVEL NATURE-INSPIRED ANTICANCER AND ANTIBACTERIAL MOTIFS AND PHARMACEUTICAL COMPOSITION THEREOF</span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">UNIVERSITY OF SHARJAH</span></p><p><span style="background-color: #f7f7f7;"><span style="color: grey; font-family: simplon, arial, meiryo, sans-serif;"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021205354&_cid=P12-KZJPKP-63707-1">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021205354&_cid=P12-KZJPKP-63707-1</a></span></span></p><div class="ps-field ps-biblio-field " id="detailMainForm:MyTabViewId:j_idt5744:j_idt6194" style="background-color: white; box-sizing: inherit; color: #1a1a1a; display: flex; flex-direction: column; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; line-height: 1.0625rem;"><span class="ps-field--label ps-biblio-field--label" style="box-sizing: inherit; margin-right: 0.1875rem;">Applicants</span><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;">UNIVERSITY OF SHARJAH </span></span></div><div class="ps-field ps-biblio-field " id="detailMainForm:MyTabViewId:j_idt5744:j_idt6239" style="background-color: white; box-sizing: inherit; color: #1a1a1a; display: flex; flex-direction: column; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; line-height: 1.0625rem;"><span class="ps-field--label ps-biblio-field--label" style="box-sizing: inherit; margin-right: 0.1875rem;"><span class="ps-field--label ps-biblio-field--label" style="box-sizing: inherit; margin-right: 0.1875rem;">Inventors</span><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;">ALTEL, Taleb H.</span></span></span><span class="ps-field--label ps-biblio-field--label" style="box-sizing: inherit; margin-right: 0.1875rem;"><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;"><br /></span></span></span><span class="ps-field--label ps-biblio-field--label" style="box-sizing: inherit; margin-right: 0.1875rem;"><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;"><span style="text-align: justify;">here is provided novel anticancer and antibacterial compounds, pharmaceutically acceptable salts thereof, and processes for their preparation. The compounds have anticancer activity, which results in the reduction of tumour cell proliferation, enhances cancers cells apoptosis and regulation of iron signalling. The compounds are also particularly active against various Gram-negative and Gram-positive multidrug-resistant bacteria, such as extended-spectrum beta-lactamase (ESBL) producing and colistin-resistant Escherichia coli, carbapenem-resistant E. coli, carbapenem-resistant Acinetobacter baumannii, and methicillin-resistant Staphylococcus aureus (MRSA) including those with reduced susceptibility to many control antibiotics.</span></span></span></span><span class="ps-field--label ps-biblio-field--label" style="box-sizing: inherit; margin-right: 0.1875rem;"><span class="ps-field--value ps-biblio-field--value" style="box-sizing: inherit; margin-bottom: 1rem; margin-top: 0.25rem;"><span class="patent-person notranslate" style="box-sizing: inherit;"><span style="text-align: justify;"><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/a/AVvXsEiEr6nqJPZx0DH2Kg2ZT2oUd9s5PE6CCy5ZSWFJ3B4RVsT2PuV-Y2Bb-aOCMpaqpUbK75wWxLyGvFUj2TRxmgMU8iOEXYjUg1UgO06VnwmTmupWfspc_z9bzgbat7OI3HqPGOwYisNgMPBZoUfdNhQvj25sZOua6qX6XzVTy-4TiFK0vnSjJJ3QNe3ACA" style="margin-left: 1em; margin-right: 1em;"><img alt="" data-original-height="165" data-original-width="217" height="240" src="https://blogger.googleusercontent.com/img/a/AVvXsEiEr6nqJPZx0DH2Kg2ZT2oUd9s5PE6CCy5ZSWFJ3B4RVsT2PuV-Y2Bb-aOCMpaqpUbK75wWxLyGvFUj2TRxmgMU8iOEXYjUg1UgO06VnwmTmupWfspc_z9bzgbat7OI3HqPGOwYisNgMPBZoUfdNhQvj25sZOua6qX6XzVTy-4TiFK0vnSjJJ3QNe3ACA" width="316" /></a></div><br /><br /></span></span></span></span></div>DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com0tag:blogger.com,1999:blog-4738331378048275307.post-53252692413382010852022-01-02T01:22:00.003-08:002022-01-02T01:22:41.228-08:00WO2021260721 - A NEW COST EFFECTIVE AND SCALABLE PROCESS FOR SYNTHESIZING PURE BRIVARACETAM<p> </p><p><span style="background-color: #f7f7f7; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 32px; font-weight: 700; letter-spacing: 2px; text-transform: uppercase;">WO2021260721 - A NEW COST EFFECTIVE AND SCALABLE PROCESS FOR SYNTHESIZING PURE BRIVARACETAM</span></p><p><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021260721&_cid=P12-KXX1JU-33531-1">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021260721&_cid=P12-KXX1JU-33531-1</a></p><p><br /></p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">EXAMPLES:</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">EXAMPLE 1: Synthesis of (3R)-N-[(1S)-1-carbamoylpropyl]-3-(hydroxymethyl) hexanamide [Intermediate 7 of scheme A of the present invention]</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">Example 1 illustrates one pot process for preparing purified (3R)-N-[(1S)-1- carbamoylpropyl]-3-(hydroxymethyl) hexanamide [Intermediate 7] from Intermediate 3 (80% ee) as developed in step 1 of scheme A of the present invention.</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;"><img height="215" id="imgf000028_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2021260721/pic/RU7H6nW931tXWS0pJTKl3HZBpIRjoPlLY61hAWSfpUx0evKl4IIQGJy7rM-wRiqbSp-cCoUtXA_4JgUPPlfsUn6ebgr0aSy3ZMiRdReagW6_QQ3nr-ICF4qL4SbBSxGepJCGpEYp-bPfOTV5YbzVH_TNVtLQSMdd4L8NDyV_D5Y" style="border: 0px; box-sizing: inherit;" width="436" /></p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">Procedure:</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">In the first step of scheme A of the present invention, a mixture of (R)/(S)-4-propyldihydrofuran-2(3H)-one (Intermediate 3, R: S isomer = 80: 20) (1 eq), (S)-2-aminobutanamide (1.1 eq), triethylamine (1.5 eq) is refluxed at a temperature of 95±5 °C for 24h. The mixture is then cooled to 60-65 °C, washed with a mixture of dichloromethane and diisopropyl ether (2.5 vol) in order to get Intermediate-7 [(3R)-N-[(1S)-1-carbamoyl-propyl]-3-(hydroxymethyl) hexanamide] (80% yield).</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">Results:</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">Formation of Intermediate 7 is confirmed further by following analytical studies: a) The <span style="box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; top: -0.5em; vertical-align: baseline;">1</span>H NMR analysis is conducted and the data as illustrated in accompanying figure 1 depicts: (400 MHz, DMSO-d<span style="bottom: -0.25em; box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; vertical-align: baseline;">6</span>): δ 0.6 (t, J= Hz, 6H), 1.07-1.18 (m, 1H), 1.21-1.35 (m, 3H), 1.45-1.43 (m, 1H), 1.61-1.72 (m, 1H), 1.75-1.90 (m, 1H), 2.03 (dd, J=6.64 & 14.08 Hz, 1H), 2.18 (dd, J=7.0 & 14.08 Hz, 1H), 3.28 (t, J=5.36 Hz, 2H), 4.07-4.18 (m, 1H), 4.43 (t, J=5.2 Hz, 1H), 6.95 (s, 1H), 7.28 (s, 1H), 7.76 (d, J=8.08 Hz, 1H).; thus, confirming formation of Intermediate 7 of the present invention.</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">b) The LCMS analysis is further conducted and the data as graphically illustrated in accompanying figure 2 provides a (M+H<span style="box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; top: -0.5em; vertical-align: baseline;">+</span>) value of 231.0; thus, confirming formation of Intermediate 7 of the present invention.</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">c) The HPLC study is also conducted and the data as graphically illustrated in accompanying figure 3 confirms formation of Intermediate 7 of the present invention with chiral purity of 97.38%</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">EXAMPLE 2: Preparation of (3R)-N-(1S)-1-amino-1-oxobutan-2-yl)-3-(chloromethyl) hexanamide [Intermediate 8A of scheme A of the present invention]: Example 2 illustrates a process for preparing (3R)-N-(1S)-1-Amino-1-oxobutan-2-yl)-3-(chloromethyl) hexanamide [Intermediate 8A] from Intermediate 7 of example 1 above as developed in the present invention.</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;"><img height="198" id="imgf000030_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2021260721/pic/aMKQPwThQx9Rcs7mr8IvGgfVrLqq46mtS7-3aNpkYCwvjH2QwROyyeFUYWtbigQQJOgzQKOpYpRELSgdE1Zx6IMpw4dk5Vt6cgV_eZtQo6AH4kJ-m3_ZwNRmRfeC0fi_ibBf2ejn1fw0ajimJSADfN-Lfh-lPWo3Y4ZUTxx6LxQ" style="border: 0px; box-sizing: inherit;" width="417" /><br style="box-sizing: inherit;" />Procedure:</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">In second step of scheme A of the present invention, the said Intermediate 7 of example 1 above that is (3R)-N-(1S)-1-Amino-1-oxobutan-2-yl)-3-(hydroxymethyl) hexanamide (~98% Chemical purity and ~97% Chiral purity) (1736.86 mmol) is dissolved in DCM (1.2 L) at RT into a RBF under N<span style="bottom: -0.25em; box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; vertical-align: baseline;">2</span> atm. Then the solution is cooled to 10-20 C and Oxaloyl chloride (2605.29 mmol) is added to this cooled solution at 10-20 °C. The mixture is stirred for 24 h at 25-40 °C under N<span style="bottom: -0.25em; box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; vertical-align: baseline;">2</span> atm. Completion of the reaction is monitored by TLC. After completion of reaction, the solvent is distilled off and the residual mass is diluted with water (6 L), stirred at 30-50 °C for 4 h. Slurry mass is then filtered and washed with water (2×400 mL) followed by MTBE (800 mL). The solid is dried under vacuum at 50-55 °C for 4-5 h to afford Intermediate 8A that is (3R)-N-(1S)-1-Amino-1-oxobutan-2-yl)-3-(chloromethyl) hexanamide as a white solid (92% yield).</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">Results:</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">Formation of Intermediate 8A is confirmed further by following analytical studies: a) The <span style="box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; top: -0.5em; vertical-align: baseline;">1</span>H NMR analysis is conducted and the data as illustrated in accompanying figure 4 depicts: <span style="box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; top: -0.5em; vertical-align: baseline;">1</span>H NMR (400 MHz, DMSO-d<span style="bottom: -0.25em; box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; vertical-align: baseline;">6</span>) : δ 0.83 (t, J=7.44 Hz, 3H), 0.85 (t, J=6.72 Hz, 3H), 1.20-1.40 (m, 4H), 1.43-1.56 (m, 1H), 2.08-2.18 (m, 1H), 2.20-2.28 (m, 2H), 3.61 (dd, J=4.6 & 10.8 Hz, 1 H), 3.67 (dd, J=4.6 & 10.8 Hz, 1H), 4.07-4.18 (m, 1H), 6.95 (s, 1H), 7.29 (s, 1H), 7.89 (d, J=8.12 Hz, 1H); thus confirming formation of Intermediate 8A of the present invention.</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">b) The LCMS analysis is further conducted and the data as graphically illustrated in accompanying figure 5 (a, b) provides a (M+H<span style="box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; top: -0.5em; vertical-align: baseline;">+</span>) value of 249.20; thus, confirming formation of Intermediate 8A of the present invention.</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">EXAMPLE 3: Process for purification of Intermediate 8A forming Intermediate 8B Example 3 illustrates a process for purifying the said Intermediate 8A of example 2 above of the present invention.</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">Procedure:</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">The Intermediate 8A as obtained in example 2 above [that is (3R)-N-(1S)-1-Amino-1-oxobutan-2-yl)-3-(chloromethyl) hexanamide] is first dissolved in a polar solvent like Acetonitrile raising the temperature to 50 to 60 °C; followed by stirring and then addition of another solvent methyl tert-butyl ether (MTBE) which is less polar in nature. The mixture is then cooled down to 0°C, the filtered mass thus obtained is dried in order to obtain a white solid of Intermediate 8B. The material thus obtained is further dissolved in THF (5 vol) at 60 °C, cooled to 20-30°C, followed by addition of heptane (5 vol), stirred at 10°C to 30 °C for 1 h. The mass obtained is filtered and washed with heptane (2×1 vol), dried under vacuum at 50-55°C in order to afford formation of purer form of Intermediate 8A that is Intermediate 8B that is (3R)-N-(1S)-1-amino-1-oxobutan-2-yl)-3-(chloromethyl) hexanamide as a white solid having a chemical purity of 99.9% along with a chiral purity of 100% (yield: 390 g).</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">Results:</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">The purification of Intermediate 8A is further confirmed by the following analytical test results:</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">a) Chiral HPLC: A Chiral HPLC as illustrated in accompanying figure 6 confirmed formation of purest form of Intermediate 8B having 100% chiral purity [Peak 1; RT (min) = 6.244; %Area=100%].</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">b) GLP-HPLC: A GLP-HPLC as illustrated in accompanying figure 7 further confirmed formation of Intermediate 8B having 99.9% chemical purity [Peak 3; BRIV8; RT = 29.278; % Area=99.90%].</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">EXAMPLE 4: Synthesis of (3R)-N-[(1S)-1-carbamoylpropyl]-3-(hydroxymethyl) hexanamide [Intermediate 7’ of scheme B of the present invention]</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">Example 4 illustrates one pot process for preparing purified (3R)-N-[(1S)-1-carbamoylpropyl]-3-(hydroxymethyl) hexanamide [Intermediate 7’] from Intermediate 6 (99.99% ee) as developed in step-1 scheme B of the present invention.</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">Procedure:</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">In another method, in the first step of scheme B of the present invention, a mixture of (R)/(S)-4-propyldihydrofuran-2(3H)-one (Intermediate 6: S isomer = 99.99% : 0.1%) (1 eq), (S)-2-aminobutanamide (1.7 eq), triethylamine (5 eq) is refluxed at a temperature between 95±5 °C for 24 h. Then, the crude reaction mass is cooled and washed with dichloromethane and diisopropyl ether mixture (2.5 vol) in order to achieve Intermediate-7’ of scheme B of the present invention [(3R)-N-[(1S)-1-carbamoylpropyl]-3-(hydroxymethyl) hexanamide] (90% yield).</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">Results:</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">The chiral purity of the formed Intermediate 7’ is analyzed by HPLC method and the data as graphically illustrated in accompanying figure 8 confirms formation of Intermediate 7’ of the present invention with chiral purity of 99.11%</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">EXAMPLE 5: Preparation of (3R)-N-(1S)-1-amino-1-oxobutan-2-yl)-3-(chloromethyl) hexanamide [Intermediate 8’ of scheme B of present invention]: Example 5 illustrates a process for preparing purest form of (3R)-N-(1S)-1-amino-1-oxobutan-2-yl)-3-(chloromethyl) hexanamide [Intermediate 8’] from Intermediate 7’ of example 4 as developed in scheme B (step 2) of the present invention.</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;"><img height="206" id="imgf000033_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2021260721/pic/Hcjs6I_b60IIpNsyoqTgjX04koCTT_MwzpKOTpsHJAC6Jjdp4D-CC3qe2QL64nVXldny9pqAs0n1R4Ywu3EDhCsi-Aj1o2FfcxcGEmMN5Tiy5SAHiggZkQIW0iSfsrhzMUwn91rQEtOkuWHmFIWNXGen6Or6aKQ30R5hgTceLMQ" style="border: 0px; box-sizing: inherit;" width="426" /><br style="box-sizing: inherit;" /></p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">Procedure:</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">In the second step of scheme B of the present invention, the intermediate 7’ of the above example 4 that is (3R)-N-(1S)-1-amino-1-oxobutan-2-yl)-3-(hydroxymethyl) hexanamide (98% Chemical purity and >99%Chiral purity) (1736.86 mmol) is dissolved in DCM (1.2 L) at RT in a round bottomed flask under N<span style="bottom: -0.25em; box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; vertical-align: baseline;">2</span> atm. Then the solution is cooled to 10-30 °C and 1-Chloro-N,N,2-trimethyl-1-propenylamine (2605.29 mmol) is added to this cooled solution at 10-30 °C. The mixture is stirred for 24 h at 25-40 °C under N<span style="bottom: -0.25em; box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; vertical-align: baseline;">2</span> atm. Completion of the reaction is monitored by TLC. After completion of the reaction, the solvent is distilled off and the residual mass is diluted with water (6 L), stirring at 30-50 °C for 4 h. The slurry mass thus obtained is then filtered and washed with water (2×400 mL) followed by methyl tert-buty ether (MTBE) (800 mL). The solid thus obtained is dried under vacuum at 50-55 °C for 4-5 h in order to afford formation of Intermediate 8’ that is (3R)-N-(1S)-1-amino-1-oxobutan-2-yl)-3-(chloromethyl) hexanamide as a white solid (92% yield).</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">Results:</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">Formation of Intermediate 8’ is confirmed further by following analytical studies: a) The <span style="box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; top: -0.5em; vertical-align: baseline;">1</span>H NMR analysis is conducted and the data as illustrated in accompanying figure 9 depicts: (400 MHz, DMSO-d<span style="bottom: -0.25em; box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; vertical-align: baseline;">6</span>): <span style="box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; top: -0.5em; vertical-align: baseline;">1</span>H NMR (400 MHz, DMSO-d<span style="bottom: -0.25em; box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; vertical-align: baseline;">6</span>) : δ 0.83 (t, J=7.44 Hz, 3H), 0.85 (t, J=6.72 Hz, 3H), 1.20-1.40 (m, 4H), 1.43-1.56 (m, 1H), 2.08-2.18 (m, 1H), 2.20-2.28 (m, 2H), 3.61 (dd, J=4.6 & 10.8 Hz, 1 H), 3.67 (dd, J=4.6 & 10.8 Hz, 1H), 4.07-4.18 (m, 1H), 6.95 (s, 1H), 7.29 (s, 1H), 7.89 (d, J=8.12 Hz, 1H); thus, confirming formation of Intermediate 8’ of the present invention.</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">b) The LCMS analysis is further conducted and the data as graphically illustrated in accompanying figure 10 provides a (M+H<span style="box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; top: -0.5em; vertical-align: baseline;">+</span>) value of 249.1; thus, confirming formation of Intermediate 8’ of the present invention.</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">c) The HPLC data as illustrated in accompanying figure 11 confirms 100% chiral purity of Intermediate 8’.</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">EXAMPLE 6: Preparation of (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl] butanamide [Brivaracetam-API]:</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">Example 6 illustrates a process for preparing (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl] butanamide [Brivaracetam API] from Intermediate 8B of example 3 or from Intermediate 8’ of example 5 as developed in step 3 of scheme A or scheme B of the present invention respectively.</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;"><img height="232" id="imgf000035_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2021260721/pic/IK1t_Ke7mj8_cwGMChEssSkvzzTqGBgbEqKrXKphE_FsYqwvML3Mx_I5cE-056D2suJGP9PHJ4vDZdx8Av0SSSA1CwRnHqGBBpy4vs97sy7r4UlBSuVuFg25a-cHf2_11_rFS3vHNn0Qgdym4bGmZrqxQjxMK5yQBDj6gyEbzmU" style="border: 0px; box-sizing: inherit;" width="400" /> Procedure:</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">In the final step of scheme A or scheme B of the present invention, the intermediate 8B of example 3 or intermediate 8’ of example 5 above that is (3R)-N-((1S)-1-Amino-1-oxobutan-2-yl)-3-(chloromethyl) hexanamide (1608.04 mmol) is dissolved in dimethyl acetamide (0.5 vol) and isopropylacetate (2 L) into a RBF at 25-30 °C under N<span style="bottom: -0.25em; box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; vertical-align: baseline;">2</span> atm. Then 18-Crown-6 (160.79 mmol) is added into the solution and stirred at RT for 30 min. Reaction mixture is then cooled to 0-10 °C and t-BuOK (1.5 eq) is added portion wise to the cooled solution over 1 h maintaining the temperature from - 0-10 °C to 25 °C under N<span style="bottom: -0.25em; box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; vertical-align: baseline;">2</span> atm. Stirring is then continued for 2 h at -10 °C to 0 °C and then for 12 h at 15-25 °C under N<span style="bottom: -0.25em; box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; vertical-align: baseline;">2</span> atm. Completion of reaction is monitored by TLC. After completion of reaction, the reaction mixture is quenched with addition of 1M HCl solution (pH~6.5-7.0). The resulting mixture is extracted with i-PrOAc (2 L) and MTBE (1 L). Water (0.5 L) is added to the combined organic extract and then filtered through celite bed, washed the bed with MTBE-i-PrOAc (1:1) (400 mL). The organic part is separated and the aqueous part is re-extracted with i-PrOAc-MTBE (1:1) (2 ×0.8 L). The combined organic phases are washed with brine solution (100 mL), dried over anhydrous Na<span style="bottom: -0.25em; box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; vertical-align: baseline;">2</span>SO<span style="bottom: -0.25em; box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; vertical-align: baseline;">4</span>, filtered and concentrated in vacuum under a rotary evaporator to afford crude API. Distillation of dimethylacetamide solvent from the crude is then done at high vacuum pressure (0.05 mm Hg) at 70 °C. Crude product is then dissolved in isopropyl acetate (1.6 L) and treated with activated charcoal (7% w/w) to afford a tech-grade crude of Brivaracetam API as a white solid (yield: 90%) with 97.82% chemical purity.</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">Results:</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">Formation of Brivaracetam API is confirmed further by following analytical studies: a) The <span style="box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; top: -0.5em; vertical-align: baseline;">1</span>H NMR analysis is conducted and the data as illustrated in accompanying figure 12 depicts: <span style="box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; top: -0.5em; vertical-align: baseline;">1</span>H NMR (400 MHz, DMSO-d<span style="bottom: -0.25em; box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; vertical-align: baseline;">6</span>) : δ 0.77 (t, J=7.32 Hz, 3H), 0.87 (t, J=7.2 Hz, 3H), 1.21-1.31 (m, 2H), 1.33-1.43 (m, 2H), 1.50-1.62 (m, 1H), 1.73-1.84 (m, 1H), 1.97 (dd, J=8.0 & 16.12 Hz, 1H), 2.18-2.28 (m, 1H), 2.37 (dd, J=8.4 & 16.14 Hz, 1H), 3.11 (dd, J=7.16 & 9.44 Hz, 1H), 3.36 (dd, J=9.2 & 17.5 Hz, 1H), 4.30 dd, J=5.44 & 10.28 Hz, 1H), 6.98 (s, 1H), 7.32 (s, 1H); thus, confirming formation of Brivaracetam API of the present invention.</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">b) The LCMS analysis is further conducted and the data as graphically illustrated in accompanying figure 13 provides a (M+H<span style="box-sizing: inherit; font-size: 10.5px; line-height: 0; position: relative; top: -0.5em; vertical-align: baseline;">+</span>) value of 213.0; thus, confirming formation of Brivaracetam API of the present invention.</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">^ Purification of Brivaracetam API:</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">The Brivaracetam thus formed above is further purified by means of dissolving the said material (307 g) in 30% i-PrOAc -MTBE (1 vol) at 55-60 °C, cool to 20-30°C. A mixture of Heptane and MTBE and DIPE (2:2:1) is added, stirred at 10 °C to 30°C for 1 h. The obtained mass is filtered and washed with heptane, which is subsequently dried under vacuum at 40-45 °C to afford (3R)-N-((1S)-1-amino-1-oxobutan-2-yl)-3-(chloromethyl) hexanamide as a white solid (yield: 80%, chiral purity 99.93% and chemical purity 99.94%).</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">Results:</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">a) Chiral HPLC: A Chiral HPLC as illustrated in accompanying figure 14 confirmed formation of purest form of Brivaracetam API having 99.93% chiral purity [Peak 2; RT (min) = 9.45; %Area=99.93%].</p><p style="background-color: white; box-sizing: inherit; color: #1a1a1a; font-family: simplon, arial, meiryo, sans-serif; font-size: 14px; margin-bottom: 0px; margin-top: 1em;">b) GLP-HPLC: A GLP-HPLC as illustrated in accompanying figure 15 further confirmed formation of Brivaracetam API having 99.9% chemical purity [Peak 2; RT = 21.138; % Area=99.94%].</p><p><br /></p><p><br /></p><p><br /></p><p><br /></p>DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com0tag:blogger.com,1999:blog-4738331378048275307.post-86270153908874942302022-01-01T03:32:00.003-08:002022-01-01T03:32:45.873-08:00NEW PATENTS, RELATED TO COVID 19<p> </p><p><br /></p><p>NEW PATENTS</p><p>1 <a class="detail-link" href="https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=33882500671E51DA7A51A036B8D633B1.wapp2nA?docId=WO2021258625&_gid=202152" id="weeklyPublicationForm:resultTable:114:woLink" name="weeklyPublicationForm:resultTable:114:woLink" style="background-color: #f7f7f7; box-sizing: inherit; color: #1a1a1a; cursor: pointer; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px; margin: 0px 0.25em;">WO/2021/258625</a><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">ANTI-SAR-COV-2 (COVID-19) FULLY HUMANIZED MONOCLONAL ANTIBODY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF</span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY CHINESE ACADEMY OF SCIENCES</span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;"><br /></span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">2 </span><a class="detail-link" href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021260164&_gid=202152" id="weeklyPublicationForm:resultTable:922:woLink" name="weeklyPublicationForm:resultTable:922:woLink" style="background-color: #f7f7f7; box-sizing: inherit; color: #1a1a1a; cursor: pointer; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px; margin: 0px 0.25em;">WO/2021/260164</a><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">THROMBIN C-TERMINAL PEPTIDES TO TREAT CORONAVIRAL INFECTIONS</span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">IN2CURE AB</span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;"><br /></span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">3 </span><a class="detail-link" href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021211332&_gid=202152" id="weeklyPublicationForm:resultTable:1001:woLink" name="weeklyPublicationForm:resultTable:1001:woLink" style="background-color: #f7f7f7; box-sizing: inherit; color: #1a1a1a; cursor: pointer; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px; margin: 0px 0.25em;">WO/2021/211332</a><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">METHODS AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF AN ANTI-Β-CORONAVIRUS ANTIBODY IN A SAMPLE</span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">ABBOTT LABORATORIES</span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;"><br /></span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">4 </span><a class="detail-link" href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021262744&_gid=202152" id="weeklyPublicationForm:resultTable:1194:woLink" name="weeklyPublicationForm:resultTable:1194:woLink" style="background-color: #f7f7f7; box-sizing: inherit; color: #1a1a1a; cursor: pointer; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px; margin: 0px 0.25em;">WO/2021/262744</a><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">KITS AND METHODS FOR ISOTHERMALLY AMPLIFYING RIBONUCLEIC ACID OF SEVERE ACUTE RESPIRATORY VIRUS COV2</span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">UNIVERSITY OF WASHINGTON</span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;"><br /></span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">5 </span><a class="detail-link" href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021262894&_gid=202152" id="weeklyPublicationForm:resultTable:1596:woLink" name="weeklyPublicationForm:resultTable:1596:woLink" style="background-color: #f7f7f7; box-sizing: inherit; color: #1a1a1a; cursor: pointer; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px; margin: 0px 0.25em;">WO/2021/262894</a><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">METHODS FOR DIAGNOSING RESPIRATORY PATHOGENS AND PREDICTING COVID-19 RELATED OUTCOMES</span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE</span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;"><br /></span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;"><br /></span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;"><br /></span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">////////////////</span></p>DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com0tag:blogger.com,1999:blog-4738331378048275307.post-43603514573056858642021-12-24T18:56:00.007-08:002021-12-24T18:56:51.340-08:00ENZYMATIC PRODUCTION OF ALLULOSE<p> </p><p><br /></p><p><a class="detail-link" href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021236632&_gid=202151" id="weeklyPublicationForm:resultTable:357:woLink" name="weeklyPublicationForm:resultTable:357:woLink" style="background-color: #f7f7f7; box-sizing: inherit; color: #1a1a1a; cursor: pointer; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px; margin: 0px 0.25em;">WO/2021/236632</a></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">ENZYMATIC PRODUCTION OF ALLULOSE</span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">BONUMOSE, INC.</span></p>DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com0tag:blogger.com,1999:blog-4738331378048275307.post-54945107074150462962021-10-08T19:51:00.001-07:002021-10-08T19:51:10.525-07:00NEW PATENT WO/2021/198525 (S,Z)-3,7-DIMETHYLNON-6-EN-1-OL AND ITS USE AS FRAGRANCE<p> <a class="detail-link" href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021198525&_gid=202140" id="weeklyPublicationForm:resultTable:2754:woLink" name="weeklyPublicationForm:resultTable:2754:woLink" style="background-color: #f7f7f7; box-sizing: inherit; color: #1a1a1a; cursor: pointer; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px; margin: 0px 0.25em;">WO/2021/198525</a></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">(S,Z)-3,7-DIMETHYLNON-6-EN-1-OL AND ITS USE AS FRAGRANCE</span></p><p><span style="background-color: #f7f7f7;"><span style="color: grey; font-family: simplon, arial, meiryo, sans-serif;"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021198525&_gid=202140">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021198525&_gid=202140</a></span></span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">GIVAUDAN SA</span></p>DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com0tag:blogger.com,1999:blog-4738331378048275307.post-61259674686793658342021-10-07T23:06:00.003-07:002021-10-07T23:06:24.566-07:00NEW PATENT WO/2021/196505 USES OF CYCLOCARYA PALIURUS LEAF FLAVONE EXTRACT IN PREPARATION OF ANTIBACTERIAL MEDICAMENTS AND/OR ANTIBACTERIAL AGENTS<p> <a class="detail-link" href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021196505&_gid=202140" id="weeklyPublicationForm:resultTable:1116:woLink" name="weeklyPublicationForm:resultTable:1116:woLink" style="background-color: #f7f7f7; box-sizing: inherit; color: #1a1a1a; cursor: pointer; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px; margin: 0px 0.25em;">WO/2021/196505</a></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">USES OF CYCLOCARYA PALIURUS LEAF FLAVONE EXTRACT IN PREPARATION OF ANTIBACTERIAL MEDICAMENTS AND/OR ANTIBACTERIAL AGENTS</span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">WEST CHINA HOSPITAL, SICHUAN UNIVERSITY</span></p><p><span style="background-color: #f7f7f7;"><span style="color: grey; font-family: simplon, arial, meiryo, sans-serif;"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021196505&_gid=202140">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021196505&_gid=202140</a></span></span></p>DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com0tag:blogger.com,1999:blog-4738331378048275307.post-14623373326305494022021-10-07T23:00:00.001-07:002021-10-07T23:00:11.386-07:00NEW PATENT, WO/2021/195763 ANTIVIRAL RUTHENATE(III) THERAPEUTICS<p> </p><p><a class="detail-link" href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021195763&_gid=202140" id="weeklyPublicationForm:resultTable:1141:woLink" name="weeklyPublicationForm:resultTable:1141:woLink" style="background-color: #f7f7f7; box-sizing: inherit; color: #1a1a1a; cursor: pointer; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px; margin: 0px 0.25em;">WO/2021/195763</a><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">ANTIVIRAL RUTHENATE(III) THERAPEUTICS</span></p><p><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021195763&_gid=202140" target="_blank"><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">BOLD THERAPEUTICS INC.</span><span style="color: grey; font-family: simplon, arial, meiryo, sans-serif;">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021195763&_gid=202140</span></a></p><p><span style="color: grey; font-family: simplon, arial, meiryo, sans-serif;"><br /></span></p>DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com0tag:blogger.com,1999:blog-4738331378048275307.post-75520168297739095092021-09-23T19:25:00.005-07:002021-09-23T19:25:50.647-07:00NEW PATENT WO/2021/189077 METHODS FOR TREATING ACNE<p> </p><p><br /></p><p><a class="detail-link" href="https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=B84412A7ED0D593D81642167F058FBEC.wapp2nA?docId=WO2021189077&_gid=202138" id="weeklyPublicationForm:resultTable:121:woLink" name="weeklyPublicationForm:resultTable:121:woLink" style="background-color: #f7f7f7; box-sizing: inherit; color: #1a1a1a; cursor: pointer; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px; margin: 0px 0.25em;">WO/2021/189077</a></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">METHODS FOR TREATING ACNE</span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;">CHEMISTRYRX</span></p><p><span style="background-color: #f7f7f7; color: grey; font-family: simplon, arial, meiryo, sans-serif; font-size: 16px;"><br /></span></p><p><span style="background-color: #f7f7f7;"><span style="color: grey; font-family: simplon, arial, meiryo, sans-serif;"><a href="https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=B84412A7ED0D593D81642167F058FBEC.wapp2nA?docId=WO2021189077&_gid=202138">https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=B84412A7ED0D593D81642167F058FBEC.wapp2nA?docId=WO2021189077&_gid=202138</a></span></span></p><p><span style="background-color: #f7f7f7;"><span style="color: grey; font-family: simplon, arial, meiryo, sans-serif;"><br /></span></span></p>DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com0tag:blogger.com,1999:blog-4738331378048275307.post-92152881285560795162021-09-23T02:03:00.001-07:002021-09-23T02:03:09.703-07:00 NEW PATENT WO/2021/180078 METHOD FOR PREPARING CHITOSAN USING SNOW CRAB SHELLS<p> <span style="background-color: white; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px;">NEW PATENT</span></p><span style="background-color: white; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px;">WO/2021/180078 METHOD FOR PREPARING CHITOSAN USING SNOW CRAB SHELLS</span><br style="background-color: white; box-sizing: inherit; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px; line-height: inherit !important;" /><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021180078&_gid=202137">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021180078&_gid=202137</a><div><br style="background-color: white; box-sizing: inherit; line-height: inherit !important;" /><span style="background-color: white; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px;">SHANDONG MEIJIA GROUP CO.LTD</span><div><br /></div><div><br /></div><div><span style="background-color: white; color: #1a1a1a; font-family: "Arial Unicode MS"; font-size: 12px;">Take 200g of fresh snow crab shells, that is, leftovers produced by fresh snow crabs just after aquatic processing in the previous process. After crushing, add 1000g of citric acid solution with a concentration of 5% by mass, soak for 15 hours, filter with gauze, and use tap water or The crab shell is washed with pure water to obtain a decalcified crab shell. The washing residue and the filtrate are combined to obtain a mixture. The mixture is filtered through a plate and frame, and the filter residue is dried to obtain calcium citrate. Add 1000g of 5% citric acid solution and repeat the above steps once to obtain decalcified crab shells; add 1000g of water to the decalcified crab shells, add 2g of flavor enzymes, keep them at 49°C for 3 hours, inactivate the enzymes, filter, and obtain The filtrate is concentrated and spray-dried to obtain crab protein powder. The obtained crab shells are added to 400 g of 10% citric acid solution, soaked for 6 hours, filtered with gauze, and the resulting filter residue is washed and dried to obtain chitin. The obtained filtrate is recovered for subsequent processing. For use, add 55% KOH solution (containing 0.1% potassium acetate) to the obtained chitin, where the mass percentage of chitin and KOH solution is 1:5, at 90°C, keep for 6 hours, filter after cooling, wash, and recover the filtrate and The washing liquid is used again after subsequent treatment. The washed filter residue is irradiated with ultraviolet rays for 12 hours, and 24.2 g of chitosan is obtained after drying.</span><br style="background-color: white; box-sizing: inherit; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px; line-height: inherit !important;" /><br style="background-color: white; box-sizing: inherit; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px; line-height: inherit !important;" /><span style="background-color: white; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px;">Every difficulty is an opportunity</span><br style="background-color: white; box-sizing: inherit; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px; line-height: inherit !important;" /><br style="background-color: white; box-sizing: inherit; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px; line-height: inherit !important;" /><a data-attribute-index="0" href="https://www.linkedin.com/feed/hashtag/?keywords=worlddrugtracker&highlightedUpdateUrns=urn%3Ali%3Aactivity%3A6844921263815766016" style="background-color: white; border: var(--artdeco-reset-link-border-zero); box-sizing: inherit; font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px; font-weight: var(--font-weight-bold); line-height: inherit !important; margin: var(--artdeco-reset-base-margin-zero); padding: var(--artdeco-reset-base-padding-zero); position: relative; text-decoration: var(--artdeco-reset-link-text-decoration-none); touch-action: manipulation; vertical-align: var(--artdeco-reset-base-vertical-align-baseline);">#worlddrugtracker</a><span style="background-color: white; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px;"> </span><a data-attribute-index="1" href="https://www.linkedin.com/feed/hashtag/?keywords=helpingmillions&highlightedUpdateUrns=urn%3Ali%3Aactivity%3A6844921263815766016" style="background-color: white; border: var(--artdeco-reset-link-border-zero); box-sizing: inherit; font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px; font-weight: var(--font-weight-bold); line-height: inherit !important; margin: var(--artdeco-reset-base-margin-zero); padding: var(--artdeco-reset-base-padding-zero); position: relative; text-decoration: var(--artdeco-reset-link-text-decoration-none); touch-action: manipulation; vertical-align: var(--artdeco-reset-base-vertical-align-baseline);">#helpingmillions</a><span style="background-color: white; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px;"> </span><a data-attribute-index="2" href="https://www.linkedin.com/feed/hashtag/?keywords=worldpeaceambassador&highlightedUpdateUrns=urn%3Ali%3Aactivity%3A6844921263815766016" style="background-color: white; border: var(--artdeco-reset-link-border-zero); box-sizing: inherit; font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px; font-weight: var(--font-weight-bold); line-height: inherit !important; margin: var(--artdeco-reset-base-margin-zero); padding: var(--artdeco-reset-base-padding-zero); position: relative; text-decoration: var(--artdeco-reset-link-text-decoration-none); touch-action: manipulation; vertical-align: var(--artdeco-reset-base-vertical-align-baseline);">#worldpeaceambassador</a><span style="background-color: white; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px;"> </span><a data-attribute-index="3" href="https://www.linkedin.com/feed/hashtag/?keywords=helpingmillions&highlightedUpdateUrns=urn%3Ali%3Aactivity%3A6844921263815766016" style="background-color: white; border: var(--artdeco-reset-link-border-zero); box-sizing: inherit; font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px; font-weight: var(--font-weight-bold); line-height: inherit !important; margin: var(--artdeco-reset-base-margin-zero); padding: var(--artdeco-reset-base-padding-zero); position: relative; text-decoration: var(--artdeco-reset-link-text-decoration-none); touch-action: manipulation; vertical-align: var(--artdeco-reset-base-vertical-align-baseline);">#helpingmillions</a><span style="background-color: white; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px;"> </span><a data-attribute-index="4" href="https://www.linkedin.com/feed/hashtag/?keywords=opensuperstar&highlightedUpdateUrns=urn%3Ali%3Aactivity%3A6844921263815766016" style="background-color: white; border: var(--artdeco-reset-link-border-zero); box-sizing: inherit; font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px; font-weight: var(--font-weight-bold); line-height: inherit !important; margin: var(--artdeco-reset-base-margin-zero); padding: var(--artdeco-reset-base-padding-zero); position: relative; text-decoration: var(--artdeco-reset-link-text-decoration-none); touch-action: manipulation; vertical-align: var(--artdeco-reset-base-vertical-align-baseline);">#opensuperstar</a><span style="background-color: white; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px;"> </span><a data-attribute-index="5" href="https://www.linkedin.com/feed/hashtag/?keywords=everydifficultyanopportunity&highlightedUpdateUrns=urn%3Ali%3Aactivity%3A6844921263815766016" style="background-color: white; border: var(--artdeco-reset-link-border-zero); box-sizing: inherit; font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px; font-weight: var(--font-weight-bold); line-height: inherit !important; margin: var(--artdeco-reset-base-margin-zero); padding: var(--artdeco-reset-base-padding-zero); position: relative; text-decoration: var(--artdeco-reset-link-text-decoration-none); touch-action: manipulation; vertical-align: var(--artdeco-reset-base-vertical-align-baseline);">#everydifficultyanopportunity</a><span style="background-color: white; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px;"> </span><a data-attribute-index="6" href="https://www.linkedin.com/feed/hashtag/?keywords=qbdking&highlightedUpdateUrns=urn%3Ali%3Aactivity%3A6844921263815766016" style="background-color: white; border: var(--artdeco-reset-link-border-zero); box-sizing: inherit; font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px; font-weight: var(--font-weight-bold); line-height: inherit !important; margin: var(--artdeco-reset-base-margin-zero); padding: var(--artdeco-reset-base-padding-zero); position: relative; text-decoration: var(--artdeco-reset-link-text-decoration-none); touch-action: manipulation; vertical-align: var(--artdeco-reset-base-vertical-align-baseline);">#qbdking</a><span style="background-color: white; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px;"> </span><a data-attribute-index="7" href="https://www.linkedin.com/feed/hashtag/?keywords=pharmadon&highlightedUpdateUrns=urn%3Ali%3Aactivity%3A6844921263815766016" style="background-color: white; border: var(--artdeco-reset-link-border-zero); box-sizing: inherit; font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px; font-weight: var(--font-weight-bold); line-height: inherit !important; margin: var(--artdeco-reset-base-margin-zero); padding: var(--artdeco-reset-base-padding-zero); position: relative; text-decoration: var(--artdeco-reset-link-text-decoration-none); touch-action: manipulation; vertical-align: var(--artdeco-reset-base-vertical-align-baseline);">#pharmadon</a><span style="background-color: white; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px;"> </span><a data-attribute-index="8" href="https://www.linkedin.com/feed/hashtag/?keywords=divyang&highlightedUpdateUrns=urn%3Ali%3Aactivity%3A6844921263815766016" style="background-color: white; border: var(--artdeco-reset-link-border-zero); box-sizing: inherit; font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px; font-weight: var(--font-weight-bold); line-height: inherit !important; margin: var(--artdeco-reset-base-margin-zero); padding: var(--artdeco-reset-base-padding-zero); position: relative; text-decoration: var(--artdeco-reset-link-text-decoration-none); touch-action: manipulation; vertical-align: var(--artdeco-reset-base-vertical-align-baseline);">#divyang</a><span style="background-color: white; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px;"> </span><a data-attribute-index="9" href="https://www.linkedin.com/feed/hashtag/?keywords=differentlyabled&highlightedUpdateUrns=urn%3Ali%3Aactivity%3A6844921263815766016" style="background-color: white; border: var(--artdeco-reset-link-border-zero); box-sizing: inherit; font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 14px; font-weight: var(--font-weight-bold); line-height: inherit !important; margin: var(--artdeco-reset-base-margin-zero); padding: var(--artdeco-reset-base-padding-zero); position: relative; text-decoration: var(--artdeco-reset-link-text-decoration-none); touch-action: manipulation; vertical-align: var(--artdeco-reset-base-vertical-align-baseline);">#differentlyabled</a></div></div>DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com0tag:blogger.com,1999:blog-4738331378048275307.post-22350823979261804842019-09-06T05:09:00.001-07:002019-09-06T05:19:18.140-07:00EP Patent Validation Service<div dir="ltr" style="text-align: left;" trbidi="on">
<br />
<figure class="reader-cover-image--grid relative" style="color: #333333; font-family: Georgia, "Times New Roman", "Bitstream Charter", Times, serif; font-size: 16px;"><div class="reader-cover-image--wrapper" style="align-items: center; background: transparent; border: 0px; box-sizing: inherit; display: flex; height: 396px; justify-content: center; margin: 0px; overflow: hidden; padding: 0px; position: relative; vertical-align: baseline;">
<div style="background: transparent; border: 0px; box-sizing: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<img alt="" class="lazy-image reader-cover-image__img loaded" data-mce-src="https://media.licdn.com/dms/image/C5112AQGGFACav4Sc2Q/article-cover_image-shrink_423_752/0?e=1573084800&v=beta&t=PcR0CiMPGgpwgNSiwmgbRuMegGBwoLHmJUQMPquhnoE" height="312" src="https://media.licdn.com/dms/image/C5112AQGGFACav4Sc2Q/article-cover_image-shrink_423_752/0?e=1573084800&v=beta&t=PcR0CiMPGgpwgNSiwmgbRuMegGBwoLHmJUQMPquhnoE" style="height: auto; max-width: 100%;" width="640" /><br />
EP Patent Validation Service<br />
Sandeep Mishra<br />
Director at De Science Infoware Pvt Ltd</div>
<span class="lt-line-clamp__line lt-line-clamp__line--last" style="background: transparent; border: 0px; box-sizing: inherit; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;"><br /></span>
<span class="lt-line-clamp__line lt-line-clamp__line--last" style="background: transparent; border: 0px; box-sizing: inherit; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;"><br /></span>
<span class="lt-line-clamp__line lt-line-clamp__line--last" style="background: transparent; border: 0px; box-sizing: inherit; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;"><br /></span>
<span class="lt-line-clamp__line lt-line-clamp__line--last" style="background: transparent; border: 0px; box-sizing: inherit; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;"><br /></span>
<span class="lt-line-clamp__line lt-line-clamp__line--last" style="background: transparent; border: 0px; box-sizing: inherit; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;"><br /></span>
<span class="lt-line-clamp__line lt-line-clamp__line--last" style="background: transparent; border: 0px; box-sizing: inherit; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;"><br /></span>
<span class="lt-line-clamp__line lt-line-clamp__line--last" style="background: transparent; border: 0px; box-sizing: inherit; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;"><br /></span>
<span class="lt-line-clamp__line lt-line-clamp__line--last" style="background: transparent; border: 0px; box-sizing: inherit; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;"><br /></span>
<span class="lt-line-clamp__line lt-line-clamp__line--last" style="background: transparent; border: 0px; box-sizing: inherit; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;"><br /></span>
<br /></div>
</figure><br />
<div class="relative reader__grid" style="color: #333333; font-family: Georgia, "Times New Roman", "Bitstream Charter", Times, serif; font-size: 16px;">
<div class="ember-view" id="ember56" style="background: transparent; border: 0px; box-sizing: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<div class="reader-article-content" style="background: transparent; border: 0px; box-sizing: inherit; margin: 0px; padding: 0px; vertical-align: baseline;">
<div style="background: transparent; border: 0px; box-sizing: inherit; color: rgba(0, 0, 0, 0.75); font-family: "Source Serif Pro", serif; font-size: 2rem; line-height: 3.2rem; margin-bottom: 3.2rem; margin-top: 3.2rem; padding: 0px; vertical-align: baseline;">
<span style="background: transparent; border: 0px; box-sizing: inherit; font-size: 20px; font-weight: 600; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;"><u style="box-sizing: inherit;">Traditional route</u></span></div>
<div style="background: transparent; border: 0px; box-sizing: inherit; color: rgba(0, 0, 0, 0.75); font-family: "Source Serif Pro", serif; font-size: 2rem; line-height: 3.2rem; margin-bottom: 3.2rem; margin-top: 3.2rem; padding: 0px; vertical-align: baseline;">
The conventional route for EP patent validation is for the client to instruct their EP attorneys to execute the validation. The EP attorneys would then instruct a validations provider (like us) or perform the validations themselves using attorney partners in each country who they use based on a reciprocity model, which is usually not cost or quality selective. The EP attorneys would add significant fees for each country.</div>
<div style="background: transparent; border: 0px; box-sizing: inherit; color: rgba(0, 0, 0, 0.75); font-family: "Source Serif Pro", serif; font-size: 2rem; line-height: 3.2rem; margin-bottom: 3.2rem; margin-top: 3.2rem; padding: 0px; vertical-align: baseline;">
<span style="background: transparent; border: 0px; box-sizing: inherit; font-size: 20px; font-weight: 600; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;">About our EP Patent Validation service</span> : Why you should go with us.</div>
<div style="background: transparent; border: 0px; box-sizing: inherit; color: rgba(0, 0, 0, 0.75); font-family: "Source Serif Pro", serif; font-size: 2rem; line-height: 3.2rem; margin-bottom: 3.2rem; margin-top: 3.2rem; padding: 0px; vertical-align: baseline;">
<span style="background: transparent; border: 0px; box-sizing: inherit; font-size: 20px; font-weight: 600; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;">Benefits of using our EP validation service :</span></div>
<div style="background: transparent; border: 0px; box-sizing: inherit; color: rgba(0, 0, 0, 0.75); font-family: "Source Serif Pro", serif; font-size: 2rem; line-height: 3.2rem; margin-bottom: 3.2rem; margin-top: 3.2rem; padding: 0px; vertical-align: baseline;">
By using a centralised validations provider like us, the client is cutting out one extra layer of cost, which is usually the most significant cost layer. All large patent filers in Europe use a centralised provider like our associate company because of benefits like the following:</div>
<div style="background: transparent; border: 0px; box-sizing: inherit; color: rgba(0, 0, 0, 0.75); font-family: "Source Serif Pro", serif; font-size: 2rem; line-height: 3.2rem; margin-bottom: 3.2rem; margin-top: 3.2rem; padding: 0px; vertical-align: baseline;">
<span style="background: transparent; border: 0px; box-sizing: inherit; font-size: 20px; font-weight: 600; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;">Reduced Risk</span></div>
<div style="background: transparent; border: 0px; box-sizing: inherit; color: rgba(0, 0, 0, 0.75); font-family: "Source Serif Pro", serif; font-size: 2rem; line-height: 3.2rem; margin-bottom: 3.2rem; margin-top: 3.2rem; padding: 0px; vertical-align: baseline;">
We with our European team are specialists in European Patent Validation, which means there is a significantly reduced risk of misunderstanding, unexpected costs, or of course the unthinkable risk of accidental loss of a patent due to the complex and constantly changing regulations around Europe.</div>
<div style="background: transparent; border: 0px; box-sizing: inherit; color: rgba(0, 0, 0, 0.75); font-family: "Source Serif Pro", serif; font-size: 2rem; line-height: 3.2rem; margin-bottom: 3.2rem; margin-top: 3.2rem; padding: 0px; vertical-align: baseline;">
<span style="background: transparent; border: 0px; box-sizing: inherit; font-size: 20px; font-weight: 600; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;">Reduced Cost</span></div>
<div style="background: transparent; border: 0px; box-sizing: inherit; color: rgba(0, 0, 0, 0.75); font-family: "Source Serif Pro", serif; font-size: 2rem; line-height: 3.2rem; margin-bottom: 3.2rem; margin-top: 3.2rem; padding: 0px; vertical-align: baseline;">
Validation is a significant part of the cost of a European Patent lifecycle, especially if many countries are required. Filing tens of thousands of validations per year, and translating millions of words into every language, means that ours buying power is enormous. We provide user-friendly and extremely efficient processes to our agents and suppliers which further reduce their costs, and all of this means we are able to pass on these savings to our customers.</div>
<div style="background: transparent; border: 0px; box-sizing: inherit; color: rgba(0, 0, 0, 0.75); font-family: "Source Serif Pro", serif; font-size: 2rem; line-height: 3.2rem; margin-bottom: 3.2rem; margin-top: 3.2rem; padding: 0px; vertical-align: baseline;">
We expect to able to reduce most client's validations costs by at least 50%<br />
<a data-mce-href="http://www.allfordrugs.com/wp-content/uploads/2019/09/s.jpg" href="http://www.allfordrugs.com/wp-content/uploads/2019/09/s.jpg" rel="attachment wp-att-11109"><img alt="s" class="alignnone wp-image-11109" data-mce-src="http://www.allfordrugs.com/wp-content/uploads/2019/09/s.jpg" src="http://www.allfordrugs.com/wp-content/uploads/2019/09/s.jpg" height="295" style="height: auto; max-width: 100%;" width="295" /></a><br />
Sandeep Mishra<br />
Director at De Science Infoware Pvt Ltd<br />
<br />
<section class="pv-contact-info__contact-type ci-vanity-url"><header class="pv-contact-info__header t-16 t-black t-bold">Sandeep’s Profile</header><div class="pv-contact-info__ci-container">
<a class="pv-contact-info__contact-link t-14 t-black t-normal" data-mce-href="https://www.linkedin.com/in/sandeep-mishra-35b215b" href="https://www.linkedin.com/in/sandeep-mishra-35b215b">linkedin.com/in/sandeep-mishra-35b215b</a></div>
</section><section class="pv-contact-info__contact-type ci-websites"><header class="pv-contact-info__header t-16 t-black t-bold">Website <a class="pv-contact-info__contact-link t-14 t-black t-normal" data-mce-href="http://www.descienceinfoware/" href="http://www.descienceinfoware/" rel="noopener" target="_blank">descienceinfoware </a><span class="t-14 t-black--light t-normal">(Company Website)</span></header></section><section class="pv-contact-info__contact-type ci-phone"><header class="pv-contact-info__header t-16 t-black t-bold">Phone</header><header class="pv-contact-info__header t-16 t-black t-bold"><span class="t-14 t-black t-normal">+91 8953745897</span> <span class="t-14 t-black--light t-normal">(Work)</span></header></section><section class="pv-contact-info__contact-type ci-email"><header class="pv-contact-info__header t-16 t-black t-bold">Email</header><header class="pv-contact-info__header t-16 t-black t-bold">sandeepm@scienceinfoware.com, </header><div class="pv-contact-info__ci-container">
<a class="pv-contact-info__contact-link t-14 t-black t-normal" data-mce-href="mailto:scienceinfoware@gmail.com" href="mailto:scienceinfoware@gmail.com" rel="noopener noreferrer" target="_blank">scienceinfoware@gmail.com</a></div>
<div class="pv-contact-info__ci-container">
<br /></div>
<div class="pv-contact-info__ci-container">
<br /></div>
<div class="pv-contact-info__ci-container">
<br /></div>
</section></div>
</div>
///////////Sandeep Mishra, Director, e Science Infoware, ep, patent</div>
</div>
<br />
<figure class="reader-cover-image--grid relative" style="background: rgb(255, 255, 255); border: 0px; box-sizing: inherit; color: rgba(0, 0, 0, 0.9); font-family: -apple-system, system-ui, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", "Fira Sans", Ubuntu, Oxygen, "Oxygen Sans", Cantarell, "Droid Sans", "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Lucida Grande", Helvetica, Arial, sans-serif; font-size: 16px; margin: auto; max-width: 744px; padding: 0px; position: relative !important; text-align: left; vertical-align: baseline;">
</figure></div>
DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com34tag:blogger.com,1999:blog-4738331378048275307.post-47319716877999740032019-07-04T02:16:00.001-07:002019-07-04T02:16:28.074-07:00New patent, Opicapone, WO 2019123066, Unichem<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019123066/pic/tvVSdFUGFmuSEIX72zFa_WOIV5MdpfaBym7JxwhPSfYHUYPzM-JXQ1drABrOaaRl3jHeNVqoHoGzHXIr56HXzK08zSZ4VaTYc5xLcyuK8w_pX1G1k73gi2eCpTSVTgO_Hw6HGwjKSN_D6FIsp2zBcFO4aDbEOacstKbhx0mISBQ" height="120" id="imgf000002_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019123066/pic/tvVSdFUGFmuSEIX72zFa_WOIV5MdpfaBym7JxwhPSfYHUYPzM-JXQ1drABrOaaRl3jHeNVqoHoGzHXIr56HXzK08zSZ4VaTYc5xLcyuK8w_pX1G1k73gi2eCpTSVTgO_Hw6HGwjKSN_D6FIsp2zBcFO4aDbEOacstKbhx0mISBQ" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="199" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
New patent, Opicapone, WO 2019123066, Unichem</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
WO-2019123066</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<a data-mce-href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019123066&tab=PCTDESCRIPTION" href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019123066&tab=PCTDESCRIPTION" style="color: #222222;">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019123066&tab=PCTDESCRIPTION</a></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Process for the preparation of opicapone and its intermediates, useful for treating parkinson's disease. Bial-Portela has developed and launched opicapone, for treating Parkinson's disease.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Opicapone is a selective and reversible catechol-O-methyltransferase (COMT) inhibitor, use as adjunctive therapy for parkinson’s disease. Opicapone was approved by European Medicine Agency (EMA) on June 24, 2016 and it is developed and marketed as ONGENTYS<span style="bottom: 1ex; font-size: 12px; height: 0px; line-height: 0; position: relative; vertical-align: baseline;">®</span> by Bial-Portela in Europe. Opicapone is chemically described as 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-l,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-l-oxide and depicted below as compound of formula (I).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019123066/pic/tvVSdFUGFmuSEIX72zFa_WOIV5MdpfaBym7JxwhPSfYHUYPzM-JXQ1drABrOaaRl3jHeNVqoHoGzHXIr56HXzK08zSZ4VaTYc5xLcyuK8w_pX1G1k73gi2eCpTSVTgO_Hw6HGwjKSN_D6FIsp2zBcFO4aDbEOacstKbhx0mISBQ" height="120" id="imgf000002_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019123066/pic/tvVSdFUGFmuSEIX72zFa_WOIV5MdpfaBym7JxwhPSfYHUYPzM-JXQ1drABrOaaRl3jHeNVqoHoGzHXIr56HXzK08zSZ4VaTYc5xLcyuK8w_pX1G1k73gi2eCpTSVTgO_Hw6HGwjKSN_D6FIsp2zBcFO4aDbEOacstKbhx0mISBQ" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="199" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Opicapone and a process for preparation of it is disclosed in US 8,168,793. The process disclosescondensation of 3, 4-dibenzyloxy-5-nitrobenzoic acid with (Z)-2, 5-dichloro-N'-hydroxy-4, 6-dimethylnicotinimidamide in presence of N, N’-Carbonyl diimidazole in N, N’-dimethylformamide. The crude condensation intermediate was subjected to tetrabutylammonium fluoride (TBAF) mediated cyclization in tetrahydrofuran to give l,2,4-oxadiazole derivative, purifying it by precipitating in 1:1 mixture of dichloromethane: diethyl ether and recrystallized it in isopropyl alcohol. Oxidation of l,2,4-oxadiazole compound is carried out using 10 fold excess of urea hydrogen peroxide complex and trifluoroacetic anhydride in dichloromethane and was purified by column chromatography. Obtained N-oxide compound was converted into opicaponecompound of formula (I) by deprotection O-benzoyl groups by exposure it to boron tribromide (BBr<span style="font-size: 12px; height: 0px; line-height: 0; position: relative; top: 0.5ex; vertical-align: baseline;">3</span>) in dichloromethane at -78°C to room temperature. Final product was purified in mixture of toluene and ethanol. Above synthetic stepsare outline in scheme 1.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019123066/pic/4SgdyzMwTHtZzB8LOoHDNq_TExYgDNtSFIccIa-x8PkrXETcrmuRDmnyeJxdSX81FXWSwKOY4yXRLh4Qv7euM_mv2h-letFFs6xycOHhRkTiydhMbRMdCdNEgDrslk3ZWew43Sai6ZiiOchcztUrrZUDn15p4FLPi9es_9eviB0" height="180" id="imgf000003_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019123066/pic/4SgdyzMwTHtZzB8LOoHDNq_TExYgDNtSFIccIa-x8PkrXETcrmuRDmnyeJxdSX81FXWSwKOY4yXRLh4Qv7euM_mv2h-letFFs6xycOHhRkTiydhMbRMdCdNEgDrslk3ZWew43Sai6ZiiOchcztUrrZUDn15p4FLPi9es_9eviB0" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="439" /><br />c eme</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
This process has several drawbacks like cyclization reaction involve use of TBAF and THF. Use of expensive TBAF, leads to high cost in the production and therefore uneconomical for industrial production, whereas use of THF during this reaction has limitation due to peroxide contents. . Similarly diethyl ether is a potential fire hazard and can form peroxides rapidly and thus should be avoided in commercial scale production. Above cyclization is also carried out in presence of DMF and CDI at l20°C.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Similar approach was reported in W02008094053 which describes preparation of opicapone by one pot cyclization of 3,4-dibenzyloxy-5-nitrobenzoic acid with (Z)-2,5-dichloro-N'-hydroxy-4,6-dimethylnicotinimidamide using N,N'-Carbonyl diimidazole in N,N'-dimethylformamide followed by heating the reaction mixture at l35°C for 5 hours to obtain l,2,4-oxadiazole derivative. This oxadiazole derivative was purified by recrystallization from isopropyl alcohol. Further oxidation using urea hydrogen peroxide complex followed by o-debenzylation using boron tribromide (BBr<span style="font-size: 12px; height: 0px; line-height: 0; position: relative; top: 0.5ex; vertical-align: baseline;">3</span>) was achieved to obtain Opicapone.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
This process also suffers from drawback like use of elevated temperature (l35°C) and use of expensive BBr<span style="font-size: 12px; height: 0px; line-height: 0; position: relative; top: 0.5ex; vertical-align: baseline;">3</span>.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
US 9,126,988 also disclose process for the preparation of opicapone, whichinvolves several chemical steps: 1) nitrating vanillic acid in presence of nitric acid in acetic acidfollowed by recrystallization with acetic acid to get nitro compound with yield 40-46%; 2)which converted into acid chloride compoundby treating it with thionyl chloride in presence of catalytic amount of N, N-dimethylformamide in dichloromethane or l,4-dioxane; 3) condensing acid chloride compound with (Z)-2, 5-dichloro-N'-hydroxy-4, 6-dimethylnicotinimidamide in presence of excess amount of pyridine in N,N-dimethyl acetamide/ tetrahydrofuran/ dichloromethane or l,4-dioxane at 5-10 °C and then heating the reaction mixture at H0-l l5°C for 5-6 hours to get 1,2,4-oxadiazole compound; 4) which was oxidized using urea hydrogen peroxide complex and trifluoroacetic anhydride in dichloromethane to get N-oxide product which was purified by repeated recrystallization (2 or more times) using mixture of formic acid and toluene to get pure product with 59% yield; 5) O-methyl group was deprotected using aluminium chloride and pyridine in N-Methyl pyrrolidone at 60 C to obtain opicapone. After completion of reaction, the crude product was isolated by quenching the reaction mixture in mixture cone. HC1: water followed by filtration, washing with water: isopropyl alcohol and recrystallization from ethanol. Final purification was done in mixture of formic acid and isopropyl alcohol. Above synthetic steps are outline in scheme 2.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019123066/pic/xt5p325y4uJUQn4AD1mhEsiVZfqA3G4oIzzqKf_kOQF5MazZnDSfNKOOOhvHy3wXEe1rodygvGk-2hbqWtIX4bPpRqIYQLi8LUfabtRvLv0QxxnyAWRTDRcH8TOcnolLIfPaHvMRpA-6f7upbovYzzwvVAywJqUt1kEv90PALx4" height="186" id="imgf000004_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019123066/pic/xt5p325y4uJUQn4AD1mhEsiVZfqA3G4oIzzqKf_kOQF5MazZnDSfNKOOOhvHy3wXEe1rodygvGk-2hbqWtIX4bPpRqIYQLi8LUfabtRvLv0QxxnyAWRTDRcH8TOcnolLIfPaHvMRpA-6f7upbovYzzwvVAywJqUt1kEv90PALx4" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="478" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Scheme 2</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
As described above, cited literature processes suffers from some drawbacks like elevated reaction temperature and longer duration, use of excess amount of pyridine for cyclization reaction which is difficult to handle on large scale preparation. Another drawback of reported procedure is unsafe workup procedures for isolation of N-oxide as residual peroxides were not quenched by any peroxide quenching reagent. Also repeated crystallizations (more than two) are required for purification of N-oxide derivative to remove unreacted starting material which is tedious and time consuming process. Also for its purification mixture of solvent i.e. formic acid and toluene are used which hamper its recovery and is not cost effective process.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
US 9,126,988 also disclosed process for the preparation of 2,5-dichloro-N'-hydroxy-4,6-dimethylnicotinimidamide compound of formula (IV), in which 2,5-dichloro-4,6-dimethylnicotinonitrile compound of formula (VIII) was reacted with hydroxyl amine solution in the presence of catalytic amount of 1,10-phenanthroline in methanokwater at 70-80°C for 6 hrs. After completion reaction mixture was cooled, filtered and dried to get 2,5-dichloro-N'-hydroxy-4,6-dimethylnicotinimidamide of formula (IV) (88%).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Bioorganic & Medicinal Chemistry 13 (2005) 5740-5749, Karl Bailey et.al. disclosed process for preparation of 3,4-dimethoxy-5-nitro benzoic acid compound of formula (Ilia). In which a solution of Cr0<span style="font-size: 12px; height: 0px; line-height: 0; position: relative; top: 0.5ex; vertical-align: baseline;">3</span>, concentrated H<span style="font-size: 12px; height: 0px; line-height: 0; position: relative; top: 0.5ex; vertical-align: baseline;">2</span>S0<span style="font-size: 12px; height: 0px; line-height: 0; position: relative; top: 0.5ex; vertical-align: baseline;">4</span> and water was added to solution of 3,4-dimethoxy-5-nitro benzaldehyde in acetone and water. The obtained solution was stirred for 24 hrs and then isopropanol was added to eliminate any unreacted Cr(VI) species to obtained crude green sludge, which was extracted into ethyl acetate and washed with 1M HC1 to remove remaining Cr(III) species. Obtained product is then recrystallized from water and ethanol to yield 69 % of 3,4-dimethoxy-5-nitro benzoic acid compound of formula (Ilia).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
US 5,358, 948 also disclosed process for preparation of 3,4-dimethoxy-5-nitro benzoic acid compound of formula (Ilia). In which a solution of potassium permanganate was added to a solution of 3,4-dimethoxy-5-nitro benzaldehyde in acetone. The mixture was then stirred at 20°C for 18 hrs togives 3,4-dimethoxy-5-nitro benzoic acid compound of formula (Ilia) with 72% yield.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Disadvantage of the above cited literature (Karl Bailey et.al and US’ 948) processes are harsh, acidic condition and involve expensive reagents. The process is both uneconomical and time consuming, (18-24 hrs) hence not suitable for commercial production.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Oxidation of aldehydes to the corresponding carboxylic acids, on the other hand, are commonly carried out using KMn04 in acidic or basic media, or K2Cr207 in acidic medium or chromic acid. These heavy metal-based reagents are hazardous and the protocols produce metal wastes that require special handling owing to their toxicities.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
It is therefore, desirable to provide efficient, robust, alternative simple process, cost effective process which is used on a large scale and allows product to be easily workup, purified and isolate without the disadvantages mentioned above.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Example 1: Preparation of 3, 4-dimethoxy-5-nitro benzoic acid (Ilia).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
To a cooled solution of 3,4-dimethoxy-5-nitro benzaldehyde (lOOg, 0.474 mole) in DMF (500 ml) was added Oxone (294.1 g, 0.478 mole) lot wise at 5-10 °C. Reaction mixture was stirred for 30 minutes at same temperature, allowed to warm to room temperature and stirred for 2-3 hours. After completion, the reaction mixture was diluted with 1500 ml of water and filtered. The solid was washed with water until all peroxides removed and drying at 50°C under vacuum afforded 3,4-dimethoxy-5-nitro benzoic acid of formula (Ilia) (l02g, 95%).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Example 2: Preparation of 2 ,5-dichloro-N' {[(3,4-dimethoxy-5-nitrophenyl) carbonyl]oxy}-4, 6-dimethylpyridine-3-carboximidamide (Va)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
To a solution of 3,4-dimethoxy-5-nitro benzoic acid of formula (Ilia) (5 g, 0.022 mole)in 60 ml of acetonitrile was added N,N'-Carbonyldiimidazole (4.28g, 0.026 mole) in portions and the reaction mixture was stirred at room temperature for 1.5 hours. Then was added 2,5-dichloro-N'-hydroxy-4,6-dimethylnicotinimidamide of formula (IV) (5.4g, 0.023 mole) and stirring was continued for 3 hours. After completion, the reaction mixture was diluted with 240 ml of water and 300 ml of dichloromethane. Organic layer was separated and washed with water (200 ml x 3), concentrated under reduced pressure to obtain 2,5-dichloro-N'{ [(3,4-dimethoxy-5-nitrophenyl)carbonyl]oxy}-4,6-dimethylpyridine-3-carboximidamide of formula (Va) (8.67g, 88.9%).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Example 3: Preparation of 2, 5-dichloro-3-[5-(3, 4-dimethoxy-5-nitrophenyl)-l,2,4-oxadiazol-3-yl]-4,6-dimethylpyridine (Via)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
To a solution of 2,5-dichloro-N'{ [(3,4-dimethoxy-5-nitrophenyl)carbonyl]oxy}- 4,6-dimethylpyridine-3-carboximidamide of formula (Va) (0.5g, 0.0011 mole)in 10 ml of dichloromethane was added isopropyl alcohol (1 ml) followed by KOH (0.075g, 0.001 lmole) dissolved in 0.1 ml of water. After stirring for 1 hour at room temperature the reaction mixture was diluted with 30 ml of dichloromethane and washed with water (lOml x 2). The reaction mixture was concentrated under reduced pressure to obtain 2,5-dichloro-3-[5-(3,4-dimethoxy-5-nitrophenyl)-l,2,4-oxadiazol-3-yl]-4,6-dimethylpyridine of formula (Via) (0.4 g, 83%).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Example 4: Preparation of 2,5-dichloro-3-[5-(3,4-dimethoxy-5-nitrophenyl)-l,2,4-oxadiazol-3-yl]-4,6-dimethylpyridine (Via) (One pot cyclization procedure)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
To a stirred solution of 3,4-dimethoxy-5-nitro benzoic acid formula (Ilia) (lOOg, 0.44 mol)in 1000 ml of dichloromethane was added N,N'-Carbonyldiimidazole (86g, 0.53 mole) in portions and the reaction mixture was stirred at room temperature for 1.5 hours. Then was added 2,5-dichloro-N'-hydroxy-4,6-dimethylnicotinimidamide of formula (IV) (l08g, 0.46 mole) and stirring was continued for 3 hours. Isopropyl alcohol (200 ml) and KOH (30g, 0.53 mole) dissolved in 30 ml of water was then added to the reaction mixture. After stirring for 1 hour at room temperature the organic layer was washed with water (1000 ml x 2). Solvent was distilled out at atmospheric pressure, added 1000 ml of isopropyl alcohol and suspension was stirred at 55-60°C for 2 hours. The reaction mixture was allowed to cool to room temperature, stirred for 2 hours and filtered. The solid was washed with isopropyl alcohol (100 ml x 2) and dried at 50-60°C under vacuum to obtain 2,5-dichloro-3-[5-(3,4-dimethoxy-5-nitrophenyl)-l,2,4-oxadiazol-3-yl]-4,6-dimethylpyridine of formula (Via) (l60g, 85%).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Example 5: Preparation of 2,5-dichloro-3-[5-(3,4-dimethoxy-5-nitrophenyl)-l,2,4-oxadiazol-3-yl]-4,6-dimethylpyridine (Via) (cyclization procedure using thionyl chloride)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
To a stirred solution of 3,4-dimethoxy-5-nitro benzoic acid of formula (Ilia) (lOOg, 0.44 mol) in 500 ml of dichloromethane was added 0.4 ml of N,N-dimethyl formamide followed bythionyl chloride (82g, 0.69 mole) drop wise at room temperature and the reaction mixture was heated at 40°C for 4 hours. After completion, dichloromethane and excess of thionyl chloride was distilled out under reduced pressure at 40°C. The obtained residue was dissolved in 500 ml of dichloromethane and was added to pre-cooled mixture of 2,5-dichloro-N'-hydroxy-4,6-dimethylnicotinimidamide of formula (IV) (l03g, 0.44 mole) and triethyl amine (73 ml, 0.53 mole) in 500 ml of dichloromethane at 5°C. After addition, the reaction mixture was allowed to warm to 25-30°C and stirred for 2 hours. Then was added isopropyl alcohol (200 ml) followed by KOH (62g, 1.1 mole) dissolved in 62 ml of water and stirring was continued for 2 hours at room temperature. The reaction mixture was washed with 1000 ml of water, 1N aqueous HC1 solution (500ml x 2) followed by 500 ml of 5% aqueous sodium bicarbonate solution. Solvent was distilled out at atmospheric pressure at 40°C. To the residue was added 1200 ml of methanol and the suspension was stirred at 55-60°C for 2 hours. The reaction mixture was allowed to cool to room temperature, maintained for 2 hours and filtered. The solid product was washed with methanol (100 ml x 2) and dried at 50°C under vacuum to obtain 2,5-dichloro-3-[5-(3,4-dimethoxy-5-nitrophenyl)- 1, 2, 4-oxadiazol-3-yl]-4, 6-dimethyl pyridine of formula (Via) (l65g, 88%).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Example 6: Preparation of 2,5-dichloro-3-[5-(3,4-dimethoxy-5-nitrophenyl)-l,2,4-oxadiazol-3-yl]-4,6-dimethylpyridine-l-oxide (Vila)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
To a cooled solution of 2,5-dichloro-3-[5-(3,4-dimethoxy-5-nitrophenyl)-l,2,4-oxadiazol-3-yl]-4,6-dimethylpyridine of formula (Via) (25g, 0.0588 mole) in 300 ml of dichloromethane was added urea hydrogen peroxide complex (l8.26g, 0.194 mole) in portions followed by trifluoroacetic anhydride (37g, 0.176 mole) maintaining temperature below l0°C. After stirring at 5-l0°C for 1 hour, the reaction mixture was allowed to warm to room temperature and stirred for 5 hours. The reaction mixture was washed with water (300 ml x 2), 300ml of 5% aqueous sodium sulphite solution to quench residual peroxides and finally with 300 ml of water. Dichloromethane layer was distilled out at atmospheric pressure. The obtained solid was suspended in 250 ml of ethyl acetate and 12.5 ml of cone. HC1 was added at room temperature. The resulting suspension was then stirred at 65-70°C for 1 hour and allowed to cool to room temperature. After stirring for 2 hours, the reaction mixture was filtered, solid was washed with ethyl acetate (50 ml x 2) followed by water (50 x 3) and dried at 50°C under vacuum to obtain (5-(3,4-bis(methoxy)-5-nitrophenyl)-l,2,4-oxadiazol-3-yl)-2,5-dichloro-4,6-dimethylpyridine 1 -oxide of formula (Vila) (18g, 69%).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Example 7: Preparation of 5-[3-(2,5-Dichloro-4,6-dimethyl-l-oxido-3-pyridinyl)-l,2,4-oxadiazol-5-yl]-3-nitro-l,2-benzenediol (Opicapone, I)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
To a cooled solution of 2,5-dichloro-3-[5-(3,4-dimethoxy-5-nitrophenyl)-l,2,4-oxadiazol-3-yl]-4,6-dimethylpyridine-l-oxide of formula (Vila) (25g, 0.056 mole) in 200 ml of N,N-Dimethylformamide was added AlCl<span style="font-size: 12px; height: 0px; line-height: 0; position: relative; top: 0.5ex; vertical-align: baseline;">3</span> (l l.34g, 0.085 mol) at 5-l0°C in portions. The reaction mixture was then heated at 85 °C for 6 hours. After completion, the reaction mixture was cooled to room temperature and poured onto cold mixture of cone. HC1 (200 ml) and water (400 ml). The reaction mixture was filtered, solid washed with water (100 ml X 3) followed by methanol (50 ml x2) and dried at 50°C under vacuum to obtain 5-[3-(2,5-Dichloro-4, 6-dimethyl- l-oxido-3-pyridinyl)- 1,2, 4-oxadiazol-5-yl]-3-nitro- 1,2-benzenediol of formula (I) (22 g, 94%).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Example 8: Preparation of 2, 5-dichloro-N'-hydroxy-4, 6-dimethyl nicotinimidamide of formula (IV)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
To a suspension of 2,5-dichloro-4,6-dimethylnicotinonitrile of formula (VIII) (lOOg, 0.497 mole) in l,4-dioxane (400 ml) and water (900 ml) was added 50% aqueous solution of hydroxyl amine (l30g) and N-methyl morpholine (50.2g, 0.497) at room temperature. The reaction mixture was then stirred at 70-80°C for 10 hours. After completion, water (1100 ml) was added to the reaction mixture at 70-80°C and allowed to cool to room temperature. After stirring for 2 hours the reaction mixture was filtered, solid was washed with water (200ml x 3) and dried at 50°C under vacuum to obtain 2,5-dichloro-N'-hydroxy-4,6-dimethylnicotinimidamide of formula (IV) (68 g, 58%).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Example 9:Preparation of 2,5-dichloro-N'-hydroxy-4, 6-dimethylnicotinimidamide of formula (IV)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
To a suspension of 2,5-dichloro-4,6-dimethylnicotinonitrile of formula (VIII) (lOOg, 0.497 mole) in methanol (600 ml) and water (800 ml) was added 50% aqueous solution of hydroxyl amine (l30g) and 2-methylpyrazine (7.02g, 0.0746) at room temperature. The reaction mixture was then stirred at 70-80°C for 6-8 hours. After completion, water (800 ml) was added to the reaction mixture at 70-80°C and allowed to cool to room temperature. After stirring for 2 hours the reaction mixture was filtered, solid was washed with water (200ml x 3) and dried at 50°C under vacuum to obtain 2,5-dichloro-N'-hydroxy-4,6-dimethylnicotinimidamide of formula (IV) (82 g, 70%).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Example 10: Preparation of 2,5-dichloro-N'-hydroxy-4,6-dimethylnicotinimidamide of formula (IV)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
To a solution of hydroxylamine hydrochloride (86.4g, 1.243 mole) in 400 ml of water was added LiOH.H<span style="font-size: 12px; height: 0px; line-height: 0; position: relative; top: 0.5ex; vertical-align: baseline;">2</span>0 (52.7g, 1.25 mole) at room temperature and heated at 50°C for 30 minutes. To the reaction mixture was added 300 ml of methanol, 2-methylpyrazine (3.5 lg, 0.037 mole) and 2,5-dichloro-4,6-dimethylnicotinonitrile of formula (VIII) (50g, 0.248 mole) at 50°C. The reaction mixture was then stirred at 70-80°C for 6 hours. After completion, water (500 ml) was added to the reaction mixture at 70-80°C and allowed to cool to room temperature. After stirring for 2 hours the reaction mixture was filtered, solid was washed with water (lOOml x 3) and dried at 50°C under vacuum to obtain 2,5-dichloro-N'-hydroxy-4,6-dimethylnicotinimidamide of formula (IV) (37.6 g, 64%).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Example 11: Purification of 5-[3-(2,5-Dichloro-4,6-dimethyl-l-oxido-3-pyridinyl)-l,2,4-oxadiazol-5-yl]-3-nitro-l,2-benzenediol (Opicapone, I)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
The crude 5-[3-(2,5-Dichloro-4, 6-dimethyl- l-oxido-3-pyridinyl)- 1,2, 4-oxadiazol-5-yl]-3-nitro-l,2-benzenediol of formula (I)(25.0g) was suspended in 250 ml of N,N-dimethylformamide and reaction mixture was heated at 60-65°C to obtain clear solution. Then was added 500 ml of methanol and reaction mixture was cooled to room temperature. After stirring for 2-3 hours, the reaction mixture was filtered, solid was washed with methanol and dried at 50°C under vacuum to obtain 5-[3-(2, 5-Dichloro-4, 6-dimethyl- l-oxido-3-pyridinyl)- 1,2, 4-oxadiazol-5-yl]-3-nitro-l,2-benzenediol of formula (I) (22.0 g, 88%).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px;">
/////////////New patent, Opicapone, WO 2019123066, Unichem, <a data-mce-href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019123066&tab=PCTDESCRIPTION" href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019123066&tab=PCTDESCRIPTION" style="color: #222222;">WO2019123066</a></div>
</div>
DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com6tag:blogger.com,1999:blog-4738331378048275307.post-88478711791020419712019-05-15T06:43:00.001-07:002019-05-15T06:43:53.246-07:00GUEST POST, POOJA KUMAR, CURRENT SCENARIO OF PATENTS IN INDIA<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img alt="Image result for INDIA" data-mce-src="https://previews.123rf.com/images/vectomart/vectomart1402/vectomart140200507/25730957-illustration-of-indian-map-showing-culture-of-india.jpg" src="https://previews.123rf.com/images/vectomart/vectomart1402/vectomart140200507/25730957-illustration-of-indian-map-showing-culture-of-india.jpg" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<strong>CURRENT SCENARIO OF PATENTS IN INDIA</strong></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
By Ms. Pooja Kumar</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<strong>(Registered Patent agent/Director of Innove Intellects)</strong></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Email id: <a data-mce-href="mailto:pooja@innoveintellects.com" href="mailto:pooja@innoveintellects.com" style="color: #222222;">pooja@innoveintellects.com</a></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Patent is a monopoly, exclusive rights given to an individual or a company or an organization to make, sell, use and import an invention for a limited period of years. In India patents are granted to inventions that meets three important criteria namely novelty, inventive step and industrial applications. Patents can be given to either product or process. The product can be a device or apparatus or any formulations.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Over the years in India, people are getting serious about the protection of intangible property. And this can be observed by the below mentioned graph:</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="http://drugapprovalsint.com/wp-content/uploads/2019/05/Capture-1.jpg" src="http://drugapprovalsint.com/wp-content/uploads/2019/05/Capture-1.jpg" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
The WTO is the governing body at the international level, which covers Trade Related Aspects<br />of Intellectual Property Rights (TRIPs) and several allied agreements. The World Intellectual<br />Property Organization (WIPO) is another international organization that helps and ensures the<br />rights of creators and owners of Intellectual Property are protected worldwide and that inventors<br />thus, recognized and rewarded for their ingenuity.<br />PATENTS IN THE INDIAN SCENARIO:</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
The laws pertaining to Patent in India is governed by the Patents Act, 1970 which has been<br />amended twice by The Patents (Amendment) Act, 1999 and The Patents (Amendment) Act,<br />2002.<br />Now-a-days, India has become one of the top patent filers in the world. This graph shows the<br />efforts of our government and the people who take the initiative to aware people about<br />Intellectual Property rights (IPR). Indian government has started various startup schemes which<br />led to the 12-fold increase in the establishment of startups in last year. India, which has 1.6<br />million active trademarks, registered a total of 339,692 new one last year, 287,139 from domestic<br />and 52,553 of foreigners, according to the WIPO. Also, government has been provided different<br />facilities such as early publication, expedited examination, online filing procedures, online<br />hearings, etc to make the procedure of getting patent easier. Recently, Indian Oil Corporation<br />emerges as the one of the top patent filing organization in India.<br />Patent applications are divided into one or more types by the patent office, and as per Indian<br />Patent Office, a patent applicant can type multiple kinds of patent applications. The documentary<br />requirements and other formalities for each patent application type are different, and hence it is<br />crucial to identify the exact type of patent application before initiating the patent filing process.<br />While filing for a patent, few things are to be considered. The first is which type of application<br />you are filling. In patents, there are five types of patent applications:<br />(a) Ordinary Application is the application which is made at the Patent Office for grant of<br />patent and does not contain any priory claims of application made in any convention country or<br />countries.<br />(b) Convention Application is a subsequent application made under Section 135 of the Patent<br />Act, 1970, claiming the priority date on the application which was filed earlier, where applicant<br />has already filed an application for grant of patent in a convention country or countries.<br />(c) PCT Application stands for Patent Cooperation Treaty. The Patent Cooperation Treaty<br />(PCT) is an international patent law treaty, concluded in 1970. It provides a unified procedure for<br />filing patent applications to protect inventions in each of its contracting states/countries. The<br />applicant gets 30-31 months’ time to enter into these countries for getting protection on its<br />invention, wherein such an application is called PCT National Phase Application. In addition,<br />patent applicants can file a PCT International Application, either with the Indian Patent Office as<br />Receiving Office, or directly with International Bureau (IB) of the World Intellectual Property<br />Organization (WIPO).<br />(d) Divisional Application is filed under two circumstances:<br />When the applicant believes that his/her application contains more than one invention and the<br />other inventions can be differentiated from the original application and filed as a separate<br />application.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
When the controller of patent is of the opinion that the application contains of claims for more<br />than one invention.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
STEPS INVOLVED PATENT FILING TO GRANT:<br />1. The Filing of an application for grant of a patent accompanied by either a provisional<br />specification or a complete specification.<br />2. In case provisional specification accompanies the original application, then filing of the<br />complete specification within 12 months from the date of filing of the provisional<br />specification.<br />3. After the expiry of 18 months time the patents get published on Indian patent office journal.<br />4. Filing of examination request can be made on form 18 within 48 months from the date of<br />filing.<br />5. The patent office send FER response to the applicant and the said response should filed<br />within 6month of time period.<br />6. Pre grant opposition can be applied by any interested person after publication and before<br />grant of patent.<br />7. Finally Grant and sealing of the patent.<br />8. Renewal or Maintenance fees paid by the applicant after the grant of patent</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
BENEFITS OF PATENTS FOR STARTUPS<br />Patents have become the yardstick for growth for the startup industry. Disruptive start-ups are<br />currently challenging the incumbent industries with their patented ideas. Having a patent in their<br />name helps the startups to get noticed in the industry and also helps in securing funding from<br />potential investors. In 2015, the Government of India announced its flagship initiative of<br />“Startup India” and offered various incentives for businesses that drives entrepreneurship and<br />innovation. The key takeaway points from the initiative are as follows:<br /> Simplifying the startup process with Single Window Clearance through a mobile app<br /> Fund of funds with a total corpus Rs 10,000 crore (Covered for four years)<br /> Compliance based Self-certification<br /> Start-up India hub – A single point of communication for the entire Startup ecosystem<br /> Patent protection – Fast track mechanisms for start-ups patent applications<br /> Exception from Capital Gain Tax and tax on earnings for three years)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Exemption from tax for incubators investing above Fair Market Value<br /> Faster Exits (90-day exit window)<br /> New initiatives for IPR rights protection<br /> Encourage entrepreneurship through Credit Guarantee Fund (Rs 500 crore per year)<br /> Promoting entrepreneurship through Atal Innovation Mission<br /> Innovation-centred initiatives for students – Five lakh schools to target ten lakh children<br />for innovation program.<br /> Establishing 35 new incubators in institutions<br />The Patents Act, 1970 has also made special provisions for startups and small entities via the<br />amendment done in 2016. Rule 24C allows for expedited examination of patent applications, if<br />the applicant is a small entity or a startup. For a company to be recognized as a startup, it must<br />satisfy the following criteria:<br /> The company is enrolled as a Private Limited company<br /> Its age should not be more than five years<br /> Its turnover has not exceeded INR 25 crore in any financial year<br /> It is working towards innovation, development, and commercialization of new product or<br />services driven by technology<br /> It has not been formed by reconstruction of an existing business already in operation or as<br />a subsidiary.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
PATENTS AND PHARMACEUTICALS<br />Since India became a TRIPS member in 1995, the Government of India had to amend the India<br />Patent Act, 1970. Prior to 2005, product patents were not allowed, only patents to novel<br />processes were granted and that too for a period of only 14 years. This all changed after 2005,<br />when the new act allowed the product patents especially of pharmaceutical products and the term<br />of patent was extended up to 20 years.<br />A pharmaceutical patent claim may cover any one of the following:<br /> Active ingredient (API) independently<br /> API along with formulations, isomers, salts, prodrugs etc<br /> A manufacturing process<br /> A manufacturing process and a product<br />Since the amendment of 2005, it has been difficult for foreign pharmaceutical companies to get<br />their drugs patented in India, since the majority of the inventions have been slight alterations of<br />the already existing drugs. Section 3(d) of the Indian Patents Act, 1970 forbids against such<br />“evergreening” of drugs as is evident from the Novartis case. In 2013, after decades long battle,</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
the Supreme Court promptly upheld the decision of the lower court and the patent office by<br />saying that the invention was a slight modification of the known drug (disclosed in 1993) and<br />that the company did not provide enough evidence to distinguish it from the prior art. This<br />stringent patent laws have allowed the development of generic drugs, which the people from<br />even the lower socio-economic groups can afford.<br />About the author:<br />POOJA KUMAR<br />She is the founder and director of Innove Intellects and is also a registered patent agent and start-<br />up facilitator with the Government of India and having more than 12+ years of experience in<br />searching, drafting, and filing patent application for diverse companies, organizations and<br />universities. Pooja has worked with Sanshadow Consultants as a Patent Consultant and also with<br />Amity University in IPR cell. She has also been involved in conducting training and awareness<br />programs related to Intellectual Property Rights in over 20+ universities. She has also been<br />awarded for women entrepreneur in 2018 by GECL foundation. She had also helped university<br />in developing IPR Policy and IPR cell. Till now she had filed more than 200 application in India<br />She had opened IPR Cell facility in Swami Vivekanad University Meerut in May 2018. Many of<br />applications from different IPR category like copyright design and trademark has been granted<br />from the patent offices. Patent status is still pending with the Indian patent office.<br />Disclaimer<br />Actual resolution of legal issues depends upon many factors, including variations of fact<br />and laws of the land. Though the author has taken utmost care in the preparation of this<br />article, the information contained herein is not intended to constitute any legal advice and<br />the firm cannot accept any responsibility towards those who rely solely on the contents of<br />this article without taking further specialist advice. The reader should always consult with<br />legal counsel before taking action on matters covered by this article.<br />Reference:<br />1)India is granting patents like never before by Ananya Bhattacharya<br />2) https://drugpatentsint.blogspot.com/search/label/INDIA<br />3)https://www.spiegel.de/international/world/india-disregards-evergreening-drug-patents-to-<br />help-companies-and-poor-a-869601.html<br />4) https://www.dr-hempel-network.com/digital-health-startups/start-up-india/<br />5) http://www.mondaq.com/india/x/27903/Patent/Patents+The+Present+Indian+Scenario</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="http://drugapprovalsint.com/wp-content/uploads/2019/05/Capture-1-1.jpg" src="http://drugapprovalsint.com/wp-content/uploads/2019/05/Capture-1-1.jpg" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" /><img data-mce-src="http://drugapprovalsint.com/wp-content/uploads/2019/05/Capture-1-2.jpg" src="http://drugapprovalsint.com/wp-content/uploads/2019/05/Capture-1-2.jpg" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" /><img data-mce-src="http://drugapprovalsint.com/wp-content/uploads/2019/05/Capture-1-3.jpg" src="http://drugapprovalsint.com/wp-content/uploads/2019/05/Capture-1-3.jpg" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" /></div>
<div data-mce-style="font-weight: 400;" style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<a data-mce-href="http://drugapprovalsint.com/wp-content/uploads/2019/05/Capture-1-4.jpg" href="http://drugapprovalsint.com/wp-content/uploads/2019/05/Capture-1-4.jpg" style="color: #222222;"><img alt="capture-1" class="alignnone size-medium wp-image-8504" data-mce-src="http://drugapprovalsint.com/wp-content/uploads/2019/05/Capture-1-4-232x300.jpg" height="300" src="http://drugapprovalsint.com/wp-content/uploads/2019/05/Capture-1-4-232x300.jpg" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="232" /></a></div>
<div data-mce-style="font-weight: 400;" style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Pooja Kumar</div>
<div data-mce-style="font-weight: 400;" style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<strong><em>Founder & Director</em></strong></div>
<div data-mce-style="font-weight: 400;" style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Innove Intellects</div>
<div data-mce-style="font-weight: 400;" style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<strong>Mobile:</strong> +91-9910627125</div>
<div data-mce-style="font-weight: 400;" style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<strong>Email:</strong> <a data-mce-href="http://Info@innoveintellects.com/" data-saferedirecturl="https://www.google.com/url?q=http://Info@innoveintellects.com&source=gmail&ust=1557928136981000&usg=AFQjCNGyG8MIUcmVNjm6qLn-Xy5IADb1_Q" href="http://Info@innoveintellects.com/" style="color: #222222;">Info@innoveintellects.com</a>, <a data-mce-href="http://pooja@innoveintellects.com/" data-saferedirecturl="https://www.google.com/url?q=http://pooja@innoveintellects.com&source=gmail&ust=1557928136981000&usg=AFQjCNGFHvi2tJw-nlOkTebU8XpDpa3o5w" href="http://pooja@innoveintellects.com/" style="color: #222222;">pooja@innoveintellects.com</a></div>
<div data-mce-style="font-weight: 400;" style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<strong>Web:</strong> <a data-mce-href="http://www.innoveintellects.com/" data-saferedirecturl="https://www.google.com/url?q=http://www.innoveintellects.com&source=gmail&ust=1557928136981000&usg=AFQjCNF3edPR8xEyQMAw-fRk2X3C3UZH2g" href="http://www.innoveintellects.com/" style="color: #222222;">www.innoveintellects.com</a></div>
<div data-mce-style="font-weight: 400;" style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
pooja@innoveintellects.com</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<br /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
/////////GUEST POST, POOJA KUMAR, CURRENT SCENARIO, PATENTS, INDIA</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<br /></div>
</div>
DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com3tag:blogger.com,1999:blog-4738331378048275307.post-26017545282492290152019-04-17T02:30:00.002-07:002019-04-17T02:30:39.577-07:00VIXOTRIGINE, NEW PATENT, WO-2019071162, BIOGEN INC<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
VIXOTRIGINE, NEW PATENT, WO-2019071162, BIOGEN INC</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<a data-mce-href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019071162&redirectedID=true" href="https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019071162&redirectedID=true" style="color: #222222;">https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019071162&redirectedID=true</a></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
vixotrigine</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Process for preparing α-carboxamide pyrrolidine derivatives (particularly vixotrigine ) and its intermediates are modulators of use-dependent voltage-gated sodium channels</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Biogen, following the acquisition of Convergence Pharmaceuticals, that previously acquired clinical assets from GSK is developing vixotrigine a voltage-gated sodium channel 1.7 inhibitor, for the oral treatment of neuropathic pain, primarily trigeminal neuralgia.</div>
<table class="mce-item-table" style="border: 1px dashed rgb(187, 187, 187); color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px;"><tbody>
<tr><td style="border: 1px dashed rgb(187, 187, 187); font-family: inherit; font-size: inherit; padding: 5px 20px;"><b>CHEN, Weirong</b>; US</td></tr>
<tr><td style="border: 1px dashed rgb(187, 187, 187); font-family: inherit; font-size: inherit; padding: 5px 20px;"><b>COUMING, Vinny</b>; US</td></tr>
<tr><td style="border: 1px dashed rgb(187, 187, 187); font-family: inherit; font-size: inherit; padding: 5px 20px;"><b>IRDAM, Erwin</b>; US</td></tr>
<tr><td style="border: 1px dashed rgb(187, 187, 187); font-family: inherit; font-size: inherit; padding: 5px 20px;"><b>KIESMAN, William, F.</b>; US</td></tr>
<tr><td style="border: 1px dashed rgb(187, 187, 187); font-family: inherit; font-size: inherit; padding: 5px 20px;"><b>KWOK, Daw-long, A.</b>; US</td></tr>
<tr><td style="border: 1px dashed rgb(187, 187, 187); font-family: inherit; font-size: inherit; padding: 5px 20px;"><b>MACK, Tamera, L.</b>; US</td></tr>
<tr><td style="border: 1px dashed rgb(187, 187, 187); font-family: inherit; font-size: inherit; padding: 5px 20px;"><b>OPALKA, Suzanne, M.</b>; US</td></tr>
<tr><td style="border: 1px dashed rgb(187, 187, 187); font-family: inherit; font-size: inherit; padding: 5px 20px;"><b>PATIENCE, Daniel, B.</b>; US</td></tr>
<tr><td style="border: 1px dashed rgb(187, 187, 187); font-family: inherit; font-size: inherit; padding: 5px 20px;"><b>WALKER, Donald, G.</b>; US</td></tr>
<tr><td style="border: 1px dashed rgb(187, 187, 187); font-family: inherit; font-size: inherit; padding: 5px 20px;"><b>LIANG, Wenli</b>; US</td></tr>
</tbody></table>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
The invention relates to a novel process for preparing a-carboxamide pyrrolidine derivatives, in particular (2S, 5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide, and to novel intermediates for use in said process along with processes for preparing said intermediates.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<br /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
(2S, 5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide:</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/US3Zbn1A_m2U0hOOGDZE3zFAPNYAGqySsvnlzIcIxT5X7ABFuI73d9cWP34dNuzUNIGOu7GhDteJeKQtJqqUIaKIRESrGBj5Jy6WRZXgoQOvzN3eE1iy-ay0XeWuxqp4SxMVENgN6HeLo6GiQ2Z-0G4EBBix76JcLCCUni9XAaI" height="147" id="imgf000002_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/US3Zbn1A_m2U0hOOGDZE3zFAPNYAGqySsvnlzIcIxT5X7ABFuI73d9cWP34dNuzUNIGOu7GhDteJeKQtJqqUIaKIRESrGBj5Jy6WRZXgoQOvzN3eE1iy-ay0XeWuxqp4SxMVENgN6HeLo6GiQ2Z-0G4EBBix76JcLCCUni9XAaI" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="226" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
is described in WO 2007/042239 as having utility in the treatment of diseases and conditions mediated by modulation of use-dependent voltage-gated sodium channels. The synthetic preparation of (2S, 5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide is described in both WO 2007/042239 and WO 2011/029762.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 1a: Methyl (S)-5-(4-(benzyloxy)phenyl)-2-((iert-butoxycarbonyl)amino)-5-oxopentanoate (D1a) (Batch Process using Grignard Procedure)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/I2LHZqQpxcVctf82mdi4f7f_PrqGdnc6fUOoeG9B0pE7RAQIXBa2EUVqdK8DtpRVBm_QXt4s3XnROuJ2wlRPPGkcX7ltLfsVP9qPTUya2Ka44D8_brHDn0kG4YWnt7pMXPiH7CYqRr491C6ya8YklBOLcF1_3Ullxe_D4-OLlGI" height="126" id="imgf000036_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/I2LHZqQpxcVctf82mdi4f7f_PrqGdnc6fUOoeG9B0pE7RAQIXBa2EUVqdK8DtpRVBm_QXt4s3XnROuJ2wlRPPGkcX7ltLfsVP9qPTUya2Ka44D8_brHDn0kG4YWnt7pMXPiH7CYqRr491C6ya8YklBOLcF1_3Ullxe_D4-OLlGI" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="395" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with THF (350 kg) and the solvent was degassed by nitrogen sparging for about 30 min at 20 - 30 °C. To the degassed THF was charged l-(benzyloxy)- 4- bromobenzene (137 kg (1.78 equiv)). The solids were dissolved at 20 - 30 °C with agitation and under an inert atmosphere of nitrogen.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with Mg (21.3 kg (3.0 equiv)) and THF (131 kg) and the mixture was degassed by nitrogen sparging for about 30 min at 20 - 30 °C. To this mixture was added -5% of the 1-(benzyloxy)-4-bromobenzene - THF solution followed by heating to 50 - 60 °C under an inert atmosphere of nitrogen. With good agitation, DIBAL-H in toluene (1 M; 2.5 kg (0.01 equiv)) was added followed by heating the mixture to 60 - 70 °C and aging for about 1 h. The remaining amount of the 1-(benzyloxy)-4-bromobenzene - THF solution was added followed by a THF rinse (36 kg) of the reactor. The mixture was aged for about 1 h at 60 - 70 °C and was cooled to 20 - 30 °C under an inert atmosphere of nitrogen.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with THF (382 kg) and the solvent was degassed by nitrogen sparging for about 30 min at 20 - 30 °C. To the degassed THF was charged l-(ferf-butyl) 2-methyl (S)- 5- oxopyrrolidine 1 ,2-dicarboxylate (71 kg (1.0 equiv)), and the resulting solution was cooled to -60 to -70 °C under an inert atmosphere of nitrogen. To this solution was added the Grignard solution while maintaining a reaction temperature of <-60 °C. The reactor that contained the Grignard solution was rinsed with THF (61 kg) and the reaction was aged at -60 to -70 °C for about 1 h. The progress of the reaction was monitored (HPLC).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Upon completion, 2-propanol (56 kg) was added while maintaining a reaction temperature of -60 to -70 °C, and the reaction was aged for about 30 min. Water (296 kg) was added while maintaining a reaction temperature of <10 °C; the contents of the reactor were warmed to 20 - 30 °C following the addition. The pH of the mixture was adjusted to 6 - 7 by addition of 51 wt% acetic acid in water (70 kg). MTBE (220 kg) was added and the mixture was agitated for about 30 min. The layers were separated, the organic layer was clarified by filtration and was concentrated to about 3 - 4V. MTBE (220 kg) was added and the resulting solution was concentrated to about 3 - 4V. MTBE (150 kg) was added and the resulting solution was heated to 35 - 45 °C. n-Heptane (250 kg) was added slowly while maintaining a reaction temperature of 35 - 45 °C, the mixture was aged for 1 - 2 h, cooled to 0 - 5 °C and aged for 3 - 5 h. The solids were isolated by filtration, washed with n-heptane (74 kg) and dried in vacuo at 50 - 60 °C to constant weight to afford 96.7 kg (77.5%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 1 b: Methyl (S)-5-(4-(benzyloxy)phenyl)-2-((iert-butoxycarbonyl)amino)-5-</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
oxopentanoate (D1 b) (Batch Process using Grignard Procedure) (Alternative</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Procedure)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with degassed THF (1090 kg) and 1-(benzyloxy)-4-bromobenzene (329 kg (1.46 equiv)). The solids were dissolved at 20 - 25 °C with agitation and under an inert atmosphere of nitrogen.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with Mg turnings (31.9 kg (1.53 equiv)) and degassed THF (389 kg) under an inert atmosphere of nitrogen. To this mixture was added -5% of the l-(benzyloxy)-4-bromobenzene - THF solution (-70 kg) followed by heating to 50 - 60 °C. With good agitation, DIBAL-H in toluene (1.5M; 4.55 kg (0.0093 equiv)) was added followed by addition of toluene (2.16 kg) into the reactor through the charging line. The mixture was heated to 60</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
- 70 °C and aged for about 1 h. The remaining amount of the 1-(benzyloxy)-4-bromobenzene</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
- THF solution was added followed by a degassed THF rinse (51 kg) of the reactor. The mixture was aged for about 1 h at 60 - 70 °C and was cooled to 20 - 30 °C under an inert atmosphere of nitrogen.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with degassed THF (1090 kg) and 1-(te/f-butyl) 2-methyl (S)-5-oxopyrrolidine 1 ,2-dicarboxylate (208 kg (1.0 equiv)), and the resulting solution was cooled to -60 to -70 °C under an inert atmosphere of nitrogen. To this solution was added the Grignard solution while maintaining a reaction temperature of <-50 °C. The reactor that contained the Grignard solution was rinsed with degassed THF (208 kg) and the reaction was aged at -60 to -70 °C for about 1 h. The progress of the reaction was monitored (HPLC).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Upon completion, 2-propanol (164 kg) was added while maintaining a reaction temperature of <-40 °C, and the reaction was aged for 20 - 30 min. Water (100 kg) was added while maintaining a reaction temperature of <-20 °C; the contents of the reactor were warmed to -10 to -20 °C following the addition. The mixture was transferred into another reactor and water (940 kg) was added while maintaining a reaction temperature of <10 °C; the contents of the reactor were warmed to 20 - 30 °C following the addition. The pH of the mixture was adjusted to 6.0 - 7.0 by addition of 50 wt% acetic acid in water (-170 kg). MTBE (647 kg) was added and the mixture was agitated for 20 - 30 min. The layers were separated, and the organic layer was stirred for 20 - 30 min with a brine solution prepared from NaCI (48 kg) and water (390 kg). The layers were separated, the organic layer was clarified by filtration and the filtration apparatus was washed with THF (30 kg). The solution was concentrated to about 5.5 - 6X the input mass of 1-(te/f-butyl) 2-methyl (S)-5-oxopyrrolidine 1 ,2-dicarboxylate at a temperature of 45 - 50 °C. MTBE (647 kg) was added and the resulting solution was concentrated to about 5.5 - 6X the input mass of 1-(te/f-butyl) 2-methyl (S)-5-oxopyrrolidine 1 ,2-dicarboxylate at a temperature of 45 - 50 °C. MTBE (661 kg) was added and the resulting solution was concentrated to about 5.5 - 6X the input mass of 1 -(te/f-butyl) 2-methyl (S)-5-oxopyrrolidine 1 ,2-dicarboxylate at a temperature of 45 - 50 °C. MTBE (77 kg) was added, the solution was sampled and analysed for residual THF content (if the result was >15%, MTBE (661 kg) was added and the solution was concentrated at 45 - 50 °C to about 5.5 - 6X the input mass of 1-(te/f-butyl) 2-methyl (S)-5-oxopyrrolidine 1 ,2-dicarboxylate). The solution was cooled to 35 - 45 °C and n-Heptane (726 kg) was added slowly while maintaining a reaction temperature of 35 - 45 °C. The mixture was aged for 1 - 2 h, cooled to 15 - 25 °C over 2 - 3 h, cooled to 0 - 5 °C and aged for 3 - 5 h. The solids were isolated by centrifugation and washed with n-heptane (214 kg). The wet solids (-328 kg) were dissolved in THF (683 kg) at 40 - 50 °C. The solution was cooled to 35 - 45 °C and n-heptane (564 kg) was added slowly while maintaining a reaction temperature of 35 - 45 °C. The mixture was aged for 1 -2 h, cooled to 15 - 25 °C over 2 - 3 h, cooled to 0 - 5 °C and aged for 3 - 5 h. The solids were isolated by centrifugation, washed with n-heptane (167 kg) and dried in vacuo at 50 - 60 °C to constant weight to afford 252 kg (69%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 1c: Methyl (S)-5-(4-(benzyloxy)phenyl)-2-((fert-butoxycarbonyl)amino)-5-oxopentanoate (D1c) (Batch Process using Magnesium "ate" Procedure)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/y4OVJc5htDBFODwUhOnNMuKHXkqkeBhyVVYjkeoMrWksUEVqir2J_vd1c6ixPWrjkJcPtZXi4fLgpnL4yG6fKVrnqYxBs9jOgJfY-QtUjaIZgSyorIst-mB556IBHqt63jcC76olBYF037H7Jrm6kHf5cLUgbTo7ISkZxWqDiLw" height="102" id="imgf000039_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/y4OVJc5htDBFODwUhOnNMuKHXkqkeBhyVVYjkeoMrWksUEVqir2J_vd1c6ixPWrjkJcPtZXi4fLgpnL4yG6fKVrnqYxBs9jOgJfY-QtUjaIZgSyorIst-mB556IBHqt63jcC76olBYF037H7Jrm6kHf5cLUgbTo7ISkZxWqDiLw" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="457" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with THF (249 kg) and the solvent was degassed by nitrogen sparging for about 30 min at 20 - 30 °C. To the degassed THF was charged l-(ferf-butyl) 2-methyl (S)-5-oxopyrrolidine 1 ,2-dicarboxylate (71 kg (1.0 equiv)), and the resulting solution was stirred at 20 to 30 °C under an inert atmosphere of nitrogen.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with THF (460 kg) and the mixture was degassed by nitrogen sparging for about 30 min at 20 - 30 °C. To the degassed THF was charged 1-(benzyloxy)-4-bromobenzene (93 kg (1.2 equiv)) and the solution was degassed in triplicate. The solution was cooled to -40 to -50 °C under an inert atmosphere of nitrogen. To this solution was added /<span style="bottom: 1ex; font-size: 12px; height: 0px; line-height: 0; position: relative; vertical-align: baseline;">'</span>-PrMgCI - THF solution (51.3 kg, 2M; 0.36 equiv) while maintaining a reaction temperature of <-40 °C. To this solution was added n-BuLi - hexane solution (71.3 kg, 2.5M; 0.90 equiv) while maintaining a reaction temperature of <-40 °C. The contents of the reactor were aged at -40 to -50 °C for 1 - 1.5 h. The solution was cooled to -60 to -70 °C under an inert atmosphere of nitrogen.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
The 1-(te/f-butyl) 2-methyl (S)-5-oxopyrrolidine 1 ,2-dicarboxylate - THF solution was added to the reactor containing the organomagnesium "ate" solution while maintaining a reaction temperature of -60 to -70 °C; the contents of the reactor were aged for about 1 h. The progress of the reaction was monitored (HPLC).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Upon completion, 10% NH4CI solution (389 kg) was added while maintaining a reaction temperature of < -40 °C. Following the addition, the contents of the reactor were warmed to 20 - 30 °C. The pH of the mixture was adjusted to 6 - 7 by addition of 50 wt% acetic acid in water (24.4 kg). n-Heptane (97 kg) was added and the mixture was agitated for 20 - 30 min at 20 - 30 °C. The layers were separated and the organic layer was concentrated in vacuo to about 270 L at <50 °C. The contents of the reactor were cooled to 20 - 30 °C and n-heptane (490 kg) was added followed by slurry aging for 2 - 3 h. The slurry was cooled to 0 - 5 °C and aged for 2 - 3 h. The solids were isolated by filtration, washed with a solution composed of n-heptane (58 kg) and THF (25 kg) and were dried in vacuo at 50 - 60 °C to constant weight to afford 102.95 kg (82.5%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with the title compound (102.95 kg) and THF (469 kg). The contents of the reactor were warmed to 40 - 50 °C, aged for 1 - 2 h, cooled to 20 - 30 °C and concentrated to a volume of about 250 L. n-Heptane (490 kg) was added and the mixture was agitated for 2 - 3 h at 20 - 30 °C. The mixture was cooled to 0 - 5 °C and aged for 2 - 3 h. The solids were isolated by filtration, washed with n-heptane (213 kg) and dried in vacuo at 50 - 60 °C to constant weight to afford 87.95 kg (70.5%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 1d: Methyl (S)-5-(4-(benzyloxy)phenyl)-2-((fert-butoxycarbonyl)amino)-5-oxopentanoate (Did) (Batch Process using Turbo Grignard Procedure)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/vbCcCgjcn5Rbc0KR6vKzgbmtjbfl0X76yECl87fNnhHM2P3UXi0hVkFqHoQhPdK4Pp07kvd7HjZqbP34ExH8eFZf4pHZL9td5bTowLJduDzJ7-9tabtpewv92w-3GzQr9zS0BNsReoRWJHKKwhjnL1YX7E4HnW_ShmBwYBRTiyQ" height="114" id="imgf000041_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/vbCcCgjcn5Rbc0KR6vKzgbmtjbfl0X76yECl87fNnhHM2P3UXi0hVkFqHoQhPdK4Pp07kvd7HjZqbP34ExH8eFZf4pHZL9td5bTowLJduDzJ7-9tabtpewv92w-3GzQr9zS0BNsReoRWJHKKwhjnL1YX7E4HnW_ShmBwYBRTiyQ" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="459" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A clean 100 mL EasyMax reactor was swept with dry nitrogen, the flow was reduced and /<span style="bottom: 1ex; font-size: 12px; height: 0px; line-height: 0; position: relative; vertical-align: baseline;">'</span>-PrMgCI-LiCI complex in THF (41.7g, 1.3M, 1.0 eq) was added to the reactor and the temperature was set to 20 °C. Bis(dimethylamino)ethyl ether (9.13 g, 1.0 eq) was added in a single portion, the mixture was stirred for 5 min, and 4-benzyloxybromobenzene (15.0 g, 1.0 eq) was added in a single portion. The reaction was heated to 40°C under an inert atmosphere of nitrogen and held at this temperature until full conversion was observed (ca. 3.5h).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A clean 100 mL EasyMax reactor was swept with dry nitrogen, the flow was reduced and dry THF (45 mL). 1-(te/f-butyl) 2-methyl (S)-5-oxopyrrolidine 1 ,2-dicarboxylate (5.0 g, 1.0 eq) was charged in a single portion and the solution was cooled to -35 °C under an inert atmosphere of nitrogen. The Grignard solution (26.4 mL, 0.85M, 1.1 eq) was then added at a rate of 0.5 mL/min while maintaining a reaction temperature of <-30°C. The progress of the reaction was monitored (HPLC). Upon completion the reaction was neutralized by the addition of a 14.6 wt% AcOH/water solution (24 mL). The reaction was then warmed to -10 °C, then to 0 °C. A 20% aqueous NH<span style="font-size: 12px; height: 0px; line-height: 0; position: relative; top: 0.5ex; vertical-align: baseline;">4</span>CI solution (10.3 g) was added followed by a pH adjustment with 1 M HCI (14 mL), then with 6M HCI to an endpoint of pH 1. The reaction mixture was transferred to a separatory funnel with the aid of 25 ml of THF. The phases were separated and the organic layer washed with saturated aqueous NaCI solution (16 g). The organic layer was concentrated under reduced pressure at <50°C to afford a crude product solution (19.4 g).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
The crude product solution was transferred to a clean 100 mL EasyMax reactor and was heated to 35 °C. Heptane (20 mL) was then added over about 30 sec. The mixture was cooled to 10°C and held for about 30 min. The solids were filtered, washed twice with 2: 1 heptane/MTBE mixture (14 mL) and dried to constant weight to afford 4.147 g (47%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 1e: Methyl (S)-5-(4-(benzyloxy)phenyl)-2-((fert-butoxycarbonyl)amino)-5-oxopentanoate (Die) (Flow Process using Intermittent Continuous Stirred Tank Reactor)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/r7zXlAoCHg_RneDEQHNkRr9zs7TEjmZ3QovZc6EeJd5K6ZsTvLl7Ad0WxIVyeSYbDe76ACC0XeD4iMU8nMLlFRo-3jUQhw7mMS4hnksd5TyZvoEarZtX9iczVRNwcAW44IC10cy6GiCNYc0Xo4-8DPqo1J07x0CkJAZGxX8jZJY" height="117" id="imgf000042_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/r7zXlAoCHg_RneDEQHNkRr9zs7TEjmZ3QovZc6EeJd5K6ZsTvLl7Ad0WxIVyeSYbDe76ACC0XeD4iMU8nMLlFRo-3jUQhw7mMS4hnksd5TyZvoEarZtX9iczVRNwcAW44IC10cy6GiCNYc0Xo4-8DPqo1J07x0CkJAZGxX8jZJY" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="396" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Reactor 1 was charged with 1-(benzyloxy)-4-bromobenzene (145 g (1.0 eq)) and the reactor was flushed with nitrogen. THF (490 g) was added and solids were dissolved at 20 - 30 °C by agitation; the solution was kept under an inert atmosphere of nitrogen.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Reactor 2 was charged with Mg (13.66 g (1.02 eq relative to reactor 1 charge)) and the reactor was flushed with nitrogen. Iodine (0.14 g (0.001 eq relative to the 1-(benzyloxy)-4-bromobenzene charge)) was charged followed by addition of 5% of the prepared 1-(benzyloxy)-4-bromobenzene - THF solution. The contents of the reactor were warmed to 50 - 65 °C and after color dissipation, the remainder of the prepared 1-(benzyloxy)-4-bromobenzene - THF solution (Reactor 1) was added while maintaining a reaction temperature of 50 - 70 °C. The contents of the reactor were stirred at 60 - 70 °C for about 1 h, cooled to 20 - 30 °C and held under an inert atmosphere of nitrogen.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Grignard Solution Batch 1</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Reactor 3 was charged with 1-(benzyloxy)-4-bromobenzene (2.755 kg (1.0 eq)) and the reactor was flushed with nitrogen. THF (9.29 kg) was added and solids were dissolved at 20 - 30 °C by gentle agitation; the solution was kept under an inert atmosphere of nitrogen. Reactor 4 was charged with Mg (259.2 g (1.02 eq relative to the reactor 3 charge)) and the reactor was flushed with nitrogen. The contents of Reactor 2 were charged and the mixture was warmed to 50 - 65 °C. The prepared 1-(benzyloxy)-4-bromobenzene - THF solution in Reactor 3 was added while maintaining a reaction temperature of 50 - 70 °C. The contents of the reactor were stirred at 60 - 70 °C for about 1 h and cooled to 20 - 30 °C. About 95% of this Grignard solution was transferred into Reactor 5 and held under an inert atmosphere of nitrogen. A sample was pulled from Reactor 5 for analysis (residual 1-(benzyloxy)-4-bromobenzene (HPLC); Grignard reagent concentration). The remaining 5% of this Grignard solution was held in Reactor 4 under an inert atmosphere of nitrogen.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Grignard Solution Batch 2</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Reactor 3 was charged with 1-(benzyloxy)-4-bromobenzene (2.90 kg (1.0 eq)) and the reactor was flushed with nitrogen. THF (9.78 kg) was added and solids were dissolved at 20 - 30 °C by gentle agitation; the solution was kept under an inert atmosphere of nitrogen.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Reactor 4 was charged with Mg (273.1 g (1.02 eq relative to the reactor 3 charge)) and the mixture was warmed to 50 - 65 °C. The prepared 1-(benzyloxy)-4-bromobenzene - THF solution in Reactor 3 was added while maintaining a reaction temperature of 50 - 70 °C. The contents of the reactor were stirred at 60 - 70 °C for about 1 h and cooled to 20 - 30 °C. About 95% of this Grignard solution was transferred into Reactor 6 and held under an inert atmosphere of nitrogen. A sample was pulled from Reactor 6 for analysis (residual 1-(benzyloxy)-4-bromobenzene (HPLC); Grignard reagent concentration). The remaining 5% of this Grignard solution was held in Reactor 4 under an inert atmosphere of nitrogen.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Grignard Solution Batch 3</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Reactor 3 was charged with 1-(benzyloxy)-4-bromobenzene (2.90 kg (1.0 eq)) and the reactor was flushed with nitrogen. THF (9.78 kg) was added and solids were dissolved at 20 - 30 °C by gentle agitation; the solution was kept under an inert atmosphere of nitrogen.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Reactor 4 was charged with Mg (273.2 g (1.02 eq relative to the reactor 3 charge)) and the mixture was warmed to 50 - 65 °C. The prepared 1-(benzyloxy)-4-bromobenzene - THF solution in Reactor 3 was added while maintaining a reaction temperature of 50 - 70 °C. The contents of the reactor were stirred at 60 - 70 °C for about 1 h, cooled to 20 - 30 °C and held under an inert atmosphere of nitrogen. A sample was pulled for analysis (residual 1-(benzyloxy)-4-bromobenzene (HPLC); Grignard reagent concentration).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Reaction of Grignard Reagent with l-(ferf-butyl) 2-methyl (S)-5-oxopyrrolidine 1 ,2-dicarboxylate</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
The reaction was performed in 12 cycles; a representative cycle is described below. In total, 6.46 kg of 1-(te/f-butyl) 2-methyl (S)-5-oxopyrrolidine 1 ,2-dicarboxylate was processed forward to the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Reactor 7 was charged with 1-(te/f-butyl) 2-methyl (S)-5-oxopyrrolidine 1 ,2-dicarboxylate (2.21 kg) and THF (5.89 kg) and the solids were dissolved at 20 - 30 °C by gentle agitation under an inert atmosphere of nitrogen.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Reactor 8 was charged with THF (0.98 kg) and the solvent was cooled to about -10 °C under an inert atmosphere of nitrogen. Solutions of the Grignard reagent (3.2 kg) in Reactor 6 and the 1-(te/f-butyl) 2-methyl (S)-5-oxopyrrolidine 1 ,2-dicarboxylate - THF solution (2.0 kg) in Reactor 7 were simultaneously pumped into Reactor 8 over 15 min while maintaining a reaction temperature of <30 °C. The contents of Reactor 8 were stirred for an additional 15 min; the final reaction temperature was 0 - 10 °C. The contents of Reactor 8 were transferred to Reactor 9, cooled to about -5 °C and the reaction was quenched by addition of 1 M aqueous H2SO4 solution (1.20 equiv) while maintaining a reaction temperature of <10 °C. The mixture was stirred for 30 min, was transferred to Reactor 10 and was heated to 25 - 30 °C. The mixture was transferred to Reactor 1 1 , toluene (2.39 kg) was charged and the mixture was agitated. The mixture was transferred to Settler 1 and the organic layer was transferred to Reactor 12 using a metering pump. Water (1.65 kg) wash charged to Reactor 12, the mixture was agitated, transferred to Settler 2 and the organic layer was transferred to a storage container using a metering pump.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Product Isolation</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
The contents of the storage container (organic streams from 12 reaction cycles) was concentrated in Reactor 13 to an endpoint of 65 °C (pot temperature) at 200 torr. The contents of the reactor were cooled to 30 °C, then to 0 to -10 °C and aged for 0.5 - 2 h. The solids were isolated by filtration, washed with toluene (7.50 kg) and dried in vacuo at 50 °C and < 10 torr to give 8.76 kg (77%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 1f: Methyl (S)-5-(4-(benzyloxy)phenyl)-2-((fert-butoxycarbonyl)amino)-5-oxopentanoate (D1f) (Flow Process using Plug Flow Reactor)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/4zCqQr1FuE-ygoIa_yI_B71FTia1_SSni13MC0M2X8fQRLv9nsYfjuD3tP_3Eauq8GQdorMVW8oiAj9HhEf24r8BDhsSu1t1hhj1j8XKbGMqOZfpaq1HeAZKQJprXpX3jd7EJ-ofMYOGwFHPAiDAt76Y5d6S0PKkLlryWatCatA" height="105" id="imgf000044_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/4zCqQr1FuE-ygoIa_yI_B71FTia1_SSni13MC0M2X8fQRLv9nsYfjuD3tP_3Eauq8GQdorMVW8oiAj9HhEf24r8BDhsSu1t1hhj1j8XKbGMqOZfpaq1HeAZKQJprXpX3jd7EJ-ofMYOGwFHPAiDAt76Y5d6S0PKkLlryWatCatA" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="375" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A flow reactor with two reagent inputs, ¾ inch tubing for reagent transfer, and two ½ inch jacketed static mixers connected in series (35 mL volume) was assembled. Gear pumps were used to transfer reagents to the flow reactor. Mass flow meters were used to measure the flow rates of the reagents. Thermocouples were placed to monitor the temperature of the (4-benzyloxy)phenylmagnesium bromide (Grignard) and l-(terf-butyl) 2-methyl (S)-5-oxopyrrolidine 1 ,2-dicarboxylate solutions prior to entering the tube-in-tube mixer T, as well as the out-flowing reaction stream from the static mixers. A fourth thermocouple measured the</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
temperature of the collection vessel. A peristaltic pump was used to transfer an aqueous acetic acid quench solution to the reaction stream as it exited from the static mixers. A standard T-mixer was used to join these reaction streams. The quenched reaction mixture flowed through a cooled coil into a jacketed collecting vessel. The approximate residence time through the static mixers was calculated to be -4.5 seconds.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Solution A: 0.57M (4-benzyloxy)phenylmagnesium bromide (Grignard) solution in THF (1.3 equiv used).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Solution B: 0.44M l-(ferf-butyl) 2-methyl (S)-5-oxopyrrolidine 1 ,2-dicarboxylate (0.750 kg) in THF (6.5 L)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Solution C: 2.9M glacial acetic acid (517 g) in water (3.013 L) to provide a 2.9 M solution. The quenched reaction mixture flowed into a collecting vessel containing 20% aqueous NH<span style="font-size: 12px; height: 0px; line-height: 0; position: relative; top: 0.5ex; vertical-align: baseline;">4</span>CI (1.465 kg) at 0 °C.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
The pre-cooling loop for Solution B was set to a bath temperature of -20 to -22 °C. The static mixer jacket coolant was set to a temperature of -25 °C. The pre-cooling loop for Solution A was set to a jacket temperature of -5 °C. The continuous quench tube reactor was set to a bath temperature of 0 °C.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
After the jacket temperatures and cooling baths were allowed to reach desired temperatures, Solution A was pumped at a rate of -250 mL/min through the outside tube of the tube-in-tube mixer and met the Solution B that was pumped through the inner tube at a rate of 250 mL/min. Simultaneously to the reagent streams, the flow rate of the 2.9M aqueous acetic acid solution was initiated and set to approximately 130 mL/min. Reagent flow rates were measured with mass flow meters and temperatures were measured with thermocouples.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
The reaction was run for about 20 min; a total of 5.663 kg of Solution B, 6.237 kg of Solution A and 3.530 kg of 2.9M aqueous acetic acid solution were charged during the reaction. The lines were rinsed with THF (1.252 kg) immediately after the reaction was finished.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
The pH of the aqueous layer in the collection vessel was measured at 6.08. The pH was adjusted to 5.05 with 1 N HCI (2.05 kg) followed by the addition of 1V: 1V AcOH/water (162 g). The reactor jacket temperature was set to 10 °C and the contents of the reactor were stirred for 12 h. The pH of the mixture was further adjusted to 2.06 by adding 37% HCI (0.301 kg) and the mixture was stirred at 0 - 10 °C for 15 to 30 min.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
The aqueous layer was separated and the organic layer was stirred for 20 min with a 25% brine solution (1.995 kg). The aqueous layer was separated; the organic layer was held at 10 °C overnight. The organic layer was concentrated at 35 - 40 °C (jacket temperature) and 25-30 mm Hg. Upon reaching a volume of about 9.5 L, a well developed slurry was noted. The concentration was continued to a volume of about 4.5 L. The slurry was warmed to 31 °C and heptane (3.145 kg) was added. The slurry was heated to 35 °C, stirred for 30 min, and was cooled to and held at 20 to 22 °C. The slurry was cooled to 10 °C and stirred for at least 2 h. Solids were collected by filtration and washed with 2: 1 heptane/MTBE (2 x 1.5 L). The solids were dried to constant weight in vacuo to yield 990 g (86.8%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 1g: methyl (S)-5-(4-(benzyloxy)phenyl)-2-((tert-butoxycarbonyl)amino)-5-oxopentanoate</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/vEp-jaBvOo84OJRAstzxJFMC5IWcMdMC3w33meMXRiygv6mAfQQ-xG96JhH0919v0d3lu-VLUs5zH-YJGKDWiY6Z7TbrwkfYagNLXmpvHybHTThseuXVrCrx1OrJj4lBRomnwpyc1Hx9rM_kTnU4vgo8-1Ju2K4C94lZSPJwIbk" height="127" id="imgf000046_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/vEp-jaBvOo84OJRAstzxJFMC5IWcMdMC3w33meMXRiygv6mAfQQ-xG96JhH0919v0d3lu-VLUs5zH-YJGKDWiY6Z7TbrwkfYagNLXmpvHybHTThseuXVrCrx1OrJj4lBRomnwpyc1Hx9rM_kTnU4vgo8-1Ju2K4C94lZSPJwIbk" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="379" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with degassed THF (1 199 kg) and 1-(benzyloxy)-4-bromobenzene (450 kg). The solids were dissolved at 20 - 25 °C with agitation and under an inert atmosphere of nitrogen. The mixture was heated to reflux for 15 min, then cooled to 20 - 30 °C.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with Mg turnings (43.6 kg) and degassed THF (399 kg) under an inert atmosphere of nitrogen. To this mixture, a solution of DIBAL-H (25% in toluene, 6.2 kg) was added followed by addition of toluene (3.7 L) into the reactor through the charging line. The mixture was heated to reflux for 10 - 15 minutes followed by charging of 5% of the 1-(benzyloxy)-4-bromobenzene - THF solution. The contents of the reactor were held for 1 h under reflux; reaction initiation was confirmed. The remainder of the 1-(benzyloxy)-4-bromobenzene - THF solution was added over 3 - 4 h. Following the charge, the temperature was adjusted to 20 - 30 °C.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with degassed THF (760 kg) and 1-(te/f-butyl) 2-methyl (S)-5-oxopyrrolidine 1 ,2-dicarboxylate (284.9 kg), and the resulting solution was heated to reflux under an inert atmosphere of nitrogen, maintained at reflux for 10 - 15 min, then cooled to -60 °C to -70 °C. To this solution was added the Grignard solution while maintaining a reaction temperature of <-50 °C. The reactor which contained the 1-(benzyloxy)-4-bromobenzene -THF solution was rinsed with degassed THF (22 kg) and the rinse was charged into the reaction. The contents of the reactor were aged at -60 to -70 °C for about 1 h. The progress of the reaction was monitored for completion (HPLC).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with 2-propanol (285 L) and THF (253 kg). With good agitation the reaction was quenched into this THF - 2-propanol solution while keeping the temperature between -20 °C and 0 °C. The reactor was rinsed forward with THF (53 kg), and the mixture was stirred vigorously for 5 - 10 min. Water (712 L) was added while maintaining a reaction temperature of <20 °C; the pH of the mixture was adjusted to 6.0 - 7.0 by addition of 50 wt% acetic acid in water (-170 kg) while controlling the temperature below 20 °C. The reaction mixture was warmed to 20 - 30 °C, stirred for 20 - 30 min and the phases were separated. Sodium chloride (42 kg) and water (255 L) were charged, the mixture was stirred for 55 - 65 min, and the phases were separated. THF (125 kg) was charged and the solution was concentrated by distillation under vacuum at a temperature of 40 - 45 °C. The distillation was stopped when the weight of the reaction mixture was between 5.5 - 6. OX the weight of the input mass of 1-(te/f-butyl) 2-methyl (S)-5-oxopyrrolidine 1 ,2-dicarboxylate. The reaction mixture was heated to 35 - 45 °C. Heptane (994 kg) was charged to the reaction mixture, the contents of the reactor were maintained at 35 - 45 °C, aged for 1 - 2 h, cooled to 15 - 25 °C over 2 - 3 h, cooled to 0 - 5 °C and aged for 3 - 5 h. The solids were isolated by centrifugation in three portions; each portion was washed with heptane (97 kg) followed by acetonitrile (59 kg) to give 389 kg of wet product. Based on LOD measurements, 375.3 kg (76.6 %) of the title compound was obtained.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 1 h: benzyl (S)-5-(4-(benzyloxy)phenyl)-2-((tert-butoxycarbonyl)amino)-5-oxopentanoate</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/b-QS5NdRdOlPHgObTs7v1hjSzoS3k_1z8b7mx8HVz1EVwAWKNXBQg3sFbQZS_wNPIX0NZo2uUxDIeJuwgEg9OLyAJkgUP_6nTPGv_yKXBRRcG2l4gWmzDZvffd5XmjSRyHUUrQ8vFoALwwaRxj4VAEJZLO6a3We9bW2BRHnZG7A" height="107" id="imgf000047_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/b-QS5NdRdOlPHgObTs7v1hjSzoS3k_1z8b7mx8HVz1EVwAWKNXBQg3sFbQZS_wNPIX0NZo2uUxDIeJuwgEg9OLyAJkgUP_6nTPGv_yKXBRRcG2l4gWmzDZvffd5XmjSRyHUUrQ8vFoALwwaRxj4VAEJZLO6a3We9bW2BRHnZG7A" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="375" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with 1-benzyl 2-methyl (S)-5-oxopyrrolidine 1 ,2-dicarboxylate (69.3 g) and anhydrous THF (450 g) and the resulting solution was cooled to about -65 °C under an</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
inert atmosphere of nitrogen. A solution of 0.8M (4-benzyloxy)phenylmagnesium bromide in THF (1.1 eq) was added over about 2 h, and the progress of the reaction was monitored by HPLC. Upon completion, the reaction was quenched by simultaneous addition of 1 M sulfuric acid (1.1 eq) and toluene (264 g) over about 30 min. The resulting mixture was warmed from -10 °C to ambient temperature and was aged for about 30 min. The phases were separated, and the organic layer was washed with 10 wt% brine (180 g) and water (180 g). The organic solution was concentrated to about 6V at about 50 °C and <170 mbar (distillate: 650 g / 710 ml_). The resulting solution was heated to about 65 °C and a solution of toluene (105 g) and methylcyclohexane (200 g) was added dropwise while maintaining a temperature of about 65 °C. The solution was cooled to 0 - 5 °C and aged for about 1 h. The solids were isolated by filtration, washed with cold (0 - 5 °C) methylcyclohexane (200 g in 6 portions) and dried at 45 °C in vacuo to constant weight to give 76.6 g (66%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 1 i: methyl (S)-2-(((benzyloxy)carbonyl)amino)-5-(4-(benzyloxy)ph oxopentan</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/GbnLc3Atm4l1Bc5PTIh82UjyiTqbsp_9O7BYWG2rw96PSISM7NDePMDhWWyBpS2MOBbXjkgZiHUSEGaR-ma2bYfxNnrMQ5bNPE_ItaRi1ryn5zCr7bk3mw0ZoVh7cjADHThpSowvByqivuhyIDTPVbJ_huRalBM-usRqj951sAk" height="137" id="imgf000048_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/GbnLc3Atm4l1Bc5PTIh82UjyiTqbsp_9O7BYWG2rw96PSISM7NDePMDhWWyBpS2MOBbXjkgZiHUSEGaR-ma2bYfxNnrMQ5bNPE_ItaRi1ryn5zCr7bk3mw0ZoVh7cjADHThpSowvByqivuhyIDTPVbJ_huRalBM-usRqj951sAk" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="379" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Solution A: 0.8M (4-benzyloxy)phenylmagnesium bromide solution in THF</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Solution B: 0.88M 1 -benzyl 2-methyl (S)-5-oxopyrrolidine 1 ,2-dicarboxylate (25.0 g) solution in anhydrous THF</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Solution C: 1 M aqueous sulfuric acid</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Equipment: plug flow reactor with a Y-mixer; 10 ml_ reaction loop</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Reaction conditions:</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
· reagent flow rates:</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
o solution A: 5.27 ml_ / min (1.3 eq)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
o solution B: 4.72 ml_ / min (1.0 eq)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
o solution C: 5.75 ml_ / min (1.5 eq)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
• residence time: 1 min</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
· reaction temperature: 25 °C</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
• collection time: 2 h (theory: 0.36 mol title product)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
• the quenched reaction mixture flowed into a collecting vessel</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Following collection of the quenched reaction mixture, the phases were separated and the upper organic layer was concentrated to dryness in vacuo. The solids were dissolved in fresh THF (5.5V) at 45 °C. The solution was cooled to -5 °C over about 160 min and was aged overnight. The solids were collected by filtration, washed with heptane (5.5V, total) and dried to constant weight at 55 °C in vacuo to afford 18.61 g (45%) of the title product.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
The combined filtrate and wash containing additional solids was transferred to a reactor, cooled to -5 °C over 2 h and aged for an additional 4 h. The solids were collected by filtration, washed with heptane (2 X 2V) and dried to constant weight at 55 °C in vacuo to afford 1 1.37 g (27%) of the title product.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 1j: methyl (S)-5-(4-(benzyloxy)phenyl)-2-((tert-butoxycarbonyl)amino)-5-oxopentanoate - flow chemistry procedure</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/kWGuLqIJM-1GUTaxAccpQ0Jp-CrWu0aLneGr4HM169rCqw1pgwfdURt-GEEZScIIQWD7_AbNK0jBxeXN4ZHBkxeos1SEWlljIpYxLE3ZsiBNBy4dEqVFjg8iU1WOVf1FfUhkm2KlFSvI0Ff35ZCS9J1f_CsYQidZFrxnCjBrAQM" height="131" id="imgf000049_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/kWGuLqIJM-1GUTaxAccpQ0Jp-CrWu0aLneGr4HM169rCqw1pgwfdURt-GEEZScIIQWD7_AbNK0jBxeXN4ZHBkxeos1SEWlljIpYxLE3ZsiBNBy4dEqVFjg8iU1WOVf1FfUhkm2KlFSvI0Ff35ZCS9J1f_CsYQidZFrxnCjBrAQM" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="447" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
The CSTR flow setup consists of one 1 L stirred tank for reaction, one 1 L settling tank and one 10L Schlenk type collection vessel. The stirred tank was equipped with a solid addition device, a reflux condenser, and a dip-tube (set to a 500 ml_ working volume) with an inner transfer line.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Step 1 : A stirred tank reactor was pre-charged with THF (70 ml), and magnesium (50.8 g, 5 eq), and stirred at room temperature overnight. The solid addition device was filled with magnesium. The reaction was initiated by adding (4-(benzyloxy)phenyl)magnesium bromide 0.77M solution (7.7 g, 5.9 mmol). The jacket temperature was increased to 55 °C. A solution of 1-bromo-4-benzylphenol (0.85 M in THF) was added at a rate of 7.8 ml/min to the stirred reaction vessel. After seven minutes, solid addition of magnesium started at a rate of 0.161 g/min. The total amount of magnesium for the entire run was (175 g, 7.18 mol,</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
1 equiv) and was calculated to keep 5 eq of magnesium in the stirred tank reactor over the course of the run. When the liquid level in the tank reached the level of the dip tube, a pump activated pulling material to the settling tank at a rate to maintain the 500 mL filling level in the CSTR. The approximate residence time of the solution in the jacketed reactor was 62 minutes. The product was transferred into the settling tank (unstirred), held for another residence time (1 hour), and subsequently transferred to a final collection vessel. The entire process was run for 18 hours.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Step 2: Grignard Addition: The equipment consists of tubular pipe reactor, heat exchanger, and a series of centrifugal phase separators. The tubular reactor accommodates mixing of two reagents for the conversion to methyl (S)-5-(4-(benzyloxy)phenyl)-2-((tert-butoxycarbonyl)amino)-5-oxopentanoate and quenching of the product solution with an acid solution. The centrifugal phase separators separate the product containing organic phase from the waste aqueous phase. The reagent (methyl-N-boc-pyroglutamate, Grignard, and sulfuric acid solutions were transferred continuously at controlled flowrates from their respective storage tank to pass through the tubular pipe reactor, heat exchanger and finally to the centrifugal extractors.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Reaction/Quench/Work-up: The 0.82 M Grignard solution was fed continuously from the storage tank at a flow rate of 32.6 mL/min (1.19 eq), simultaneously a 0.817 M methyl N-boc-pyroglutamate solution stream was fed continuously at 27.4 ml/min through a heat exchanger to pre-cool it to -8°C. The tubular reactor where the reaction between the reagent N-boc-pyroglutamate and Grignard solution occurred was attached to a heat exchange unit with chiller fluid set at 10°C. After passing through the reaction zone, 1.0 M sulfuric acid was introduced at a rate 22.4 ml/min. The residence time of the solution from reagent introduction to acid quench was 8 seconds. From sulfuric acid introduction to phase split the residence time was ca. 80 seconds. The quenched mixture passed through another heat exchanger to increase the temperature to 30°C for phase split. This material was directly fed into a centrifugal extractor to remove the aqueous component. The obtained organic layer was subsequently mixed with a solution of brine and sodium bicarbonate (14.5 ml/min) in a second centrifugal extractor. The final product containing organic layer was collected into a glass bottle. The process was run for 3.7 hours.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Crystallization: The product-containing organic layer above was transferred to a 10 L reactor for solvent switch to a lower water content THF-Heptane solvent system by vacuum distillation. A total of 6867 mL THF (appx. 9.5% v/v) in Heptane was added to the reactor and</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
subsequently distilled in appx. 2 equal portions maintaining distillation under reduced pressure (appx. 600-700 mbar) at temperature within 60-65<span style="bottom: 1ex; font-size: 12px; height: 0px; line-height: 0; position: relative; vertical-align: baseline;">°</span>C to replace the original solvent (water-containing THF).<span style="bottom: 1ex; font-size: 12px; height: 0px; line-height: 0; position: relative; vertical-align: baseline;">3</span> The final solution obtained (appx. 11.5L) was cooled to 0-5°C with a cooling rate 0.5C/min and the resulting slurry was filtered, washed with Heptane and dried under vacuum at 60°C to obtain 1.765 kg of product.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 2a: Methyl (S)-5-(4-(benzyloxy)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/yIhZ9Kcxr3mR1ggBBj7sL_NAx_1HoAqF-NaWO7CpjQFLPCXT9ymgj1cVQtG8O3r3PJl239uoKV_bIgFb4k5nyChqU-ceb62SV5B0DsSFDla891FwTxprrbId3ao2RGFTSA2-ZHSj83tZ8Zm1f9l36qrDVxg7HGAOSBba7UsQvDQ" height="88" id="imgf000051_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/yIhZ9Kcxr3mR1ggBBj7sL_NAx_1HoAqF-NaWO7CpjQFLPCXT9ymgj1cVQtG8O3r3PJl239uoKV_bIgFb4k5nyChqU-ceb62SV5B0DsSFDla891FwTxprrbId3ao2RGFTSA2-ZHSj83tZ8Zm1f9l36qrDVxg7HGAOSBba7UsQvDQ" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="363" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with methyl (S)-5-(4-(benzyloxy)phenyl)-2-((te/f-butoxycarbonyl)amino)-5-oxopentanoate (180 kg) and ACN (486 kg) and the slurry temperature was adjusted to 10 - 15 °C. A solution of methanesulfonic acid (117.5 kg (2.9 eq)) in ACN (75 kg) was added while maintaining a reaction temperature of <25 °C. The reaction temperature was adjusted to 22 - 26 °C and the contents of the reactor were stirred for 1 - 1.5 h. The progress of the reaction was monitored (HPLC). Upon completion, the contents of the reactor were cooled to 10 - 15 °C and a solution of 4. ON NH<span style="font-size: 12px; height: 0px; line-height: 0; position: relative; top: 0.5ex; vertical-align: baseline;">4</span>OH (299 kg) was added to a pH of 7 - 8 while maintaining a reaction temperature of <25 °C. The phases were separated and the upper organic layer was heated to 30 - 40 °C. While maintaining a reaction temperature of 30 - 40 °C, 2-propanol (101 kg) and water (430 kg) were added to the reactor. The solution was cooled to 17 - 19 °C and was seeded (1.8 kg). The slurry was stirred for 1 - 2 h at 14 - 19 °C, cooled to 7 - 12 °C, aged for 1 - 2 h and cooled to 2 - 7 °C. Water (890 kg) was added and the slurry was aged for 2 - 3 h at 2 - 7 °C. The solids were isolated by filtration, washed with a solution composed of 2-propanol (61 kg) and water (270 kg) and dried in vacuo at 50 - 60 °C to constant weight to afford 1 19.6 kg (90%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 2b: Methyl (S)-5-(4-(benzyloxy)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate (D2b) (Alternative Procedure)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with methyl (S)-5-(4-(benzyloxy)phenyl)-2-((tert-butoxycarbonyl)amino)-5-oxopentanoate (532 kg) and ACN (1670 kg) and the slurry temperature was adjusted to 20 - 25 °C. Methanesulfonic acid (346 kg (2.9 eq)) was added while maintaining a reaction temperature of <26 °C. The contents of the reactor were stirred for 1 h; the progress of the reaction was monitored (HPLC). Upon completion, the contents of the reactor were cooled to <10 °C and a solution of 4.6N NH40H (773 kg) was added until a pH of 7 - 8 was reached while maintaining a reaction temperature of <25 °C. The phases were separated and the upper organic layer was heated to 30 - 35 °C. The organic layer was filtered through a plate filter to remove small particulates. While maintaining a reaction temperature of 30 - 35 °C, 2-propanol (301 kg) and water (1277 kg) were added to the reactor. The solution was cooled to 18 - 22 °C and precipitation occurred. The slurry was stirred for at least 30 minutes at 18 - 22 °C and then cooled to 0 - 10 °C. While maintaining a temperature of 0 - 10 °C, water (2128 kg) was added and the reaction mixture was aged for not less than 2 hours at 0 - 10 °C. The solids were isolated by filtration, washed with a solution composed of 2-propanol (188 kg) and water (798 kg) and dried in vacuo at 50 - 55 °C to constant weight to afford 319 kg (83%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 2c: methyl (S)-5-(4-(benzyloxy)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate - flow chemistry procedure with MsOH/ACN</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/Ptw7KGYlwuEiQTDr_NSs52jQLePIaUE8xo4P7Q-L63WVizD0ry2ojoxpFNZf8tcTteFgiYDrlDSrrQTUBrNC9IwcO-Tds1RHS4D-Wrd3Ev_wfLk4iPaAJeD2be-3CjfgSUkR2qWAPd_P2oli1oz4JUAhucxJTaML5Od2YdJVRHQ" height="98" id="imgf000052_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/Ptw7KGYlwuEiQTDr_NSs52jQLePIaUE8xo4P7Q-L63WVizD0ry2ojoxpFNZf8tcTteFgiYDrlDSrrQTUBrNC9IwcO-Tds1RHS4D-Wrd3Ev_wfLk4iPaAJeD2be-3CjfgSUkR2qWAPd_P2oli1oz4JUAhucxJTaML5Od2YdJVRHQ" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="365" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Solution A: 0.79M methanesulfonic acid in anhydrous ACN</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Solution B: 0.25M l-(terf-butyl) (S)-5-(4-(benzyloxy)phenyl)-2-((tert-butoxycarbonyl)amino)-5-oxopentanoate solution in anhydrous THF</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Solution C: 4.6N NH<span style="font-size: 12px; height: 0px; line-height: 0; position: relative; top: 0.5ex; vertical-align: baseline;">4</span>OH solution in water</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Equipment: plug flow reactor with a Y-mixer; 10 ml_ stainless steel reaction loop</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Reaction equivalents:</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
· solution A: 3.0 (3.764 mL / min)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
• solution B: 1.0 (3.946 mL / min)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
• solution C: 2.7 (0.579 mL / min)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Residence time: 1.3 min</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Reaction temperature: 130 °C</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
After reaching steady state, the reaction stream was collected for 102 min in a 1 L flask immersed in an ice water bath. The base solution from pump C and the reaction stream</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
were simultaneously collected with good stirring. Following the run, the pH was adjusted to 7 with by charging additional 4.6N ammonium hydroxide solution (about 15 mL). The phases were split, and the organic layer was concentrated to dryness by rotary evaporation in vacuo. The resulting residue was dissolved in ACN (120 mL) and distilled water (5 mL) at 25 °C and 500 rpm in a 100 mL EZMax reactor. The solution was cooled to 22 °C and water - I PA solution (2/1 (v/v), 80 mL) was added over about 30 min. The solution was further cooled to 18 °C, seeded (5 wt%) and cooled to about 0 °C over 2 h. Water (139 mL) was added to the slurry over about 30 min, and the mixture was aged for about 20 min. The temperature of the slurry was raised to 20 °C, held for about 40 min, re-cooled to about 0 °C over 90 min and aged for an additional 90 min. The solids were collected by filtration and dried to constant weight in vacuo at 55 °C to give 28.9 g (92%, corrected for seed) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 2d: methyl (S)-5-(4-(benzyloxy)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate - flow chemistry procedure with H2SO4/ACN</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/8bUukTWS4TKc89k73x9QMheHJeqvurIXWLwkpjzaWPM4udo-0_OeUCG7IqeTIWH_j9Iz0aokHFKdUpBSI4sL7b6Hnn2R2_Y53CuEHQf_k3k85VdpZLQonkNhZmFRLI8FQwOvsjOGSCoXl2c0kZlO1r2UHo2ogeuDo6NTk-XWZ20" height="98" id="imgf000053_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/8bUukTWS4TKc89k73x9QMheHJeqvurIXWLwkpjzaWPM4udo-0_OeUCG7IqeTIWH_j9Iz0aokHFKdUpBSI4sL7b6Hnn2R2_Y53CuEHQf_k3k85VdpZLQonkNhZmFRLI8FQwOvsjOGSCoXl2c0kZlO1r2UHo2ogeuDo6NTk-XWZ20" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="365" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Three solutions were prepared for the flow reaction. Solution A: 0.25M l-(terf-butyl) (S)-5-(4-(benzyloxy)phenyl)-2-((tert-butoxycarbonyl)amino)-5-oxopentanoate solution in anhydrous THF; Solution B: 0.75M sulfuric acid in anhydrous ACN;</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A plug flow reactor with a Y-mixer and a 10 mL reaction loop was used with 1 reaction equivalent of solution A, and 2 reaction equivalents of solution B; a residence time of 7.5 minutes; a reaction temperature of 95 °C; and a collection time: 73.7 minutes (theory: 22.1 mmol title product).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
The collected product stream was neutralized to pH 7 - 8 using 4.6N NH4OH solution in water. HPLC analysis of the organic layer showed it contained 98.0 area% of the desired product. The lower organic layer was removed, and the organic layer was cooled to about 22 °C, aged for about 30 min and cooled to 0 - 5 °C over about 1 h. Water (38 mL) was added over 10 min, and the resulting slurry was filtered, and was washed with a solution composed of IPA (0.45V) and water (1.5V). The solids were dried in vacuo at 55 °C to yield 2.62 g (38%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 2e: methyl (S)-5-(4-(benzyloxy)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate - flow chemistry procedure with MsOH/THF-PhMe</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/HsysycNlUmhLWq5EdkGHKDKIOukc83cYyqkPV5AzisEy1NB4QqKKg_6mD9cmjuOmXngXXNJudQeUjcDB0rfjR4mJ44PY1BikxL8gyMykZNEHCxf3A_3hz0OHln05jNXHjA1XSHnnDfXVk0SQJnUh0GgsIUkBtzvzr39jnpArlTA" height="96" id="imgf000054_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/HsysycNlUmhLWq5EdkGHKDKIOukc83cYyqkPV5AzisEy1NB4QqKKg_6mD9cmjuOmXngXXNJudQeUjcDB0rfjR4mJ44PY1BikxL8gyMykZNEHCxf3A_3hz0OHln05jNXHjA1XSHnnDfXVk0SQJnUh0GgsIUkBtzvzr39jnpArlTA" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="425" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Solution A: 1.5M methanesulfonic acid in 1 : 1 (v/v) anhydrous THF - anhydrous PhMe Solution B: 0.25M l-(terf-butyl) (S)-5-(4-(benzyloxy)phenyl)-2-((tert-butoxycarbonyl)amino)-5-oxopentanoate solution in anhydrous THF</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Solution C: 4.6N NH4OH solution in water</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Equipment: plug flow reactor with a Y-mixer; 10 ml_ PFA coil reactor</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Reaction equivalents:</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
• solution A: 3.0 (1.667 mL / min)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
· solution B: 1.0 (3.333 mL / min)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
• solution C: 6.0 (1.087 mL / min)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Residence time: 2.0 min</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Reaction temperature: 150 °C</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
After reaching steady state, the reaction stream was collected for 1 17 min in a 1 L flask immersed in an ice water bath. The base solution from pump C and the reaction stream were simultaneously collected with good stirring for the first 60 min; for the remainder of the collection time, only the reaction stream was collected. Following the run, the pH was adjusted to 7 with by charging additional 4.6N ammonium hydroxide solution. The phases were split, and the organic layer was concentrated to dryness by rotary evaporation in vacuo. The resulting residue was transferred to a 400 mL EZMax reactor using ACN (120 mL) and the temperature of the mixture was raised to 35 °C. To the mixture was added water - IPA solution (2/1 (v/v), 78 mL) over about 10 min. The resulting solution was cooled to 18 °C over about 30 min, seeded (208 mg), further cooled to about 0 °C over 2 h and aged overnight. Water (135 mL) was added to the slurry over about 1 h, and the mixture was aged for about 4 h. The temperature of the slurry was raised to 13 °C, re-cooled to about 0 °C over 3 h and aged overnight. The solids were collected by filtration and dried to constant weight in vacuo at 55 °C to give 8.18 g (27%, corrected for seed) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 2f: methyl (S)-5-(4-(benzyloxy)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate - method A</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/2n12rc3bcRcvGHAX9J63Z8j-gIQJEyQ-KZHgSc3yUBqVGTclAy0POd9KWLyxpPT6jzFI2EIYFqhj4SAVCg8E0aZ3EyazVM8hbI-g5m_6TDGCVeQGJ7apVSikRbUTVhv_DIjoyPDILsu9EJuzItmVC2eAEEnCseag8TZwRNODQJU" height="85" id="imgf000055_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/2n12rc3bcRcvGHAX9J63Z8j-gIQJEyQ-KZHgSc3yUBqVGTclAy0POd9KWLyxpPT6jzFI2EIYFqhj4SAVCg8E0aZ3EyazVM8hbI-g5m_6TDGCVeQGJ7apVSikRbUTVhv_DIjoyPDILsu9EJuzItmVC2eAEEnCseag8TZwRNODQJU" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="365" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with methyl (S)-5-(4-(benzyloxy)phenyl)-2-((te/f-butoxycarbonyl)amino)-5-oxopentanoate (100.0 g) and ACN (400 ml_) and the reaction temperature was adjusted to about 25 °C. Concentrated sulfuric acid (45.3 g) was added over about 10 min while maintaining a reaction temperature of <50 °C. The contents of the reactor were stirred at 40 - 50 °C; the progress of the reaction was monitored for completion (HPLC). Upon completion, the reaction was cooled to about 25 °C. A solution of 4.6N NH<span style="font-size: 12px; height: 0px; line-height: 0; position: relative; top: 0.5ex; vertical-align: baseline;">4</span>OH (215 ml_) was added with good stirring to a pH of about 7. The phases were separated, and the organic layer was split into two equal portions of about 256 ml_ for product isolation studies.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Portion A</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
To one portion was added a solution composed of 2-propanol (36.5 ml_) and water (120 ml_) with good stirring at about 22 °C. The resulting slurry was aged briefly at 22 °C, then cooled to 5 °C over about 1 h. Water (100 ml_) was added to the slurry while maintaining a reaction temperature of <10 °C. The solids were filtered, washed with a solution composed of 2-propanol (27.5 ml_) and water (75 ml_) and dried to constant weight in vacuo to give 30.87 g (85%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Portion B</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
To one portion was added water (150 ml_) with good stirring at about 22 °C. The resulting slurry was aged briefly at 22 °C, then cooled to 5 °C over about 1 h. Water (100 ml_) was added to the slurry while maintaining a reaction temperature of <10 °C. The solids were filtered, washed with a solution composed of 2-propanol (27.5 ml_) and water (75 ml_) and dried to constant weight in vacuo to give 31.90 g (88%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 2g: methyl (S)-5-(4-(benzyloxy)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate - method B</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/OfktqZKaA9WQ75EblYUZi-1BHWu8YBG1UTiqXEhx3IzFn76-qGw_OZPoVxShCsT4gghZk4Y_N0p5K425N3xFaUXxcsAGlIJfawLXJWW7SrFdmXUcZHERdC1YTGavryZaCGl8RsfTv0nKN_sbkSU0bFiL62OBmzTMacr_Ti0l1YE" height="86" id="imgf000056_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/OfktqZKaA9WQ75EblYUZi-1BHWu8YBG1UTiqXEhx3IzFn76-qGw_OZPoVxShCsT4gghZk4Y_N0p5K425N3xFaUXxcsAGlIJfawLXJWW7SrFdmXUcZHERdC1YTGavryZaCGl8RsfTv0nKN_sbkSU0bFiL62OBmzTMacr_Ti0l1YE" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="366" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with methyl (S)-5-(4-(benzyloxy)phenyl)-2-((te/f-butoxycarbonyl)amino)-5-oxopentanoate (776.5 kg) and ACN (1743.5 kg) and the slurry temperature was adjusted to 15 - 25 °C. Methanesulfonic acid (482.1 kg) was added while maintaining a reaction temperature of <26 °C. The contents of the reactor were stirred at 20 - 25 °C for about 1 h. The progress of the reaction was monitored (HPLC); while awaiting results, the contents of the reactor were cooled to 0 - 10 °C. A solution of 4.6N NH4OH (590 kg) was added over about 25 min to a pH of 2 - 3 while maintaining a reaction temperature of <30 °C. Additional 4.6N NH<span style="font-size: 12px; height: 0px; line-height: 0; position: relative; top: 0.5ex; vertical-align: baseline;">4</span>OH solution (519 kg) was added to a final pH of 7 - 8 while maintaining a reaction temperature of <25 °C. The phases were separated and the upper organic layer was heated to 25 - 30 °C. The organic layer was filtered and the filtrate was cooled to 20 - 25 °C. While maintaining this temperature range, a solution of 2-propanol (362.8 kg) and water (924.3 kg) were added to the reactor. The solution was cooled to 15 -20 °C and was seeded (3.7 kg, 0.5 wt%). The slurry was cooled to 0 - 5 °C over at least 2 h and aged for at least 30 min. Water (2403.1 kg) was added while maintain a reaction temperature of <20 °C. The slurry was cooled to 0 - 5 °C and aged for 30 - 40 min. The slurry was warmed to 15 - 20 °C, aged for 30 - 40 min, cooled to 0 - 5 °C over at least 1 h and aged for at least 2 h. The solids were isolated by filtration, washed with a solution composed of 2-propanol (283.2 kg) and water (1079.5 kg) and dried in vacuo at 50 - 55 °C to constant weight to afford 466.0 kg (87%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 3a: l-(ferf-butyl) 2-methyl (2S, 5 ?)-5-(4-hydroxyphenyl)pyrrolidine-1 ,2-dicarboxylate (D3)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/PsvKDjBiF1IE9uqTSF2Hu8ocLvzGmyWr4lj13hnxr_5F1T8F9xoAYSjdscivxUtVQJZQZHAFpEEqmehiywU6XyYfhJUsbd5qXiuSCJk1wmHHgsMJ4YftCMR3COPJQrGTgUrVZ8q0wvNd8lREIMCSdRN2dbwaOoULjrRCR8WtI1s" height="56" id="imgf000056_0002" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/PsvKDjBiF1IE9uqTSF2Hu8ocLvzGmyWr4lj13hnxr_5F1T8F9xoAYSjdscivxUtVQJZQZHAFpEEqmehiywU6XyYfhJUsbd5qXiuSCJk1wmHHgsMJ4YftCMR3COPJQrGTgUrVZ8q0wvNd8lREIMCSdRN2dbwaOoULjrRCR8WtI1s" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="365" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A hydrogenation reactor was charged with methyl (S)-5-(4-(benzyloxy)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate (30 kg) and MeOH (120 kg), and the slurry was heated to solution at 30 - 40 °C. The solution was cooled to 15 - 25 °C followed by addition of d -tert-butyldicarbonate (21.8 kg, 1.03 eq) and water wet 20% Pd(OH)<span style="font-size: 12px; height: 0px; line-height: 0; position: relative; top: 0.5ex; vertical-align: baseline;">2</span>/C (0.9 kg, 3 wt%). The</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
contents of the reactor were degassed under vacuum followed by pressurization with nitrogen. The contents of the reactor were degassed under vacuum followed by pressurization with hydrogen (3 - 4 bar). After 2 h at 22 - 27 °C, the reactor was vented and re-pressurized with hydrogen (3 - 4 bar). The progress of the reaction was monitored for completion (HPLC). After 4.5 h, the reactor was vented and MeOH (90 kg) was charged. The contents of the reactor were warmed to 32 - 42 °C and held for 20 - 30 min. The catalyst was removed by filtration through a bed of diatomite (13 kg) and the spent filter cake was washed with warm (40 - 45 °C) MeOH (25 kg). The combined filtrate and wash was concentrated in vacuo to 2 volumes at <40 °C and MeOH was charged (56 kg). The slurry was heated to 50 - 56 °C and the solution was aged for about 1.5 h. The solution was cooled to 20 - 30 °C, the slurry was aged for about 1 h, water (60 kg) was added and the slurry was aged for about 2 h. The slurry was cooled to about -5 °C and aged for about 8 h. The solids were isolated by centrifugation, washed with 1 :4 (v/v) MeOH - water (57.5 kg) and dried in vacuo at 50 - 60 °C to constant weight to afford 27.6 kg (88.5%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 3b: 1 -(tert-butyl) 2-methyl (2S, 5R)-5-(4-hydroxyphenyl)pyrrolidine-1,2-dicarboxylate - method A</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/hUFylScDHOllIN2DBfxqdBfQkeYbKkkOxiJ7igaNQwbO_yX5tV55x8rI4lzPLRYiaiWt2jVq30BAa6B3qaWL2qXgiffsZ0jcLh3_bV8D5gtWDXv3Io_zlm4g5r_ApFSDpMthsFDbdCDjjhDiwwYNuEsgfq-gmn333zi1-XW0zn4" height="57" id="imgf000057_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/hUFylScDHOllIN2DBfxqdBfQkeYbKkkOxiJ7igaNQwbO_yX5tV55x8rI4lzPLRYiaiWt2jVq30BAa6B3qaWL2qXgiffsZ0jcLh3_bV8D5gtWDXv3Io_zlm4g5r_ApFSDpMthsFDbdCDjjhDiwwYNuEsgfq-gmn333zi1-XW0zn4" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="364" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A hydrogenation reactor was charged with 20% Pd(OH)2/C (water wet; 5.7 kg), methyl (S)-5-(4-(benzyloxy)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate (186.4 kg), MeOH (8.85V), water (20 kg) and di-te/f-butyldicarbonate (132 kg). The reactor was pressurized with nitrogen followed by venting (three times). The reactor was pressurized with hydrogen followed by venting (three times). The reactor was pressurized with hydrogen (15 bar). After about 2 h at 25 °C, the reactor was vented and re-pressurized with hydrogen (15 bar). The progress of the reaction was monitored for completion (HPLC). After about 4.25 h, the reactor was vented and its contents were filtered, and the filtrate was concentrated in vacuo to about 4.4 volumes at about 35 °C and at about 240 mbar. The contents of the reactor were reheated to 55 - 60 °C, the solution was cooled to 20 - 30 °C over about 2 h and the slurry was aged for about 1 h. Water (285 kg) was added over about 1 h and the slurry was aged for about 1 h. The slurry was cooled to 3 - 7 °C over about 2 h and aged for about 3 h. The solids were isolated by filtration, washed with 1 :4 (v/v) MeOH - water (359 kg) and dried in vacuo at 50 - 55 °C to constant weight to afford 174.6 kg (90%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 3c: l-(tert-butyl) 2-methyl (2S, 5R)-5-(4-hydroxyphenyl)pyrrolidine-1 ,2-dicarboxylate - method B</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/p1LD8i-jHfhqz_X4E8KUrfhAwQxleyQfxBQGUFETx4bKVavwMI-LgsFBscdKLoRfQ9sfjZkcEPdvu9l9-UBUIft8SQT9qE3YtCms4fxV-PHMhSvVT3QBiGiIIGpVcZEGBOg3U6sVex4rmFCEc0zi4RArU30J9L6WHZCzIIhK2i4" height="55" id="imgf000058_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/p1LD8i-jHfhqz_X4E8KUrfhAwQxleyQfxBQGUFETx4bKVavwMI-LgsFBscdKLoRfQ9sfjZkcEPdvu9l9-UBUIft8SQT9qE3YtCms4fxV-PHMhSvVT3QBiGiIIGpVcZEGBOg3U6sVex4rmFCEc0zi4RArU30J9L6WHZCzIIhK2i4" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="365" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A hydrogenation reactor was charged with 20% Pd(OH)2/C (water wet; 3 wt%), methyl (S)-5-(4-(benzyloxy)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate (100 g), MeOH (4.5V), water (5 g) and 90 wt% di-te/f-butyldicarbonate in THF (1.00 eq). The reactor was pressurized with nitrogen followed by venting (three times). The reactor was pressurized with hydrogen followed by venting (three times). The reactor was pressurized with hydrogen (15 bar). After 1 h at 25 °C, the reactor was vented and re-pressurized with hydrogen (15 bar). The progress of the reaction was monitored for completion (HPLC). After 5 h, the reactor was vented and its contents were warmed to about 45 °C. The catalyst was removed by filtration through a warmed filter, and the filtrate was re-heated to 45 - 55 °C and held for about 30 minutes. The filtrate was concentrated in vacuo to about 4.4 volumes at 30 - 40 °C. The residue was cooled to 20 - 30 °C over at least 1 h, water (1.5V) was added over about 45 minutes and the slurry was aged for about 1 h. The slurry was cooled to 3 - 7 °C over about 2 h and aged for about 3 h. The solids were isolated by filtration, washed with 1 :4 (v/v) MeOH - water (2V) and dried in vacuo at 50 - 60 °C to constant weight to afford 88.9 g (86%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 3d: 1 -(tert-butyl) 2-methyl (2S, 5R)-5-(4-hydroxyphenyl)pyrrolidine-1,2-dicarboxylate - flow chemistry procedure</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
reaction 2</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/2Sh859t49sZTRSb1BNn7X2q1yn_hJZxqwsdPuCNfbHcfnvgMcb_MAYCR1uffyM_6WY2Bxc48vx0wNHb0M0_CZIlX6VHOzIfkhCAikpzVNyUojRTgIjmQBgwO0jutESRWfvsH6H14PyltSNd5zbL0lgICC86LJHk7iw5F5IsleW0" height="128" id="imgf000058_0002" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/2Sh859t49sZTRSb1BNn7X2q1yn_hJZxqwsdPuCNfbHcfnvgMcb_MAYCR1uffyM_6WY2Bxc48vx0wNHb0M0_CZIlX6VHOzIfkhCAikpzVNyUojRTgIjmQBgwO0jutESRWfvsH6H14PyltSNd5zbL0lgICC86LJHk7iw5F5IsleW0" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="372" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
The flow direction was from top to bottom (feed solution and hydrogen); and the hydrogen flow rate was 50 ml_ / min (while maintaining desired reaction pressure).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A 25 ml_ tube was packed with glass wool, sand, spherical catalyst beads (3% Pd/0-AI<span style="font-size: 12px; height: 0px; line-height: 0; position: relative; top: 0.5ex; vertical-align: baseline;">2</span>0<span style="font-size: 12px; height: 0px; line-height: 0; position: relative; top: 0.5ex; vertical-align: baseline;">3</span> (1.0 - 1.2 mm spherical pellets)), sand and glass wool to give a 10 ml_ packed bed volume. 4 wt% methyl (S)-5-(4-(benzyloxy)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate and di-ferf- butyldicarbonate (1.2 eq) in MeOH at -5 °C (feed solution 1) was then passed through the flow reactor at 0.08 - 0.10 ml_ / min, at a temperature of 53 - 61 °C and at a pressure of 10 - 15 bar. The collected solution contained a mixture of 1-(te/f-butyl) 2-methyl (2S,5f?)-5-(4- (benzyloxy)phenyl)pyrrolidine-1 ,2-dicarboxylate and 1-(te/f- butyl) 2-methyl (2S, 5f?)-5-(4- hydroxyphenyl)pyrrolidine-1 ,2-dicarboxylate in MeOH (feed solution 2) was passed through the flow reactor at 0.10 mL / min, at a temperature of 78 - 81 °C and at a pressure of 3 bar to produce about 600 g of a methanol solution primarily containing 1-(te/f-butyl) 2-methyl (2S, 5f?)-5-(4-hydroxyphenyl)pyrrolidine-1 ,2-dicarboxylate. This solution was concentrated in vacuo at a temperature of about 40 °C to a net weight of about 3.6X the amount of the input methyl (S)-5-(4-(benzyloxy)phenyl)-3,4-dihydro-2H-pyrrole-2-carboxylate. After stirring the mixture at ambient temperature for 15 - 20 min, water (2V) was added over about 30 min, the resulting mixture was aged for about 30 min, cooled to about 0 °C and aged for about 30 min. Solids were isolated by filtration, washed with ice cold 1 :4 (v/v) MeOH - water (2 X 1V) and dried to constant weight in vacuo at 55 °C to afford 23.51 g (88%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 4a: iert-butyl (2S, 5/?)-2-carbamoyl-5-(4-((2- fluorobenzyl)oxy)phenyl)pyrrolidine-1-carboxylate (D4a) (K2CO3 / ACN procedure using 2-fluorobenzyl bromide)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/1IFSDUcMbhFc1S8GsiIIv48mj7bB-XRgPbEyARTxOLZFwrqLwURvZ-uxPL8Rbhz_H-d_qR2E22OkQyCZKefxuHzGDVBMAxBlRlE4R0T7fZoKE4IFvvkbP6cK9797gRN9EamvsopchJ6mTnqsJc58u18Fm17nP30ZC4JTQV8RI7Q" height="151" id="imgf000059_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/1IFSDUcMbhFc1S8GsiIIv48mj7bB-XRgPbEyARTxOLZFwrqLwURvZ-uxPL8Rbhz_H-d_qR2E22OkQyCZKefxuHzGDVBMAxBlRlE4R0T7fZoKE4IFvvkbP6cK9797gRN9EamvsopchJ6mTnqsJc58u18Fm17nP30ZC4JTQV8RI7Q" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="535" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with 1-(te/f-butyl) 2-methyl (2S, 5f?)-5-(4-hydroxyphenyl)pyrrolidine- 1 ,2-dicarboxylate (1 10 kg), powdered K2CO3 (71.5 kg (1.5 equiv)) and ACN (429 kg). With good stirring, 2-fluorobenzyl bromide (68.2 kg (1.05 equiv)) and ACN (15 kg) were charged and the mixture was heated to 86 - 94 °C; the progress of the reaction was monitored (HPLC). Upon completion, the slurry was cooled to 40 - 50 °C, filtered and the spent filter cake was washed with fresh ACN (175 kg).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
To the ACN filtrate was charged powdered K2CO3 (94.6 kg (2.0 equiv)) and formamide (308 kg (20 equiv)) and the mixture was heated to 86 - 94 °C; the progress of the reaction was monitored (HPLC). Upon completion, the slurry was cooled to 70 - 75 °C and water (1 150 kg) was added while maintaining a reaction temperature of >70 °C. Following the addition the solution was aged for about 30 min, cooled to 65 - 70 °C, seeded (0.55 kg) and aged for 3 - 4 h. The slurry was cooled to 50 - 60 °C, aged 3 - 4 h, cooled to 20 - 30 °C and aged for 3 - 4 h. The solids were isolated by centrifugation, washed twice with water (220 kg) and dried in vacuo at 30 - 40 °C for 4 - 8 h and at 50 - 60 °C for 4 - 8 h to yield 128.75 kg (87.5%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 4b: iert-butyl (2S, 5 ?)-2-carbamoyl-5-(4-((2- fluorobenzyl)oxy)phenyl)pyrrolidine-1-carboxylate (D4b) (NaOMe - MeOH procedure using 2-fluorobenzyl bromide in DMF)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/ghdOqdJEEayox3cHH8IFKlmJaP_5q2Nm6F3ONr8mtOWnAg9w7Pk8fOmKgkpsUSjr0gyQvwrMts-ApdMNGO4e4VmyEqPLIIT0JZgayCFjZpLzZbmk7a6MGeHEDpwfVrsW1gwJMKUGJJwcZH4hu3u5npwWt7eWI-L6oU8NuErFKBY" height="150" id="imgf000060_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/ghdOqdJEEayox3cHH8IFKlmJaP_5q2Nm6F3ONr8mtOWnAg9w7Pk8fOmKgkpsUSjr0gyQvwrMts-ApdMNGO4e4VmyEqPLIIT0JZgayCFjZpLzZbmk7a6MGeHEDpwfVrsW1gwJMKUGJJwcZH4hu3u5npwWt7eWI-L6oU8NuErFKBY" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="539" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with 1-(te/f-butyl) 2-methyl (2S, 5f?)-5-(4-hydroxyphenyl)pyrrolidine- 1 ,2-dicarboxylate (1.0 kg), anhydrous DMF (2.9 L), 2-fluorobenzyl bromide (430 mL (1.12 equiv)) and anhydrous DMF (0.1 L). The solution was cooled to about 15 °C. With good stirring, 741 mL (1.05 equiv) 4.4M NaOMe-MeOH solution was added while maintaining a temperature of <20 °C. Following the charge, the contents of the reactor were warmed to about 25 °C, aged for about 1 h and 44 mL (0.06 equiv) 4.4M NaOMe-MeOH solution was added over about 5 min. The progress of the reaction was monitored (HPLC).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Upon completion, formamide (2.5 L) was charged followed by addition of 81 1 mL (1.15 equiv) 4.4M NaOMe-MeOH solution while maintaining a temperature of <25 °C. The contents of the reactor were aged for about 1 h and 516 mL (0.73 equiv) 4.4M NaOMe-MeOH solution was added while maintaining a temperature of <25 °C. The progress of the reaction was monitored (HPLC). Upon completion, a solution of glacial acetic acid (350 mL (2.0 equiv) in water (2.2 L)) was added over about 10 min. The slurry was heated to about 70 °C and aged for about 1 h. Water (1.8 L) was added over about 1 h and the slurry was cooled to about 3 °C over 3 h and aged for about 10 h. The solids were isolated by filtration, washed twice with water (2 L) and dried to constant weight in vacuo at 80 °C to afford 1.21 kg (94%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 4c: iert-butyl (2S, 5 ?)-2-carbamoyl-5-(4-((2- fluorobenzyl)oxy)phenyl)pyrrolidine-1-carboxylate (D4c) (NaOMe - MeOH procedure using 2-fluorobenzyl bromide in DMF) (Alternative Procedure)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/HNhzyLW5Jcs9u52yGa2rPGOToP4wQ1PFB104FmXGL8mVqSwxAX6Nx-UBk1pR3P0AjYiX6C8tEAX2TIs5ewfrOEWzKAp90lmB87AhVcOQvb-KI00Hdz34vX-6z0mtaB0T_rp7dBr2vKYkNLbzmxED8ccLbBYNPdY46g76kt2sMms" height="150" id="imgf000061_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/HNhzyLW5Jcs9u52yGa2rPGOToP4wQ1PFB104FmXGL8mVqSwxAX6Nx-UBk1pR3P0AjYiX6C8tEAX2TIs5ewfrOEWzKAp90lmB87AhVcOQvb-KI00Hdz34vX-6z0mtaB0T_rp7dBr2vKYkNLbzmxED8ccLbBYNPdY46g76kt2sMms" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="536" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with 1-(te/f-butyl) 2-methyl (2S, 5f?)-5-(4-hydroxyphenyl)pyrrolidine- 1 ,2-dicarboxylate (100 g), anhydrous DMF (290 mL), 2-fluorobenzyl bromide (42.2 mL (1.10 equiv)) and anhydrous DMF (10 mL). The solution was cooled to about 15 °C. With good stirring, 75 mL (1.06 equiv) 4.4M NaOMe-MeOH solution was added over a period of approximately 30 min while maintaining a temperature of <20 °C. Following the charge, the contents of the reactor were warmed to about 25 °C and aged for about 2 h. The progress of the reaction was monitored (HPLC).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Upon completion, formamide (250 mL) was charged followed by addition of 133 mL (1.88 equiv) 4.4M NaOMe-MeOH solution over approximately 45 min while maintaining a temperature of <25 °C. The contents of the reactor were aged for about 4 h. The progress of the reaction was monitored (HPLC). Upon completion, a solution of glacial acetic acid (35 mL (2.0 equiv) in water (100 mL) was added over about 30 min. The slurry was heated to about 60 °C. Water (300 mL) was then charged to the reactor over about 1 h, and the slurry was aged for about 1 h. The slurry was cooled to about 3 °C over 3 h and aged for about 1 h. The solids were isolated by filtration, washed twice with water (200 mL) and dried to constant weight in vacuo at 80 °C to afford 120.0 g (93%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 4d: iert-butyl (2S, 5/?)-2-carbamoyl-5-(4-((2- fluorobenzyl)oxy)phenyl)pyrrolidine-1-carboxylate (D4d) (NaOMe - MeOH procedure using 2-fluorobenzyl chloride in DMF)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/bpFkrg9j_kDKoj_HrY7rNIjB7eMaFSFz0OoquhyxCRPl2aYtPvLwA0fSe-5DuNVcS6Tt3Xi3Nw7hD22AHUCDwS1GRvNQK2uQpshDAXeG4F92YMvnmvnVOoZ_rbZz3BPxBvUxYKjOzhJEOiVCx6KuIs73F8wF-65aky61JeFnwfk" height="150" id="imgf000062_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/bpFkrg9j_kDKoj_HrY7rNIjB7eMaFSFz0OoquhyxCRPl2aYtPvLwA0fSe-5DuNVcS6Tt3Xi3Nw7hD22AHUCDwS1GRvNQK2uQpshDAXeG4F92YMvnmvnVOoZ_rbZz3BPxBvUxYKjOzhJEOiVCx6KuIs73F8wF-65aky61JeFnwfk" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="532" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with 1-(te/f- butyl) 2-methyl (2S, 5R)-5-(4-hydroxyphenyl)pyrrolidine- 1 ,2-dicarboxylate (7.50 g), anhydrous DMF (22.5 mL) and 2-fluorobenzyl chloride (3.20 mL (1.15 equiv)). The solution was cooled to about 15 °C. With good stirring, 5.6 mL (1.06 equiv) 4.4M NaOMe-MeOH solution was added while maintaining a temperature of <25 °C. Following the charge, the contents of the reactor were warmed to about 45 °C over 20 min. The progress of the reaction was monitored (HPLC).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Upon completion, the contents of the reactor were cooled to about 25 °C over about 10 min. Formamide (19 mL) was charged followed by addition of 5.8 mL (1.1 equiv) 4.4M NaOMe- MeOH solution while maintaining a temperature of <25 °C. The contents of the reactor were aged for about 1 h and 3.7 mL (0.7 equiv) 4.4M NaOMe-MeOH solution was added while maintaining a temperature of <25 °C. The progress of the reaction was monitored (HPLC). Upon completion, a solution of glacial acetic acid (2.6 mL (2.0 equiv)) in water (7.5 mL) was added over about 25 min. The slurry was heated to about 65 °C and water (22.5 mL) was added to the solution over about 1 h. The slurry was aged for about 30 min, was cooled to 0 - 5 °C over about 3 h and aged for about 30 min. The solids were isolated by filtration, washed twice with water (7.5 mL) and dried to constant weight in vacuo at 80 °C to afford 8.39 g (90%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 4e: iert-butyl (2S, 5/?)-2-carbamoyl-5-(4-((2- fluorobenzyl)oxy)phenyl)pyrrolidine-1-carboxylate (D4e) (NaOMe - MeOH procedure using 2-fluorobenzyl chloride in DMSO)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/8kSF82R5ZBuJQWiIKD-3azNWmL05ASnnm9UP-qY6MqnOymKccnqtkzuBgNR7cvwB0H3Q1lzn0gzX3V9kJJRa4ORdJLf-J8IJVsqt26Vv47P86Gwt7K-axBxtPRFrQQuBFoO8uX22sFUFBXn0H27uw3EIrbeHhNg6qu6R-Xy3t2c" height="65" id="imgf000063_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/8kSF82R5ZBuJQWiIKD-3azNWmL05ASnnm9UP-qY6MqnOymKccnqtkzuBgNR7cvwB0H3Q1lzn0gzX3V9kJJRa4ORdJLf-J8IJVsqt26Vv47P86Gwt7K-axBxtPRFrQQuBFoO8uX22sFUFBXn0H27uw3EIrbeHhNg6qu6R-Xy3t2c" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="426" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/Js4PgXpYXK1Pp7AoxnNOVUNDoS5GG0M1z_06sON5SORLzer1x3bgb5uKJC6N6uL12df1Y76rHMyFpJheym6jlNM_cJl65dM-oytVeq9wRB343ENHWGO4JA6X7nzH1pMzki2Cgh1LfNo9zyqiRIsSybkE1Q305jjs0mTldjHJraM" height="56" id="imgf000063_0002" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/Js4PgXpYXK1Pp7AoxnNOVUNDoS5GG0M1z_06sON5SORLzer1x3bgb5uKJC6N6uL12df1Y76rHMyFpJheym6jlNM_cJl65dM-oytVeq9wRB343ENHWGO4JA6X7nzH1pMzki2Cgh1LfNo9zyqiRIsSybkE1Q305jjs0mTldjHJraM" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="177" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with 1-(te/f- butyl) 2-methyl (2S, 5R)-5-(4-hydroxyphenyl)pyrrolidine-1 ,2-dicarboxylate (7.50 g), anhydrous DMSO (22.5 mL) and 2-fluorobenzyl chloride (3.20 mL (1.15 equiv)). The solution was cooled to about 15 °C. With good stirring, 5.5 mL (1.06 equiv) 4.5M NaOMe-MeOH solution was added while maintaining a temperature of <25 °C. Following the charge, the contents of the reactor were warmed to about 25 °C over 5 min. The progress of the reaction was monitored (HPLC).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Upon completion, formamide (19 mL) was charged followed by addition of 9.73 mL (1.88 equiv) 4.5M NaOMe-MeOH solution over about 45 min. The progress of the reaction was monitored (HPLC). Upon completion, a solution of glacial acetic acid (2.6 mL (2.0 equiv)) in water (7.5 mL) was added over about 25 min. The slurry was heated to about 65 °C and water (22.5 mL) was added to the solution over about 1 h. The slurry was aged for about 30 min, was cooled to 0 - 5 °C over about 3 h and aged for about 30 min. The solids were isolated by filtration, washed twice with water (7.5 mL) and dried to constant weight in vacuo at 80 °C to afford 8.72 g (90%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 4f: iert-butyl (2S, 5/?)-2-carbamoyl-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-1-carboxylate (D4f) (f-BuOK procedure using 2-fluorobenzyl bromide in ACN - formamide)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
f-BuOK <img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/NuJ9VH64xDH82v5937U7RL9kAG9DSzODnAA5m_rD4X20MIrhAVVbye-ZBVEj-hp1-BoXT-PXrgZdZogLLkN3TOh5aBdoujB2JlIkoM8w2RzvggR0hlJvHLcSLFjtQhEXqGBXnms_dMGfFczEOLBhBR3-D-vSpd6mr8vxHjOrhJ0" height="64" id="imgf000063_0003" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/NuJ9VH64xDH82v5937U7RL9kAG9DSzODnAA5m_rD4X20MIrhAVVbye-ZBVEj-hp1-BoXT-PXrgZdZogLLkN3TOh5aBdoujB2JlIkoM8w2RzvggR0hlJvHLcSLFjtQhEXqGBXnms_dMGfFczEOLBhBR3-D-vSpd6mr8vxHjOrhJ0" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="424" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/2W5slCRHSo5rPQ3ec_cxLrxFD_ITc4u6viPqTL9BExUhBWp5K9l_epd-yq85_XqImPfrdHYWGEQIJNtL6lxAM_1ytFHy3mDsLokC_LQfZCb4hPo7NE0WcVsGgoKKgEIVZ2wfmUzDWX2RXB-4KfHejOFKAoFFk7bi6A6LseJoRNs" height="54" id="imgf000063_0004" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/2W5slCRHSo5rPQ3ec_cxLrxFD_ITc4u6viPqTL9BExUhBWp5K9l_epd-yq85_XqImPfrdHYWGEQIJNtL6lxAM_1ytFHy3mDsLokC_LQfZCb4hPo7NE0WcVsGgoKKgEIVZ2wfmUzDWX2RXB-4KfHejOFKAoFFk7bi6A6LseJoRNs" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="177" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with 1-(te/f- butyl) 2-methyl (2S, 5R)-5-(4-hydroxyphenyl)pyrrolidine-1 ,2-dicarboxylate (10.0 g), anhydrous ACN (30 mL), 2-fluorobenzyl bromide (4.18 mL (1.05 equiv)) and formamide (10 mL). The solution was cooled to 0 - 5 °C. With good stirring, 3.67 g (1.05 equiv) f-BuOK was added followed by warming the contents of the reactor to about 15 °C. The progress of the reaction was monitored (HPLC).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Upon completion, the contents of the reactor were cooled to 0 - 5 °C and 4.71 g (1.35 equiv) f-BuOK was added followed by warming the contents of the reactor to about 15 °C. The progress of the reaction was monitored (HPLC). Upon completion, the contents of the reactor were warmed to about 65 °C and a solution of glacial acetic acid (4.14 mL (2.3 equiv)) in water (10 mL) was added. Additional water (40 mL) was added over about 30 min. The contents of the reactor were cooled to 0 - 5 °C and filtered. The filter cake was washed twice with water (10 mL) and dried to constant weight in vacuo at 80 °C to afford 10.93 g (85%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 4g: iert-butyl (2S, 5 ?)-2-carbamoyl-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-1-carboxylate (D4g) (f-BuONa procedure using 2-fluorobenzyl bromide in ACN - formamide)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
f-BuONa-THF</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/J04dX7LhQUf1oK2YXBpkgRIW5O1yv_pDNiux9aEH9La8emzURUmtQRvmloV_W-9qdRYO4TQVEV2ofASV27yIUjVjMX3s5nFuUzLDF8tyVDIRLik-P6hK0LuZAwuWop20JI8xGOEDVO9t0I1F2QF7AMHd1CfFs6YLkRxvu_uDF8Y" height="149" id="imgf000064_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/J04dX7LhQUf1oK2YXBpkgRIW5O1yv_pDNiux9aEH9La8emzURUmtQRvmloV_W-9qdRYO4TQVEV2ofASV27yIUjVjMX3s5nFuUzLDF8tyVDIRLik-P6hK0LuZAwuWop20JI8xGOEDVO9t0I1F2QF7AMHd1CfFs6YLkRxvu_uDF8Y" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="429" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with 1-(te/f- butyl) 2-methyl (2S, 5R)-5-(4-hydroxyphenyl)pyrrolidine-1 ,2-dicarboxylate (10.0 g), anhydrous ACN (30 mL), 2-fluorobenzyl bromide (4.18 mL (1.05 equiv)) and formamide (1.5 mL). The solution was cooled to 0 - 5 °C. With good stirring, 16.4 mL (1.05 equiv) 2M f-BuONa - THF solution was added followed by warming the contents of the reactor to about 15 °C. The progress of the reaction was monitored (HPLC).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Upon completion, the contents of the reactor were cooled to 0 - 5 °C and formamide (8.5 mL) was added, followed by 21 mL (1.35 equiv) 2M f-BuONa - THF solution, and the contents of the reactor were warmed to about 15 °C. The progress of the reaction was monitored (HPLC). Upon completion, the contents of the reactor were warmed to about 65 °C and a solution of glacial acetic acid (4.14 mL (2.3 equiv)) in water (10 mL) was added. Additional water (40 mL) was added over about 30 min. The contents of the reactor were cooled to 0 - 5 °C and filtered. The filter cake was washed twice with water (10 mL) and dried to constant weight in vacuo at 80 °C to afford 11.06 g (86%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 4h: tert-butyl (2S, 5S)-2-carbamoyl-5-(4-((2-</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/a3Ytn46_FcM6xBTT5N-bBDppTsyY7bMmeMGaGPznmbiHqTo8cllGgUldwXuBne395NJ1tgT5LN0O2-RxAQBtRH11vp_QMoitp9AkzHAV_4ZTPQSjBs3HnJtRECDQjDFCMbu2rIDMHjQB_uxAo6KOArs_BKtx4fgDYRT5GXLCG1I" height="172" id="imgf000065_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/a3Ytn46_FcM6xBTT5N-bBDppTsyY7bMmeMGaGPznmbiHqTo8cllGgUldwXuBne395NJ1tgT5LN0O2-RxAQBtRH11vp_QMoitp9AkzHAV_4ZTPQSjBs3HnJtRECDQjDFCMbu2rIDMHjQB_uxAo6KOArs_BKtx4fgDYRT5GXLCG1I" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="516" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with 1-(te/f-butyl) 2-methyl (2S, 5f?)-5-(4-hydroxyphenyl)pyrrolidine-1 ,2-dicarboxylate (264 Kg), anhydrous DMF (748 kg) and 2-fluorobenzyl bromide (171 Kg (1.10 eq)). The solution was cooled to about 15 °C. With good stirring, 157 Kg (1.06 eq) 30% NaOMe-MeOH solution was added over at least 30 min while maintaining a temperature between 20 - 30 °C. Following the charge, the line was rinsed forward with MeOH (18 kg), and the batch was maintained at about 25 °C for at least 1 h. The progress of the reaction was monitored for completion (HPLC).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Upon completion, formamide (749 Kg) was charged followed by a line rinse with MeOH (18 kg). 279 Kg (1.88 eq) 30% NaOMe-MeOH solution was added over at least 45 min while maintaining a temperature of about 25 °C followed by a line rinse with MeOH (18 kg). The contents of the reactor were maintained at about 25 °C with agitation for about 4 h. The progress of the reaction was monitored for completion (HPLC). Upon completion, the batch was transferred to a second reactor and the equipment was rinsed forward with MeOH (155 Kg). Glacial acetic acid (97 Kg) was added to the batch over at least 15 min while maintaining a temperature of 20 - 30 °C followed by the addition of water (264 Kg). The batch was heated to 60 °C and water (792 Kg) was added over at least 2 h with good agitation. The batch was maintained at 60 °C with agitation for at least 1 h. The batch was cooled to about 2 °C over at least 3 h and aged for at least 1 h. The solids were isolated by filtration and washed twice with water (528 Kg per wash). The wet cake was dried to constant weight in vacuo at 67 °C to afford 315.4 kg (93%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 4i: tert-butyl (2S, 5S)-2-carbamoyl-5-(4-((2-</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/G_FYaHCzaSzjlV5CuqttwCYXUrxz5nhLFilgFPfgKVGEYBvUjbmr1GKJbghMohqjgI74P5LxYjyc__lheS9NS7z_ofLVUTKT7zsND7Vj2q5uzOKFaunu1WW1CNOduILdRMp5rRmReBfByBqgsEOsowf6e_FuMSI8Onmy801rIs0" height="170" id="imgf000066_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/G_FYaHCzaSzjlV5CuqttwCYXUrxz5nhLFilgFPfgKVGEYBvUjbmr1GKJbghMohqjgI74P5LxYjyc__lheS9NS7z_ofLVUTKT7zsND7Vj2q5uzOKFaunu1WW1CNOduILdRMp5rRmReBfByBqgsEOsowf6e_FuMSI8Onmy801rIs0" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="516" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with 1-(te/f-butyl) 2-methyl (2S, 5f?)-5-(4-hydroxyphenyl)pyrrolidine-1 ,2-dicarboxylate (70 g), anhydrous DMF (198.2 g) and 2-fluorobenzyl bromide (45.3 g (1.10 equiv)). With good agitation, 41.4 g (1.06 equiv) 30% NaOMe-MeOH solution was added over about 60 min while maintaining a temperature of 20 - 30 °C. The addition funnel was rinsed forward into the reactor with MeOH (2.4 g). The batch was maintained at about 25 °C for at least 1 h; the progress of the reaction was monitored for completion (HPLC).</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Upon completion, formamide (238.1 g) was charged followed by rinsing forward the charging equipment with MeOH (2.4 g). 30% NaOMe-MeOH solution (66.5 g (1.70 equiv)) was added over 45 min while maintaining temperature at about 25 °C. The addition funnel was rinsed forward into the reactor with MeOH (2.4 g). The batch was stirred for about 4 h at 25 °C; the progress of the reaction was monitored for completion (HPLC). Upon completion, the batch was transferred to a second reactor and the equipment was rinsed forward with MeOH (20.6 g). Glacial acetic acid (25.7 g) was added while maintaining a temperature of 20 - 30 °C. Water (70 g) was added over about 20 min and the batch was heated to 60 °C. Water (280 g) was added over at least 2 h with good agitation. The batch was maintained at 60 °C with agitation for at least 1 h, cooled to 0-3 °C over at least 3 h and aged for at least 1 h. The solids were isolated by filtration, washed with water/MeOH 70:30 v/v (140 ml_) and water (140 g). The wet cake was dried to constant weight in vacuo at 80 °C to afford 83.7 g (93%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 5a: (2S,5 ?)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide (E1)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/asqeY_fDX7EFLeU1xzWxDXGOhGinV2e5kvB6YOxP9FeTYYhjMGh9IUc7Ci-9MgNXSRifbANpEi-AZP2x6ilXZDU8Vv2_48Qq69wVRvy-yVyTK5Qjs9xQ2QjpBS2_ofVKsE9W0HQAMn2l6XFNsMBFhoCBjGVKNDOSEqIymmjoyrU" height="53" id="imgf000067_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/asqeY_fDX7EFLeU1xzWxDXGOhGinV2e5kvB6YOxP9FeTYYhjMGh9IUc7Ci-9MgNXSRifbANpEi-AZP2x6ilXZDU8Vv2_48Qq69wVRvy-yVyTK5Qjs9xQ2QjpBS2_ofVKsE9W0HQAMn2l6XFNsMBFhoCBjGVKNDOSEqIymmjoyrU" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="438" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with te/f-butyl (2S, 5f?)-2-carbamoyl-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-1-carboxylate (which may be prepared as described in Description 4) (375.1 kg) and ACN (825.6 kg). With good agitation, methanesulfonic acid (1 14.8 kg (1.3 equiv) was added while maintaining a reaction temperature of 20 - 25 °C followed by ACN (50 kg). The contents of the reactor were warmed to 40 - 50 °C and aged for 2 - 3 h. The progress of the reaction was monitored (HPLC). Upon completion, a solution of 1.0N NH4OH (377 kg) was added while maintaining a reaction temperature of 40 - 50 °C. The reaction temperature was raised to 48 - 52 °C and 1.0N NH4OH (1495 kg) was added slowly with good stirring while maintaining the reaction temperature within this range. The slurry was cooled to -3 to 3 °C over 3 - 4 h and was aged for 1 - 2 h. The solids were isolated by centrifugation (3 drops) and each portion was washed twice with water (182 - 189 kg). The solids were dried in vacuo at 30 °C for 4 h, at 50 °C for 4 h and to constant weight at 80 °C (10 h) to afford 256.4 kg (90.5%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 5b: (2S,5 ?)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide hydrochloride (1 :1 ) (E2)</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/O3Tn2OZTxSVZcNefDdkyBuz5iMvaGs5Npd3grylF0X9wa9Rna9yRBFjYpe5b5e8fxyLJPs7tKIIeCBPHwovSJTxnaE9IB8ebQvAthBbIDzEmjOJLY6nNlnEs-0hU9fZq-dbFvf3ZUyAHipduY9hTCKomrRWmkwwsQIbEcT7aeOo" height="53" id="imgf000067_0002" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/O3Tn2OZTxSVZcNefDdkyBuz5iMvaGs5Npd3grylF0X9wa9Rna9yRBFjYpe5b5e8fxyLJPs7tKIIeCBPHwovSJTxnaE9IB8ebQvAthBbIDzEmjOJLY6nNlnEs-0hU9fZq-dbFvf3ZUyAHipduY9hTCKomrRWmkwwsQIbEcT7aeOo" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="436" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with 2-propanol (672 kg) and the solvent was cooled to -10 to 0 °C. With good agitation, HCI (90 kg) was introduced while maintaining a reaction temperature of -10 - 0 °C. A sample of the solution was removed for concentration determination.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with te/f-butyl (2S, 5f?)-2-carbamoyl-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-1-carboxylate (which may be prepared as described in Description 4) (160 kg) and 2-propanol (1280 kg). Wth good agitation, the prepared HCI - 2- propanol solution (5.3 eq) was added while maintaining a reaction temperature of 20 - 30 °C. The contents of the reactor were warmed to 30 - 35 °C and aged for 12 - 16 h. The progress of the reaction was monitored (HPLC). Upon completion, the contents of the reactor were cooled to 0 - 10 °C, concentrated and aged for 2 - 3 h at 0 - 10 °C. The solids were filtered, washed with 2-propanol (105 kg) and dried in vacuo at 60 - 70 °C for 15 - 20 h to afford 132 kg (96%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 5c: (2S,5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide - method A</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/V54S1E4qX_DzhqaDX52j6pJkyfkIJHL2GU7zrjAZrxmtggZEi8Ti3nvN1PxG6QWy3KHMXpKrUhQyaYb3ZHC5_OUqpnjCeIVq6TZcN8zVtD_V70T9BrUR5edje2YsYPhEixKNvkq1WE5bfi0DjSeBOvlTk66qtjevCU6830Xflco" height="68" id="imgf000068_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/V54S1E4qX_DzhqaDX52j6pJkyfkIJHL2GU7zrjAZrxmtggZEi8Ti3nvN1PxG6QWy3KHMXpKrUhQyaYb3ZHC5_OUqpnjCeIVq6TZcN8zVtD_V70T9BrUR5edje2YsYPhEixKNvkq1WE5bfi0DjSeBOvlTk66qtjevCU6830Xflco" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="504" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with terf-butyl (2S, 5S)-2-carbamoyl-5-(4-((2- fluorobenzyl)oxy)phenyl)pyrrolidine-1-carboxylate (307 Kg) and acetonitrile (612 Kg). With good agitation, methanesulfonic acid (30 Kg (1.28 equiv)) was added over at least 30 min while maintaining a reaction temperature of 20 - 30 °C. The batch was warmed to 30 °C, aged for about 30 min and heated to 45 °C over about 30 min. The batch was maintained at 45°C for 2 h; the progress of the reaction was monitored for completion (HPLC). Upon completion, the batch was transferred to a second reactor, rinsed forward with acetonitrile (108 Kg) and 1.7% aqueous NH4OH solution (304 Kg) was added while maintaining a temperature of about 40 - 50 °C. The reaction temperature was raised to about 46 - 52 °C and 1.7% NH<span style="font-size: 12px; height: 0px; line-height: 0; position: relative; top: 0.5ex; vertical-align: baseline;">4</span>OH solution (1216 Kg) was added slowly over 2 h with good stirring while maintaining the reaction temperature within this range. The batch was aged at 50 °C for about 1 h, cooled to 0 °C over at least 3 h and aged for about 1 h. The solids were isolated by filtration and washed twice with water (614 Kg per wash). The solids were dried in vacuo at 70 °C to constant weight to afford 218 Kg (94%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 5d: (2S,5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide - meth</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/n1FiPZXLtC6FPV5b-vsOQIu5xtdkZtLJjy2Spm-4zJw1O_Zgl3KHe6JLcHChkC_UpmJjzLEYJ3ShVAHBKkhybULBEzIxI5exJy9-dzrEfRVPbFqqempvw57XaT96eVv5C6clYPqYXoJmc_t3U9X9JtLxNMhNhDaCSDCCs77BN34" height="53" id="imgf000068_0002" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/n1FiPZXLtC6FPV5b-vsOQIu5xtdkZtLJjy2Spm-4zJw1O_Zgl3KHe6JLcHChkC_UpmJjzLEYJ3ShVAHBKkhybULBEzIxI5exJy9-dzrEfRVPbFqqempvw57XaT96eVv5C6clYPqYXoJmc_t3U9X9JtLxNMhNhDaCSDCCs77BN34" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="438" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with terf-butyl (2S, 5S)-2-carbamoyl-5-(4-((2- fluorobenzyl)oxy)phenyl)pyrrolidine-1-carboxylate (100 g) and ACN (199.5 g). With good agitation, methanesulfonic acid (29.7 g (1.28 equiv)) was added while maintaining a reaction temperature of 20 - 30 °C. The batch was warmed to 30 °C, aged for at least 30 min and heated to 45 °C over at least 30 min. The batch was maintained at 45 °C for 2 h; the progress of the reaction was monitored for completion (HPLC). Upon completion, the batch was transferred to a second reactor; the first reactor was rinsed forward with ACN (35.4 g). A solution of 1.7% aqueous NH4OH (99.0 g) was added at 40 - 50 °C over at least 15 min. The reaction temperature was raised to 49 °C and 1.7% NH4OH solution (396.0 g) was added slowly over at least 2 h with good stirring while maintaining the reaction temperature at about 49 °C. The slurry was aged for 30 - 90 min, cooled to 0°C over 3 h and aged for at least 1 h. The solids were isolated by filtration and washed with water/acetonitrile 90: 10 v/v (200 mL) and water (200 g). The solids were dried in vacuo at 70 °C to constant weight to afford 71.6 g (94%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 5e: (2S,5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide hydrochloride</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/8o9zVgVys0JNDQYkwkra0Z3k_4WbnBBJSi727_yvJtGFSZiyu1TeMEJMo4l3yyIVF8JkO3sXiVUCNM5tP14QZO_F2cnHepYQBlmqecX9Y-UYpdqfHfhjxbdJ7pWJTom7UR0j90fA3RS0-u23lsbth22VRh3cMDNRHUUS6OvAf74" height="66" id="imgf000069_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/8o9zVgVys0JNDQYkwkra0Z3k_4WbnBBJSi727_yvJtGFSZiyu1TeMEJMo4l3yyIVF8JkO3sXiVUCNM5tP14QZO_F2cnHepYQBlmqecX9Y-UYpdqfHfhjxbdJ7pWJTom7UR0j90fA3RS0-u23lsbth22VRh3cMDNRHUUS6OvAf74" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="437" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A reactor was charged with terf-butyl (2S, 5S)-2-carbamoyl-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-1-carboxylate (160 kg) and isopropanol (1280 kg) at 20 -30 °C. A solution of 2.6M HCI in isopropanol (5.3 eq) was added over about 2 h at 20 - 35 °C. The contents of the reactor were warmed to 30 - 35 °C, and the progress of the reaction was monitored for completion (HPLC). The contents of the reactor were cooled to about 10 °C over about 3 h, concentrated in vacuo for about 1 h and aged at 5 - 10 °C for about 2 h under an inert atmosphere of nitrogen. Solids were filtered, washed with isopropanol (125 kg) and dried to constant weight in vacuo at 60 - 70 °C to give 132.05 kg (96%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 6a: l-(tert-butyl) 2-methyl (2S, 5R)-5-(4-hydroxyphenyl)pyrrol</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
dicarbo</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/XK1pBNvvslDgCRuD6D-kigRplpuGCF1VtngJs-RFGMupjFqvF3HOnUFuBheu0cRScwWZLyCHRXC9SiTonot5jY50F_FbTleQ6Dk-meO_3sPmeWTnNg06rmdOrshT06Ac2gs_NGV9L6dFHrBMsFPOaX8CPLgQclYNckoxg-VHm_I" height="108" id="imgf000069_0002" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/XK1pBNvvslDgCRuD6D-kigRplpuGCF1VtngJs-RFGMupjFqvF3HOnUFuBheu0cRScwWZLyCHRXC9SiTonot5jY50F_FbTleQ6Dk-meO_3sPmeWTnNg06rmdOrshT06Ac2gs_NGV9L6dFHrBMsFPOaX8CPLgQclYNckoxg-VHm_I" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="417" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A hydrogenation reactor was charged with 10% Pd(OH)2/C (water wet; 1.06 g), benzyl (S)-5-(4-(benzyloxy)phenyl)-2-((tert-butoxycarbonyl)amino)-5-oxopentanoate (23 g), MeOH (140</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
ml_) and di-te/f-butyldicarbonate (1 1.3 g, 1.02 eq). The reactor was pressurized with hydrogen (8 bar) and stirred (300 rpm) for 3 h at ambient temperature followed by stirring at 50 °C for an additional 5 h. The contents of the reactor were cooled to ambient temperature and filtered. The filtrate was concentrated to dryness and the residue was reconstituted in warm MeOH (30 ml_). The contents of the flask were cooled to ambient temperature. The solids were isolated by filtration and dried in vacuo at 60 °C to constant weight to afford 9.6 g (60%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
Description 6b: 1 -(tert-butyl) 2-methyl (2S, 5R)-5-(4-hydroxyphenyl)pyrrolidine-1,2-dicarbo</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<img data-mce-src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/p7oYHNp7FEH4-C9yao3vPhSdlaHg4qaOss7k8Y0Xzx3XvQ9ngHn5IYwNvEbXBMaJ9LN6DQuMh4kCI8Mrmr8azOFX0D2gid3uaIpJmiKRgU1ScGgqyUed0zajtletH7ODAjQ3KbusuZDQ-YWPrBftbefwQKPvRgH3HQ6kbP93n_s" height="108" id="imgf000070_0001" src="https://patentscope.wipo.int/search/docs2/nat/WO2019071162/pic/p7oYHNp7FEH4-C9yao3vPhSdlaHg4qaOss7k8Y0Xzx3XvQ9ngHn5IYwNvEbXBMaJ9LN6DQuMh4kCI8Mrmr8azOFX0D2gid3uaIpJmiKRgU1ScGgqyUed0zajtletH7ODAjQ3KbusuZDQ-YWPrBftbefwQKPvRgH3HQ6kbP93n_s" style="height: auto; margin-bottom: 10px; margin-top: 8px; max-width: 100%;" width="417" /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
A hydrogenation reactor was charged with 20% Pd(OH)2/C (water wet; 2.25 g), benzyl (S)-5-(4-(benzyloxy)phenyl)-2-((terf-butoxycarbonyl)amino)-5-oxopentanoate (74.59 g (71.00 g activity)), di-terf-butyldicarbonate (35.27 g, 1.01 eq) and MeOH (415 g). Following three vacuum / nitrogen break cycles, the reactor was pressurized with hydrogen (4 bar) and stirred (-2200 rpm) for about 105 min at 25 °C, then heated to 35 °C and held for an additional 1 h. The reactor was vented, additional MeOH (59 g) was charged, and the reduction was continued at 35 °C, 4 bar and -2200 rpm. The progress of the reaction was monitored for completion (HPLC). Celite® (2.5 g) was added, and the mixture was filtered through a pad of Celite® (2.5 g) and the spent pad was washed with warm MeOH (59 g). The filtrate was concentrated at 40 °C and 200 mbar to a net weight of about 179 g. The contents of the flask were warmed to solution at about 55 °C, slowly cooled to ambient temperature and aged for about 30 min. Water (100 g) was added over about 1 h, and the mixture was aged overnight at ambient temperature. The mixture was cooled to 0-5 °C, aged for about 3 h and filtered. The solids were washed with cold 1 :4 (v/v) MeOH - water (2 X 48 g) and dried in vacuo at 55 °C to constant weight to afford 43.98 g (89%) of the title compound.</div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px 0px 1em;">
<br /></div>
<div style="color: #222222; font-family: "Open Sans", Tahoma, Verdana, Segoe, sans-serif; font-size: 16px; padding: 0px;">
///////////VIXOTRIGINE, NEW PATENT, WO-2019071162, BIOGEN INC</div>
</div>
DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com6tag:blogger.com,1999:blog-4738331378048275307.post-64641450842322589772018-05-02T03:40:00.001-07:002018-05-02T03:40:21.622-07:00NEW PATENTS<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<div class="MsoNormal" style="background-color: white; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<table border="0" cellpadding="0" cellspacing="0" class="m_-4074227035675163036m_-3467028666573152227m_7002886133043969538MsoNormalTable" style="background-color: white; border-collapse: collapse; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;"><tbody>
<tr style="height: 7.05pt;"><td style="border: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">Sr no<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<span style="color: #1f497d;">Patent number<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #1f497d;">name<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #1f497d;">company<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #1f497d; font-family: "Arial Black", sans-serif;">INDICATION<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #1f497d;">REMARKS, WAIT FOR STR TO APPEAR<u></u><u></u></span></div>
</td></tr>
<tr style="height: 7.05pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">1<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">US-20180107407</span></u><span style="color: red;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">ORIPAVINE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">JOHNSON<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Drug dependence; Pain</span><i><span style="color: red; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Oripavin.svg" class="CToWUd" height="116" id="m_-4074227035675163036m_-3467028666573152227m_7002886133043969538Picture_x0020_2" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1631951765d0d743&attid=0.0.5&disp=emb&realattid=18abfbbc2a4146d5_0.1&attbid=ANGjdJ-_s_TMfTshZ9NASAjhsqONUgnTnICL4z1XNvZxQUYrf8D-tfnH9Gr9SLOXnU04BmldsrgfIdgvdnUSgjlR0hg2XlVOPr6Z2Hb2A2pR8D1wqd5EqDSRn-6KiTI&sz=w300-h232&ats=1525257314249&rm=1631951765d0d743&zw&atsh=1" width="150" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">2<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018071564</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">LEVODOPA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">TEXAS<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_-4074227035675163036m_-3467028666573152227m_7002886133043969538ng-binding">Dystonia; Parkinsons disease</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Image result for LEVADOPA" class="CToWUd" height="126" id="m_-4074227035675163036m_-3467028666573152227m_7002886133043969538Picture_x0020_3" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1631951765d0d743&attid=0.0.1&disp=emb&realattid=18abfbbc2a4146d5_0.3&attbid=ANGjdJ8EiinIy4FtofY8gIY1VRjE935CqB0EFk5oYpmDKkS0CWgSaOeLVEv3LYLaCjYD4XO_oOF2vfbf5nsio8YXunXgDaO8SXT8_U2-uPn2Wb9W-9NdfQl4gfpAJWQ&sz=w500-h252&ats=1525257314251&rm=1631951765d0d743&zw&atsh=1" width="250" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">3<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018069941</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #ed7d31;">VENETOCLAX<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #ed7d31;">MYLAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_-4074227035675163036m_-3467028666573152227m_7002886133043969538ng-binding">Chronic lymphocytic leukemia</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Venetoclax.svg" class="CToWUd" height="138" id="m_-4074227035675163036m_-3467028666573152227m_7002886133043969538Picture_x0020_4" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1631951765d0d743&attid=0.0.7&disp=emb&realattid=18abfbbc2a4146d5_0.4&attbid=ANGjdJ_9MC7et6SQGfmFjIy0pYya-BW5nByjzzqW3VbUS4ROEwQ4aUuYbhcZyBmlcUVS9ellqz1Npb0jVF-ZOP5DmfwjMmT4T0JTEfMFS6HLdpQfxPGqv5w0PIhtMJc&sz=w550-h276&ats=1525257314251&rm=1631951765d0d743&zw&atsh=1" width="275" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 92.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">4<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018069936</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">BETRIXABAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">MYLAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Thromboembolism</span><i><span style="color: #7030a0; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Betrixaban.svg" class="CToWUd" height="186" id="m_-4074227035675163036m_-3467028666573152227m_7002886133043969538Picture_x0020_5" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1631951765d0d743&attid=0.0.2&disp=emb&realattid=18abfbbc2a4146d5_0.5&attbid=ANGjdJ99066ycbnDyB6heClsl94WWfUsze0blF_QJ_NHdnv1WqyNAbT9Z_BFV-orSbqqk7wIf9FcBq6RyyMIB_VBsflhFMx_cIWRFpOaM-latWjs1uqglSn6k9mjRJM&sz=w440-h372&ats=1525257314261&rm=1631951765d0d743&zw&atsh=1" width="220" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 116.4pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">5<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018069243</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">EMPAGLIFLOZIN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">BOEHRINGER<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Non-insulin dependent diabetes</span><i><span style="color: #00b050; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Empagliflozin.svg" class="CToWUd" height="65" id="m_-4074227035675163036m_-3467028666573152227m_7002886133043969538Picture_x0020_6" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1631951765d0d743&attid=0.0.6&disp=emb&realattid=18abfbbc2a4146d5_0.6&attbid=ANGjdJ92cjQ7rCNeGPWHSwcXDRQzMxwM-GrcAmhKX2Fe_pQLzcpE6EaIUO2-PneO_LJZa9S1tetXTaNBAE7vUTSDu6lRmmmOSMBTrGsnrECuUAbgfekqzDJ8RXqcn54&sz=w500-h130&ats=1525257314268&rm=1631951765d0d743&zw&atsh=1" width="250" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 124.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">6<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018068733</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">NINTEDANIB<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">SHANGHAI<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_-4074227035675163036m_-3467028666573152227m_7002886133043969538ng-binding">Idiopathic pulmonary fibrosis</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Nintedanib" class="CToWUd" height="156" id="m_-4074227035675163036m_-3467028666573152227m_7002886133043969538Picture_x0020_7" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1631951765d0d743&attid=0.0.4&disp=emb&realattid=18abfbbc2a4146d5_0.7&attbid=ANGjdJ-S3xfKhtyUuI0HK6j0IIHeRHcSL6wjRC1CDCdzT8DykkfOrsVb5U-6mehegiGuVjNOUi_qVv4ArWnA5GI-K6FV5TAUdMqxXnjUsEA2c_Itm_-TYxyzpQ4R0Ns&sz=w440-h312&ats=1525257314270&rm=1631951765d0d743&zw&atsh=1" width="220" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 90.6pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">7<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018068690</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">BREXPIPRAZOLE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">SHANGHAI<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Depression; Psychiatric disorder; Schizophrenia</span><i><span style="color: #00b050; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Brexpiprazole.svg" class="CToWUd" height="181" id="m_-4074227035675163036m_-3467028666573152227m_7002886133043969538Picture_x0020_8" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1631951765d0d743&attid=0.0.3&disp=emb&realattid=18abfbbc2a4146d5_0.8&attbid=ANGjdJ-kCDHe6Bonlmeg5mFEL1JJq7TLdDKtQanM-9bWba5ElZHVU0tJjhmc4vmjroLYlq2oJlNR6xLqJCwQ7_91T-AOcm6M1XQfSzluwi3qkpqGm9YWp-EGuejgtaw&sz=w350-h362&ats=1525257314272&rm=1631951765d0d743&zw&atsh=1" width="175" /></span></div>
</td></tr>
</tbody></table>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<table border="0" cellpadding="0" cellspacing="0" class="m_-4268130746304824795MsoNormalTable" style="background-color: white; border-collapse: collapse; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;"><tbody>
<tr style="height: 7.05pt;"><td style="border: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">Sr no<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<span style="color: #1f497d;">Patent number<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #1f497d;">name<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #1f497d;">company<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #1f497d; font-family: "Arial Black", sans-serif;">INDICATION<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #1f497d;">REMARKS, WAIT FOR STR TO APPEAR<u></u><u></u></span></div>
</td></tr>
<tr style="height: 7.05pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">1<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018073839</span></u><span style="color: red;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">OSIMERTINIB<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">MYLAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_-4268130746304824795ng-binding">Metastatic non small cell lung cancer</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Osimertinib.svg" class="CToWUd" height="147" id="m_-4268130746304824795Picture_x0020_2" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1631ecf5e6516bcf&attid=0.2&disp=emb&attbid=ANGjdJ8sTZJP935hi56lb9wDH7Ej27XP7pFeU62tXu-cnAEyiQ3dDuQvEkTUpKc6-CwPSixhfVyPTwFBdlKzBiuTNGQ4a9AHlSTHgRA0YPfLi2AxnKoDmJBfutlf2Bk&sz=w500-h294&ats=1525257314000&rm=1631ecf5e6516bcf&zw&atsh=1" width="250" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">2<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018072662</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">ROXADUSTAT<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">MYLAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Anemia</span><i><span style="color: red; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Roxadustat structure.png" class="CToWUd" height="133" id="m_-4268130746304824795Picture_x0020_3" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1631ecf5e6516bcf&attid=0.3&disp=emb&attbid=ANGjdJ8u_xwDVGgT1S8dNskqZHx-5HGzE7OCje5A9zuJhw6fpRphk4yupmiS7oqXrs2PdZDaTq54IezDJgU2Cix_LpfGh8_tnqExV8lXyKwafeZA4I6o5pJ2uc8etYI&sz=w500-h266&ats=1525257314002&rm=1631ecf5e6516bcf&zw&atsh=1" width="250" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">3<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018072300</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #ed7d31;">ENZALUTAMIDE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #ed7d31;">HINOVA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Prostate tumor</span><b><i><span style="color: #ed7d31; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></b></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Enzalutamide-01.svg" class="CToWUd" height="122" id="m_-4268130746304824795Picture_x0020_4" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1631ecf5e6516bcf&attid=0.4&disp=emb&attbid=ANGjdJ_O4cHsHf3E2dNaS-mucRxQIiSYphLBZigG6Klv4f78qmoXcajo-_ry8cmo4cUGaQjKQv8ssVYeDlwuKoNd9hOFR6NsBV36vM9uvVaGpR-woNjX8O8ofp_zkiw&sz=w500-h244&ats=1525257314002&rm=1631ecf5e6516bcf&zw&atsh=1" width="250" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"></td></tr>
<tr style="height: 116.4pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
</tbody></table>
</div>
DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com0tag:blogger.com,1999:blog-4738331378048275307.post-19982378025417744472018-04-17T06:34:00.002-07:002018-04-17T06:34:26.634-07:00APRIL 2018 New patents<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">APRIL 2018</span><span style="color: #c00000; font-size: 20pt;"><u></u><u></u></span></div>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="color: #ed7d31; font-size: 20pt;">New patents,<u></u><u></u></span></div>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<table border="0" cellpadding="0" cellspacing="0" class="m_-3912433730556978381MsoNormalTable" style="background-color: white; border-collapse: collapse; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;"><tbody>
<tr style="height: 7.05pt;"><td style="border: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">Sr no<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<span style="color: #1f497d;">Patent number<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #1f497d;">name<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #1f497d;">company<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #1f497d; font-family: "Arial Black", sans-serif;">INDICATION<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #1f497d;">REMARKS, WAIT FOR STR TO APPEAR<u></u><u></u></span></div>
</td></tr>
<tr style="height: 7.05pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">1<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">EP-03305769</span></u><span style="color: red;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">ROXADUSTAT<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">ZENTIVA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: red; font-family: "Arial Black", sans-serif;">ANEMIA<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Roxadustat structure.png" class="CToWUd" height="133" id="m_-3912433730556978381Picture_x0020_2" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162d199f755af8f7&attid=0.2&disp=emb&attbid=ANGjdJ8UoEK8sRHH7jD_dneHgZq6SMgOJKdQTeXD8OcpwhCIXEw-vMvIbqk2i_uJ1Y2BqgNXzfsaqU4OwofW2rxc6_IP3gO-OzJJbhY9NMT__8K8Kxu8O1Yuv_fsEhs&sz=w500-h266&ats=1523971695078&rm=162d199f755af8f7&zw&atsh=1" width="250" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">2<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">EP-03305799</span></u><span style="color: red;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">OBETICHOLIC ACID<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">LUPIN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: red; font-family: "Arial Black", sans-serif;">P</span></i><span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"> rimary biliary cirrhosis</span><i><span style="color: red; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Obeticholic acid.svg" class="CToWUd" height="149" id="m_-3912433730556978381Picture_x0020_3" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162d199f755af8f7&attid=0.3&disp=emb&attbid=ANGjdJ89XztD7e25tvQMkpOFuNG897sgQIsR64NxvXhz4kSM_rMRKYOrcBYujYrcaPYAFB88Js0qv557BgqoMo2Y8TJit_OmhyRBDm-gXW81nuaLMN8KmbinRWaeRGE&sz=w500-h298&ats=1523971695080&rm=162d199f755af8f7&zw&atsh=1" width="250" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">3<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018067945</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #ed7d31;">VALBENAZINE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #ed7d31;">ASSIA TEVA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Huntingtons chorea; Tardive dyskinesia; Tourette syndrome</span><b><i><span style="color: #ed7d31; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></b></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Valbenazine.svg" class="CToWUd" height="198" id="m_-3912433730556978381Picture_x0020_4" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162d199f755af8f7&attid=0.4&disp=emb&attbid=ANGjdJ8y7N_ATJtSkcXbGa_NRqxKFwlTwM4SV7mmd14NYt5srtCsCSrhWhXC8sJrfZN1wiuuSistOvl24MxSIwIktOyDwHPzlPo5hjCcptrgBAdI4TqG9XHmOi-9iFM&sz=w440-h396&ats=1523971695081&rm=162d199f755af8f7&zw&atsh=1" width="220" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 92.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">4<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018067805</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">SOTAGLIFLOZIN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">TEVA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Diabetes mellitus</span><i><span style="color: #7030a0; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Image result for SOTAGLIFLOZIN" class="CToWUd" height="250" id="m_-3912433730556978381Picture_x0020_5" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162d199f755af8f7&attid=0.5&disp=emb&attbid=ANGjdJ8fUPaF9Wg_De85tyLxWxxsablM9cphUuKd6w52jS93DGmHvfZbKG5GplenL3ecfNov051dWzFpwnwiwPC_uVcd37tusUDweTUFpmn6Vs_7UgaTQABDl_ZTJdA&sz=w500-h500&ats=1523971695085&rm=162d199f755af8f7&zw&atsh=1" width="250" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 116.4pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">5<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018066004</span></u><span style="color: #00b050;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">DORZOLAMIDE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">INDOCO<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Glaucoma; Ocular hypertension</span><i><span style="color: #00b050; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Dorzolamide.svg" class="CToWUd" height="166" id="m_-3912433730556978381Picture_x0020_6" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162d199f755af8f7&attid=0.6&disp=emb&attbid=ANGjdJ-2NUcDhdOJ6y7ZiAM5dII6LHmjobwy3hHrQA5eKiIdM95aC4mCngjM22LdqwyD87VT2l8OMOR6ltOGLLI7zCAkXHFi1E2LIvr9pwb3q83ASIEmf8tfplECm1Q&sz=w400-h332&ats=1523971695087&rm=162d199f755af8f7&zw&atsh=1" width="200" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 124.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">6<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018065999</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">PALBOCICLIB<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">MYLAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Breast tumor</span><i><span style="color: #00b050; font-family: "Albertus Medium", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Palbociclib.svg" class="CToWUd" height="115" id="m_-3912433730556978381Picture_x0020_7" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162d199f755af8f7&attid=0.7&disp=emb&attbid=ANGjdJ8xUqb5w13TQ-W-JNXe5CKpXyDHmphTIGp2aRxcDuTrxrcBUgq6nWK0WQqJpqrJwhlUIPEt5WveNsl3Er5Y3CW0Ry6LrTMeojHnJnAX3lP8EAbGG8ueXZyJ8Ao&sz=w440-h230&ats=1523971695089&rm=162d199f755af8f7&zw&atsh=1" width="220" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 90.6pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">7<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018065924</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">BINIMETINIB<u></u><u></u></span></div>
<div class="MsoNormal">
<span style="color: #00b050;">SELUMETINIB<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">SUN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Cancer; Melanoma</span><i><span style="color: #00b050; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Selumetinib skeletal.svg" class="CToWUd" height="126" id="m_-3912433730556978381Picture_x0020_9" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162d199f755af8f7&attid=0.8&disp=emb&attbid=ANGjdJ-Cf34fJtDTJv3TDP1BKX5UYGkjeJNnxm86U4FXvGYcy2GQBocJ9GO6qa6jAKohyB57GgGBBtLliuW9PRqgPjQTtP45RjgvLbw1pUr0Ay8CMUNySvvZ6xceIkY&sz=w440-h252&ats=1523971695091&rm=162d199f755af8f7&zw&atsh=1" width="220" /><img alt="Binimetinib.svg" class="CToWUd" height="182" id="m_-3912433730556978381Picture_x0020_8" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162d199f755af8f7&attid=0.9&disp=emb&attbid=ANGjdJ93GQLGd73bhpml79z91bH4d1DG88hFgiIkMqCU_tVXIL6O0Gq2Ata_2iDrnvKIOPByw5OBF64EDdiOGxhO04iuVqwfk8564OX_5SJ8--36Cw5bmuvTGlYd23c&sz=w440-h364&ats=1523971695091&rm=162d199f755af8f7&zw&atsh=1" width="220" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 85.45pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">8<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018064797</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">ACALABRUTINIB<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">SOLIPHARMA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Autoimmune disease; Inflammatory disease; Lymphoma</span><i><span style="color: #7030a0; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Acalabrutinib.svg" class="CToWUd" height="155" id="m_-3912433730556978381Picture_x0020_10" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162d199f755af8f7&attid=0.10&disp=emb&attbid=ANGjdJ9M8FgRKq4uZ2kUt1nUXQCnMLgeoU0C6a3aTbq-_VDN7NQvGY-FUs1UrlyZ0DvUniaNRtdRUIiX3mDcxOo_KfjRi-u0mKGfUApLSFmjj_jkRSd2XtUgud-fkv0&sz=w440-h310&ats=1523971695093&rm=162d199f755af8f7&zw&atsh=1" width="220" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 75.9pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">9<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"></td></tr>
</tbody></table>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="color: #1f497d; font-size: 24pt;"><u></u> </span><span style="color: #ed7d31; font-size: 20pt;">,</span></div>
<div class="MsoNormal" style="background-color: white; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<table border="0" cellpadding="0" cellspacing="0" class="m_-7172525831720680631m_3187354923923376211MsoNormalTable" style="background-color: white; border-collapse: collapse; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;"><tbody>
<tr style="height: 7.05pt;"><td style="border: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">Sr no<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<span style="color: #1f497d;">Patent number<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #1f497d;">name<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #1f497d;">company<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #1f497d; font-family: "Arial Black", sans-serif;">INDICATION<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #1f497d;">REMARKS, WAIT FOR STR TO APPEAR<u></u><u></u></span></div>
</td></tr>
<tr style="height: 7.05pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">1<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018064585</span></u><span style="color: red;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">ODALASVIR<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">ACHILLION<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_-7172525831720680631m_3187354923923376211ng-binding">Hepatitis C virus infection</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Odalasvir structure.svg" class="CToWUd" height="97" id="m_-7172525831720680631m_3187354923923376211Picture_x0020_2" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162b3e5517ef2036&attid=0.0.9&disp=emb&realattid=9d9ff93b64edd440_0.1&attbid=ANGjdJ9ozddEZG3wPZv8reAAsoyG16sK3uDH5CQW182JFdefw2UkPKRQF44anLrNsImqh0NntumvAPYLbrJvapEcUGoJyFh1zgvgt3cN5Od6NZnUhwGVyLuV8YvuKAo&sz=w600-h194&ats=1523971698080&rm=162b3e5517ef2036&zw&atsh=1" width="300" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">2<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<span style="background: rgb(250, 250, 252); color: #505050; font-family: sourceSansProRegular; font-size: 9.5pt;"><a data-saferedirecturl="https://www.google.com/url?hl=en-GB&q=https://www.cortellis.com/intelligence/report/ci/patentFamily/4001847&source=gmail&ust=1524058098107000&usg=AFQjCNEDyv9WBVxOBCn67WXvdcvoMFVxaw" href="https://www.cortellis.com/intelligence/report/ci/patentFamily/4001847" style="color: #1155cc;" target="_blank"><span style="color: #0078ae; font-size: 10.5pt;">WO-2018062799</span></a></span><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">ASIVATREP<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">AMOREPACIFIC<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Asthma; Chronic obstructive pulmonary disease; Dermatological disease; Inflammatory bowel disease; Inflammatory disease; Irritable bowel syndrome</span><i><span style="color: red; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Asivatrep.png" border="0" class="CToWUd a6T" height="300" id="m_-7172525831720680631m_3187354923923376211Picture_x0020_3" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162b3e5517ef2036&attid=0.0.4&disp=emb&realattid=9d9ff93b64edd440_0.2&attbid=ANGjdJ-DYvKOSYEjPisq7E8jolV7N_w-BCeTKfDRkt6m4Mb1uGl5c-nUmUlcx4AtEoev5FjiijeZkAth_zI16mkQxjSBm7-YY86F3I7DpxkgpA3l0waejiy1P8ClKK0&sz=w600-h600&ats=1523971698082&rm=162b3e5517ef2036&zw&atsh=1" style="cursor: pointer; outline: 0px;" tabindex="0" width="300" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">3<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018061034</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #ed7d31;">APREMILAST<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #ed7d31;">SUN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Arthritis</span><b><i><span style="color: #ed7d31; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></b></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Apremilast.svg" border="0" class="CToWUd" height="160" id="m_-7172525831720680631m_3187354923923376211Picture_x0020_4" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162b3e5517ef2036&attid=0.0.1&disp=emb&realattid=9d9ff93b64edd440_0.3&attbid=ANGjdJ-gWp0kMdP5bb-wdzRWIzC7q3wk3E_Iwucj3reRm4lAVF3Eye0An3mwa_axXjbOy_Z98jYPfxtLB28aBxQamx9UrezX4dAmfjJTxH9acJ-ecnHzudrGgVdvXWE&sz=w430-h320&ats=1523971698082&rm=162b3e5517ef2036&zw&atsh=1" width="215" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 92.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">4<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018060916</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">BREXPIPRAZOLE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">ALEMBIC<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_-7172525831720680631m_3187354923923376211ng-binding">Major depressive disorder; Schizophrenia</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Brexpiprazole.svg" border="0" class="CToWUd" height="181" id="m_-7172525831720680631m_3187354923923376211Picture_x0020_5" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162b3e5517ef2036&attid=0.0.3&disp=emb&realattid=9d9ff93b64edd440_0.4&attbid=ANGjdJ85UO_n4z71C-JYUEz0ik-KPjX3XiLJWzhNgzva-bpRwkvkPBDmkkeawmdEqCaMmDyTSY1Ky1e3a3jyUiFZFj9cx2P8MgLbGUioIRkoOl3iAkMQpUzYhRpu0WQ&sz=w350-h362&ats=1523971698086&rm=162b3e5517ef2036&zw&atsh=1" width="175" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 116.4pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">5<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018060781</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">LACOSAMIDE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">UNICHEM<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Epilepsy; Partial seizure</span><i><span style="color: #00b050; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Lacosamide.svg" border="0" class="CToWUd" height="126" id="m_-7172525831720680631m_3187354923923376211Picture_x0020_6" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162b3e5517ef2036&attid=0.0.7&disp=emb&realattid=9d9ff93b64edd440_0.5&attbid=ANGjdJ-XS7mLMP3-SDmV7oK6Thodp6A_sg0tSfhrJl9j9WPQGbySvVJAcstIZGTxcr-xhxc9r9vRv7LY2JhiKMPvSXQqpDJruBM0io7SQYuxxweWxvlLm6AbaOQyuj0&sz=w440-h252&ats=1523971698088&rm=162b3e5517ef2036&zw&atsh=1" width="220" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 124.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">6<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018059914</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">GADOBUTROL<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">BAYER<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Artery disease; Brain tumor; Breast tumor; Central nervous system disease; Vascular disease</span><i><span style="color: #00b050; font-family: "Albertus Medium", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Gadobutrol skeletal.svg" border="0" class="CToWUd" height="187" id="m_-7172525831720680631m_3187354923923376211Picture_x0020_7" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162b3e5517ef2036&attid=0.0.10&disp=emb&realattid=9d9ff93b64edd440_0.6&attbid=ANGjdJ8Lg0yhqlRfklefn6eL_rUHkAz6lxc3JmPIJ_5A4QNus76qyKG5ls6xIX7LYM50ygNfoYXoasta_9NJ-hjDsyRrbrEUAgYS24ZmHqI9I4EPUmWHIXRFtB8bpbA&sz=w440-h374&ats=1523971698090&rm=162b3e5517ef2036&zw&atsh=1" width="220" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 90.6pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">7<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018059556</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">VOROLANIB<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">BETTA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_-7172525831720680631m_3187354923923376211ng-binding">Gastrointestinal stromal tumor; Renal cell carcinoma</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Vorolanib.png" border="0" class="CToWUd a6T" height="300" id="m_-7172525831720680631m_3187354923923376211Picture_x0020_8" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162b3e5517ef2036&attid=0.0.5&disp=emb&realattid=9d9ff93b64edd440_0.7&attbid=ANGjdJ96R9eNs5K6ejkULMkmpb1rRGMn8ouGUUnhf5FcUIB4_mY8flBtOHRUpyqVbAvxbjO_-ncVXn0_IJ2Ruaud_CYtqTL-vfVTXYX8JOsK_T7HWV8AaxqP63_ifww&sz=w600-h600&ats=1523971698091&rm=162b3e5517ef2036&zw&atsh=1" style="cursor: pointer; outline: 0px;" tabindex="0" width="300" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 85.45pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">8<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<span style="background: rgb(250, 250, 252); color: #505050; font-family: sourceSansProRegular; font-size: 9.5pt;"><a data-saferedirecturl="https://www.google.com/url?hl=en-GB&q=https://www.cortellis.com/intelligence/report/ci/patentFamily/4001276&source=gmail&ust=1524058098107000&usg=AFQjCNGo0YeGUT2C1gDehcmUTd8oTTWjFA" href="https://www.cortellis.com/intelligence/report/ci/patentFamily/4001276" style="color: #1155cc;" target="_blank"><span style="color: #0078ae; font-size: 10.5pt;">WO-2018059531</span></a></span><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">TOZADENANT<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">CRYSTAL<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Alzheimers disease; Anxiety disorder; Attention deficit hyperactivity disorder; Depression; Huntingtons chorea; Parkinsons disease; Schizophrenia</span><i><span style="color: #7030a0; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Tozadenant.png" border="0" class="CToWUd a6T" height="300" id="m_-7172525831720680631m_3187354923923376211Picture_x0020_9" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162b3e5517ef2036&attid=0.0.8&disp=emb&realattid=9d9ff93b64edd440_0.8&attbid=ANGjdJ_zpAOj0AVT-ae2SCsTTg-OjLniiJiYyyClJTuB4TCvGT24AMZmsmdlWj-CKb_Z7FWdijx-WRqjIkClXAFakdeAD44s7vrDkFALGEJ0Re0Au3KZNT068YNmvSo&sz=w600-h600&ats=1523971698093&rm=162b3e5517ef2036&zw&atsh=1" style="cursor: pointer; outline: 0px;" tabindex="0" width="300" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 75.9pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">9<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018059288</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">MACITENTAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">SEASONS<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Idiopathic pulmonary arterial hypertension</span><i><span style="color: #00b050; font-family: "Albertus Medium", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Macitentan skeletal.svg" border="0" class="CToWUd" height="104" id="m_-7172525831720680631m_3187354923923376211Picture_x0020_10" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162b3e5517ef2036&attid=0.0.6&disp=emb&realattid=9d9ff93b64edd440_0.9&attbid=ANGjdJ8yNj-kvp9ZalBIqinvvCWWzZc40g3g9woJbPyZQJjUGmaI8Nq-oykGqvvYPqpkd3Urr9lZAi8jVKzd3ayQAI44Gy1I7wr7JcwGedoSkTAanPeZYl6NpWZHJnY&sz=w440-h208&ats=1523971698095&rm=162b3e5517ef2036&zw&atsh=1" width="220" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">10<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018058296</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">AZELIRAGON<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">SOLIPHARMA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Alzheimers disease</span><i><span style="color: #00b050; font-family: "Albertus Medium", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Azeliragon.png" border="0" class="CToWUd a6T" height="300" id="m_-7172525831720680631m_3187354923923376211Picture_x0020_11" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=162b3e5517ef2036&attid=0.0.2&disp=emb&realattid=9d9ff93b64edd440_0.10&attbid=ANGjdJ-uEI5bQ-B5Rv5bjrg219NJxUAlLvrZsq5V0XOA1RgvJvlyvCm5y_uW_BY3G3zRsbocDo8224TEU9MQbuCwCIh5-rc4po28NcaxBJvUmDdr4DaZONVtEf80Yho&sz=w600-h600&ats=1523971698095&rm=162b3e5517ef2036&zw&atsh=1" style="cursor: pointer; outline: 0px;" tabindex="0" width="300" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 14pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"></td></tr>
</tbody></table>
<div class="MsoNormal" style="background-color: white; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<div class="MsoNormal" style="background-color: white; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<div>
<span style="color: #00b0f0; font-size: 22pt;"><br /></span></div>
</div>
DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com2tag:blogger.com,1999:blog-4738331378048275307.post-2404217257561915312018-04-03T07:01:00.001-07:002018-04-03T07:01:16.645-07:002 APRIL 2018 NEW PATENTS<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal">
<span style="color: #c00000; font-size: 20pt;">New patents<u></u></span></div>
<div class="MsoNormal">
<span style="background: white; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">APRIL 2018</span><span style="color: #c00000; font-size: 20pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<span style="color: #ed7d31; font-size: 20pt;">9 new patents,<u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
<table border="0" cellpadding="0" cellspacing="0" class="m_1163272300761642575MsoNormalTable" style="border-collapse: collapse;"><tbody>
<tr style="height: 7.05pt;"><td style="border: 1pt solid windowtext; font-family: arial, sans-serif; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">Sr no<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; font-family: arial, sans-serif; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<span style="color: #1f497d;">Patent number<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; font-family: arial, sans-serif; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #1f497d;">name<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; font-family: arial, sans-serif; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #1f497d;">company<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; font-family: arial, sans-serif; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #1f497d; font-family: "Arial Black", sans-serif;">INDICATION<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; font-family: arial, sans-serif; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #1f497d;">REMARKS, WAIT FOR STR TO APPEAR<u></u><u></u></span></div>
</td></tr>
<tr style="height: 7.05pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">1<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018055642</span></u><span style="color: red;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">TIOTROPIUM<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">GBR<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background: white; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Asthma; Chronic obstructive pulmonary disease</span><i><span style="color: red; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Tiotropium.svg" class="CToWUd" height="107" id="m_1163272300761642575Picture_x0020_2" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1628988501d3330b&attid=0.1&disp=emb&attbid=ANGjdJ8z1_RqKk6vau-NRhwFUdQZ3B9sWbMG-0C86QzNBtcjN_TnSRC9xcw1Ekl5GLtbkUfDHlbwRvPhZeJygbjSEgXfNFIRMJGmIRkiO5J6wJUwz42uUUKYerQjbaI&sz=w300-h214&ats=1522763580426&rm=1628988501d3330b&zw&atsh=1" width="150" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">2<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018055528</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">ELUXADOLINE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">SUN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background: white; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Diarrhea predominant irritable bowel syndrome</span><i><span style="color: red; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Eluxadoline.svg" class="CToWUd" height="178" id="m_1163272300761642575Picture_x0020_3" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1628988501d3330b&attid=0.3&disp=emb&attbid=ANGjdJ9-SG_2MuMp1ynM6bitYyk11uPJfsHvT96ibD-aFZz0Wt4sRitZrzr8JstDOz7_cw3guLd40WiBhRLbMb0suh2EtIS3DiWWWPYzj-VlrpYxvR43cdPG-YXtSsI&sz=w510-h356&ats=1522763580428&rm=1628988501d3330b&zw&atsh=1" width="255" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">3<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018055499</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #ed7d31;">LINEZOLID<u></u><u></u></span></div>
<div class="MsoNormal">
<span style="color: #ed7d31;">RIVAROXABAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #ed7d31;">PHALANX<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_1163272300761642575ng-binding">Bacterial pneumonia; Bacterial skin infection; Coronary artery disease; Deep vein thrombosis; Diabetic foot ulcer; Gram positive bacterium infection; Lung embolism; Peripheral vascular disease; Thromboembolism</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Skeletal formula of linezolid" class="CToWUd" height="111" id="m_1163272300761642575Picture_x0020_4" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1628988501d3330b&attid=0.4&disp=emb&attbid=ANGjdJ_r6rDLexZyREozFw4iKn3jVNE6A7PLOULpENZDnWqFdI-A47WrrRFECzRlc_QGSwRQHqUzL0-k4DqEu4B3AMiBWd_LmoddayCsYFEnrJow58rpxBGoZ8WM09Y&sz=w440-h222&ats=1522763580428&rm=1628988501d3330b&zw&atsh=1" width="220" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Rivaroxaban2DCSD.svg" class="CToWUd" height="144" id="m_1163272300761642575Picture_x0020_6" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1628988501d3330b&attid=0.5&disp=emb&attbid=ANGjdJ_j5enby5sNZT-WmFEIGgGxLk40fxwooEhVUd-T8qSEMo-j3T56morj4SSsQ0qPASta7H5rTmWN-vSpwkU9GoOeeYvY9VzEb2kuDFpu1ht7ebLhbCy3NSkvHMg&sz=w500-h288&ats=1522763580428&rm=1628988501d3330b&zw&atsh=1" width="250" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 92.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">4<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018055496</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">ERTUGLIFLOZIN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">GRANULES<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background: white; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Non-insulin dependent diabetes</span><i><span style="color: #7030a0; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Ertugliflozin.svg" class="CToWUd" height="74" id="m_1163272300761642575Picture_x0020_7" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1628988501d3330b&attid=0.6&disp=emb&attbid=ANGjdJ_ujX7bkuIMYM4Qy0nk-vq5yleHs4bvxqVXz4vBbd03z_UcRF4uxSyDus6FZHZ2pa1obhH6kTsOgI8UD2hErLYRM6Az_rVliGnu_VoiyMAT8KLmD6mOU8pozLw&sz=w440-h148&ats=1522763580430&rm=1628988501d3330b&zw&atsh=1" width="220" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 116.4pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">5<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018054792</span></u><span style="color: #00b050;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">LENVATINIB<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">INDENA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #00b050; font-family: "Arial Black", sans-serif;">CANCER<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Lenvatinib skeletal.svg" class="CToWUd" height="126" id="m_1163272300761642575Picture_x0020_8" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1628988501d3330b&attid=0.7&disp=emb&attbid=ANGjdJ8THLCXdI9ORYEQEgqEeMZo3zcOo2Xsm3HLWs9bo2as5jTxsi77NF-9y7N9cOx1xNoAP2w7paNVcPXGUoZiY9pkEpHzNMEiJsYEHuWoRFycfbH3T1096NSqM-k&sz=w440-h252&ats=1522763580431&rm=1628988501d3330b&zw&atsh=1" width="220" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 124.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">6<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018054359</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">CANERTINIB<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">SHANGHAI<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #00b050; font-family: "Albertus Medium", sans-serif;">CANCER<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Canertinib.svg" class="CToWUd" height="106" id="m_1163272300761642575Picture_x0020_9" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1628988501d3330b&attid=0.8&disp=emb&attbid=ANGjdJ8xXv-poiUb6BmTG59fwdc1JGm3ot9qSKdLt_U4PmxdPyzW8T02vnVVCHOfeKYVm23BTsNl6mN_Cnxa_fQMOO592j5G360HtvL7y0izP1o2OjEtsK2vadJZdTM&sz=w400-h212&ats=1522763580432&rm=1628988501d3330b&zw&atsh=1" width="200" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 90.6pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">7<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018054300</span></u><span style="color: #00b050;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">OBETICHOLIC ACID<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">JIANGSU<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_1163272300761642575ng-binding">Cancer; Cardiovascular disease; Gastrointestinal disease; Stroke</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Obeticholic acid.svg" class="CToWUd" height="149" id="m_1163272300761642575Picture_x0020_10" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1628988501d3330b&attid=0.9&disp=emb&attbid=ANGjdJ_c3UX7M52_vOxJuRXmRm9VfJKq-_xcEPv04XoWrTQI_BYxg3XfwrFNLUAwUgFzsA-oEdqvY_-fOE0AkRYfNSJSX__aCnfyWJ3cY2Z2YF-9tnJJbk1efZUEosM&sz=w500-h298&ats=1522763580433&rm=1628988501d3330b&zw&atsh=1" width="250" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 85.45pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">8<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018057576</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">BEFIRADOL<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">AUSPEX<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_1163272300761642575ng-binding">Anxiety disorder; Bipolar disorder; Depression; Migraine</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="F-13640 structure.png" class="CToWUd" height="209" id="m_1163272300761642575Picture_x0020_11" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1628988501d3330b&attid=0.10&disp=emb&attbid=ANGjdJ9q_9RqOmPbXJxbxkeMVQMXDVFj87CESH1LCWYs7HDtV_nMPI3F0nBfYjLd669GpIxVz2YKTcP5kzuMZYsE6idgpCyZrB7JN_MC7OP135raoMZ1ovAaacOpqtc&sz=w440-h418&ats=1522763580434&rm=1628988501d3330b&zw&atsh=1" width="220" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 75.9pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">9<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018054270</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">VELTAPASVIR<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">SHANGHAI<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Hepatitis C virus infection</span><i><span style="color: #00b050; font-family: "Albertus Medium", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; font-family: arial, sans-serif; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Velpatasvir.svg" class="CToWUd" height="230" id="m_1163272300761642575Picture_x0020_12" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1628988501d3330b&attid=0.11&disp=emb&attbid=ANGjdJ9qpfsxK9Q0_ixMhQAesm5FOpBwp_-ewgJN7Pb9WrepDsEPaqUbvWV-Dtt-xf-i6VC6eXp3GLzwZpHRM0rtjLI4amTX1lybnLaNItbp01rqAjhnLKu_X3g1e3w&sz=w550-h460&ats=1522763580435&rm=1628988501d3330b&zw&atsh=1" width="275" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="background-color: white; border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; color: #222222; font-family: arial, sans-serif; font-size: 12.8px; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="background-color: white; border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; color: #222222; font-family: arial, sans-serif; font-size: 12.8px; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="background-color: white; border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; color: #222222; font-family: arial, sans-serif; font-size: 12.8px; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="background-color: white; border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; color: #222222; font-family: arial, sans-serif; font-size: 12.8px; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="background-color: white; border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; color: #222222; font-family: arial, sans-serif; font-size: 12.8px; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="background-color: white; border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; color: #222222; font-family: arial, sans-serif; font-size: 12.8px; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"></td></tr>
</tbody></table>
</div>
DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com0tag:blogger.com,1999:blog-4738331378048275307.post-20958225532357802492018-03-28T17:54:00.004-07:002018-03-28T17:54:42.405-07:00NEW PATENTS<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="color: #c00000; font-size: 20pt;">New patents </span></div>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">END march 2018</span><span style="color: #c00000; font-size: 20pt;"><u></u><u></u></span></div>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="color: #ed7d31; font-size: 20pt;">8 new patents,<u></u><u></u></span></div>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<table border="0" cellpadding="0" cellspacing="0" class="m_6202508574827272349MsoNormalTable" style="background-color: white; border-collapse: collapse; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;"><tbody>
<tr style="height: 7.05pt;"><td style="border: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">Sr no<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<span style="color: #1f497d;">Patent number<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #1f497d;">name<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #1f497d;">company<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #1f497d; font-family: "Arial Black", sans-serif;">INDICATION<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #1f497d;">REMARKS, WAIT FOR STR TO APPEAR<u></u><u></u></span></div>
</td></tr>
<tr style="height: 7.05pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">1<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018053057</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">RELEBACTAM<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">MERCK<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Bacterial infection</span><i><span style="color: red; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Relebactam anhydrous.png" class="CToWUd a6T" height="300" id="m_6202508574827272349Picture_x0020_3" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16265a0263dc1cea&attid=0.3&disp=emb&attbid=ANGjdJ-nnJQh8pHnQv1i_dH55cAQea_RXU3k2PJODQU6T8pIk-W69c46uHk9eOFTmw6HTVFuOqLwNjeviuNxhRC_E1wdfitfZVOiloqaUJGFjNB4jJyDQyIT0ltwJgQ&sz=w600-h600&ats=1522284269084&rm=16265a0263dc1cea&zw&atsh=1" style="cursor: pointer; outline: 0px;" tabindex="0" width="300" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">2<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018051280</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">RIBOCICLIB<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">REDDYS<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Metastatic breast cancer</span><i><span style="color: red; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Ribociclib skeletal.svg" class="CToWUd" height="107" id="m_6202508574827272349Picture_x0020_2" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16265a0263dc1cea&attid=0.2&disp=emb&attbid=ANGjdJ_ZPoNk4ccYf7vk14Evmubq2mIHGYshHh4yqi4kmmxhP7s2Rbl2-Idk3pabqUhvp2_EIhaR-j2V0CqBc74UmnKYroAMUkEfw0GiFAxkLsxWpeDkTt9H7Tbw_VI&sz=w440-h214&ats=1522284269085&rm=16265a0263dc1cea&zw&atsh=1" width="220" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">3<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018051237</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #ed7d31;">CARFILZOMIB<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #ed7d31;">FRASENIUS<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Multiple myeloma</span><i><span style="color: #ed7d31; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Carfilzomib structure.svg" class="CToWUd" height="138" id="m_6202508574827272349Picture_x0020_4" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16265a0263dc1cea&attid=0.4&disp=emb&attbid=ANGjdJ-PKx87XLsOppJtevA741kktfMLs-diXEBRNwuIYDG6VIqcs9a-wBWGfm0AKB74WW3kay4MddDlnEcTmJNqwKxy8xjinbMC7-i5qrdHoRIbvzhUwh5DK6zyMLE&sz=w550-h276&ats=1522284269086&rm=16265a0263dc1cea&zw&atsh=1" width="275" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 92.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">4<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018051042</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">AGOMELATINE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Les Laboratoires Servier</span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #7030a0; font-family: "Arial Black", sans-serif;">DEPRESSION<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Agomelatine formula.svg" class="CToWUd" height="138" id="m_6202508574827272349Picture_x0020_5" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16265a0263dc1cea&attid=0.5&disp=emb&attbid=ANGjdJ_m2b7ngBXOaj2K-7t7LKIFnrvoMtgjcOV47Ts2gi0vUQciUz4tq__-kW7tmRzVjRtKVJNH46fwodMMa4RWlOznsrawZDHdre8rTZPkgivMibmnWvxgd0AvSGA&sz=w440-h276&ats=1522284269091&rm=16265a0263dc1cea&zw&atsh=1" width="220" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 116.4pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">5<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018049836</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">PIMAVANSERIN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">SHANGHAI<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_6202508574827272349ng-binding">Psychotic disorder</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Pimavanserin structure.svg" class="CToWUd" height="115" id="m_6202508574827272349Picture_x0020_6" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16265a0263dc1cea&attid=0.6&disp=emb&attbid=ANGjdJ9lh5A2wRc6KDs03u0YGUPhBVvsga0DOg1VcuhtmfwQdjN86rgA32Af-Sw_MrrKfrn4RtNNKLjo6P-xtfe8uAAhfLVT9LI4PUMkgdRiGosau04hrqvWFDKskOo&sz=w500-h230&ats=1522284269094&rm=16265a0263dc1cea&zw&atsh=1" width="250" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 124.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">6<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018049634</span></u><span style="color: #00b050;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">VENETOCLAX<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">SOLIPHARMA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #00b050; font-family: "Albertus Medium", sans-serif;">CANCER<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Venetoclax.svg" class="CToWUd" height="138" id="m_6202508574827272349Picture_x0020_7" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16265a0263dc1cea&attid=0.7&disp=emb&attbid=ANGjdJ-EuQE1-l_xV7oCCzfNpX3WTbx_Glil6MNi7ZU6O1JYV8bcVkaD4imfwmYm6ddYqPyMvYShKDAovoAm2hUK6gpzAQk1MIxbZ1PrDNATfG3KcCV7pP7_20jMZeI&sz=w550-h276&ats=1522284269097&rm=16265a0263dc1cea&zw&atsh=1" width="275" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 90.6pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">7<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;"><br />WO-2018049632</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">OZANIMOD<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">SOLIPHARMA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_6202508574827272349ng-binding">Adult respiratory distress syndrome; Arthritis; Multiple sclerosis; Transplant rejection; Ulcerative colitis</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Ozanimod.svg" class="CToWUd" height="139" id="m_6202508574827272349Picture_x0020_8" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16265a0263dc1cea&attid=0.8&disp=emb&attbid=ANGjdJ8JzqJUsRD9LyBt0N4H6S30_2hTVgZhPI7Y35OdV5rXlYv7JFTe4_jDOxC34PtnjVZMm9Ot9sx_3XVwzN6YvR4vUFafAhBBNHK3tJieQqWMQ6aYHKFrmz1GEsE&sz=w570-h278&ats=1522284269099&rm=16265a0263dc1cea&zw&atsh=1" width="285" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 85.45pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">8<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /></span><u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018049733</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">EPSILON CAPROLACTONE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">SOUTH CHINA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">MRSA infection</span><i><span style="color: #7030a0; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="ε-Caprolactone 97%" class="CToWUd" height="200" id="m_6202508574827272349Picture_x0020_9" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16265a0263dc1cea&attid=0.9&disp=emb&attbid=ANGjdJ8vy_SaiLzd3NS4X7tRFrKOlbGl8bFV4QZpu61_Q4uW8epw-zwAu1isI-S-ztUIoTelNicV8fwWLEgLUXaPUrzqkUhCjy4JhUASUZAGV_dyQ1jYJJhzcSpQi9U&sz=w456-h400&ats=1522284269101&rm=16265a0263dc1cea&zw&atsh=1" width="228" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 75.9pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
</tbody></table>
</div>
DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com0tag:blogger.com,1999:blog-4738331378048275307.post-47375700033131289392018-03-21T17:51:00.003-07:002018-03-21T17:51:45.827-07:0019 march 2018 New patents<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">19 march 2018</span><span style="color: #c00000; font-size: 20pt;"><u></u><u></u></span></div>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="color: #ed7d31; font-size: 20pt;">7 new patents,<u></u><u></u></span></div>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<table border="0" cellpadding="0" cellspacing="0" class="m_5731915688253576374MsoNormalTable" style="background-color: white; border-collapse: collapse; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;"><tbody>
<tr style="height: 7.05pt;"><td style="border: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">Sr no<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<span style="color: #1f497d;">Patent number<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #1f497d;">name<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #1f497d;">company<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #1f497d; font-family: "Arial Black", sans-serif;">INDICATION<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #1f497d;">REMARKS, WAIT FOR STR TO APPEAR<u></u><u></u></span></div>
</td></tr>
<tr style="height: 7.05pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">1<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018048871</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">SOLRIAMFETOL<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">JAZZ<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Cataplexy; Depression; Drug dependence; Hypersomnia; Narcolepsy; Sexual dysfunction</span><i><span style="color: red; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Solriamfetol.svg" class="CToWUd" height="105" id="m_5731915688253576374Picture_x0020_2" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16241a3915149869&attid=0.2&disp=emb&attbid=ANGjdJ8MLMMOUWiJ5lmRJZ-pCRDvKNgiMOq2iOKCFQsuSjS3xZVdZa92zXCGygIYjkxtiXpZRcd6q3khmrLMumYJ9lvqpO6WWMUBKzVt9XzLNdKFL4bSiIvKqpj2NMo&sz=w440-h210&ats=1521679711598&rm=16241a3915149869&zw&atsh=1" width="220" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">2<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018047131</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">ELUXADOLINE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">SUN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Irritable bowel syndrome</span><i><span style="color: red; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Image result for ELUXADOLINE" class="CToWUd" height="250" id="m_5731915688253576374Picture_x0020_3" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16241a3915149869&attid=0.3&disp=emb&attbid=ANGjdJ-TGlmQj5vZnzQA7onJ3jsEa-QePfx4SpCBQLhpAfn0_8gsief2EsN0pMFvn5gz14BVoJaTzeErZyGCNaZ7ChRqg7i4ulgw_0Uyk-hu4TQy0IO_K5LMWkuJDqM&sz=w500-h500&ats=1521679711600&rm=16241a3915149869&zw&atsh=1" width="250" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">3<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018046401</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #ed7d31;">BETRIXABAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #ed7d31;">SANDOZ<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Phlebothrombosis</span><i><span style="color: #ed7d31; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Image result for BETRIXABAN" class="CToWUd" height="179" id="m_5731915688253576374Picture_x0020_4" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16241a3915149869&attid=0.9&disp=emb&attbid=ANGjdJ8110Yxsef2C0cMcvhnngb4qBdF_IseNmZZhkpW8z2NHfpWZPQJ-eOhkYcV7eo_HZlRY_ICtIZ6at7x3OTYVvC2t6yjGU2uCmn3x82Alm0Ef_Y1nE9GoOrY7_k&sz=w424-h358&ats=1521679711600&rm=16241a3915149869&zw&atsh=1" width="212" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 92.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">4<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018046337</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">INGENOL<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">INDENA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_5731915688253576374ng-binding">Keratosis</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Ingenol 3-angelate.svg" class="CToWUd" height="179" id="m_5731915688253576374Picture_x0020_5" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16241a3915149869&attid=0.4&disp=emb&attbid=ANGjdJ_iAHZbH1dwj-AgFRT-LnX3zSbDZyWXHoyqTGCjffJN2BTEuJ6tBq5DlkoSg8o0fye1sEfrw10mcvgIaPpksckdxOrFVrNMbjZS9Hz1m3yZfS2TDdyNwpeGd5U&sz=w440-h358&ats=1521679711605&rm=16241a3915149869&zw&atsh=1" width="220" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 116.4pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">5<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018045997</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">SOFOSBUVIR<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">CHIA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Hepatitis C virus infection</span><i><span style="color: #00b050; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Sofosbuvir.svg" class="CToWUd" height="171" id="m_5731915688253576374Picture_x0020_6" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16241a3915149869&attid=0.5&disp=emb&attbid=ANGjdJ_XQgtpeRkajGaw29Ccon_7INT-9Ox5SAS_E4NnbsTHgS4pDCS9gtm0poIKAk6XM42ZmsQojgJegRS4Q2zwd92Ptyg-uIyrKUhTJl2u9w9FPM38FyJL2BznFRE&sz=w440-h342&ats=1521679711607&rm=16241a3915149869&zw&atsh=1" width="220" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 124.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">6<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018045889</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">ORITAVANCIN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">JHEJIANG<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Angina; Bacterial skin infection; Enterococcus faecalis infection; Gram positive bacterium infection; MRSA infection; Streptococcus agalactiae infection; Streptococcus pyogenes infection</span><i><span style="color: #00b050; font-family: "Albertus Medium", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Oritavancin.svg" class="CToWUd" height="190" id="m_5731915688253576374Picture_x0020_7" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16241a3915149869&attid=0.6&disp=emb&attbid=ANGjdJ-yxwlwVPXg6T8eWAoIBQxSbzuX8_0qc7ph2M7SkROz4fnd2uI1GEHFdtOw3l_EkXIFzKrZm6zNlb761p2OIzwkXwKVUKDE0zP7TGSOiqxPznuFl8R8bAQrw5c&sz=w440-h380&ats=1521679711609&rm=16241a3915149869&zw&atsh=1" width="220" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 90.6pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">7<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018045505</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">SACUBITRIL<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">NORATECH<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Cardiac failure; Hypertension; Myocardial disease</span><i><span style="color: #00b050; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Sacubitril skeletal.svg" class="CToWUd" height="166" id="m_5731915688253576374Picture_x0020_8" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16241a3915149869&attid=0.7&disp=emb&attbid=ANGjdJ9WJ4bE6lbNYebZ3xFKOaVoPsPEIxATGU-cRgV_kCZPhOYjZJtO8C2XiNUiplZ_flocfp4-U-d0Eo_lw3sOsXUlqrGdR4sY0UGRTiqq3Xo3plPykCg3trXtyNM&sz=w440-h332&ats=1521679711612&rm=16241a3915149869&zw&atsh=1" width="220" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 85.45pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">8<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018048977</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">ELECLAZINE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">AUSPEX<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Acute coronary syndrome; Angina; Cancer; Congestive heart failure; Diabetes mellitus; Inflammatory disease; Ischemic heart disease; Myocardial infarction</span><i><span style="color: #7030a0; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Image result for ELECLAZINE" class="CToWUd" height="88" id="m_5731915688253576374Picture_x0020_9" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16241a3915149869&attid=0.8&disp=emb&attbid=ANGjdJ-SA-I7ZgAlo-sOimyXOCv9UK4PZpwKBlfe--QvdywgXlPPsOR9aI5gyixls7mBE26HSmYV3sNDNa4UiIG9g5Z9ROvVYftYP65RNemQCxJ6Mv8vGcrjLYkhw7c&sz=w494-h176&ats=1521679711614&rm=16241a3915149869&zw&atsh=1" width="247" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 75.9pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"></td></tr>
</tbody></table>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
</div>
DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com2tag:blogger.com,1999:blog-4738331378048275307.post-53276744051819554922018-03-13T03:05:00.000-07:002018-03-13T03:05:02.410-07:0012 March new patents<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">12 march 2018</span><span style="color: #c00000; font-size: 20pt;"><u></u><u></u></span></div>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="color: #ed7d31; font-size: 20pt;">6 new patents,<u></u><u></u></span></div>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<table border="0" cellpadding="0" cellspacing="0" class="m_9069134610377535087MsoNormalTable" style="background-color: white; border-collapse: collapse; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;"><tbody>
<tr style="height: 7.05pt;"><td style="border: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">Sr no<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<span style="color: #1f497d;">Patent number<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #1f497d;">name<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #1f497d;">company<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #1f497d; font-family: "Arial Black", sans-serif;">INDICATION<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #1f497d;">REMARKS, WAIT FOR STR TO APPEAR<u></u><u></u></span></div>
</td></tr>
<tr style="height: 7.05pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">1<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018042393</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">BRIVARACETAM<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">MICROLABS<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Epilepsy; Partial seizure</span><i><span style="color: red; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Brivaracetam.svg" class="CToWUd" height="165" id="m_9069134610377535087Picture_x0020_2" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16218e68410fdc68&attid=0.2&disp=emb&attbid=ANGjdJ8HWmyUoxHv9TqKsBxUHKZm2Hfmcve9oKbKfhpWUWAL8A3LtxWjSAl55aH69xHSSo_Y39w5n4iFUaoPsWbsYCcup6iP2eGMsitIN7D9kETjKwk2S8GCWUidmeA&sz=w260-h330&ats=1520935187530&rm=16218e68410fdc68&zw&atsh=1" width="130" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">2<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018042320</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">BETRIXABAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">REDDYS<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Phlebothrombosis</span><i><span style="color: red; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Betrixaban.svg" class="CToWUd" height="186" id="m_9069134610377535087Picture_x0020_3" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16218e68410fdc68&attid=0.3&disp=emb&attbid=ANGjdJ-sts8n7JJ2GERJD7pf6EKlCpCE5CczHz6RVzkIIpEdIKPd_99_izvSOpoROyk_mrpMg9yqg_2rmaNYmML_PRrtmCxZaxGNOnx4zIdPoeNlx_woRiAolEGMqHg&sz=w440-h372&ats=1520935187531&rm=16218e68410fdc68&zw&atsh=1" width="220" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">3<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018040065</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #ed7d31;">VALSARTAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #ed7d31;">NORATECH<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Fibrosis; Hypertension; Non-insulin dependent diabetes; Obesity; Renal disease</span><i><span style="color: #ed7d31; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Valsartan skeletal.svg" class="CToWUd" height="161" id="m_9069134610377535087Picture_x0020_4" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16218e68410fdc68&attid=0.4&disp=emb&attbid=ANGjdJ8_MAqewR8b6boiFdYmuPMcKiDcMswWumf69NG_99mRdtygeVgS38tDktYp-jIY9TKEa-j424lmJ6FVgJ4f1UjHsivSn9RwtYpqLBTL9-XPKyOxeGB0CIqG7Dg&sz=w440-h322&ats=1520935187531&rm=16218e68410fdc68&zw&atsh=1" width="220" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 92.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">4<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018039923</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">DIOSMIN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">CHENGDU<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_9069134610377535087ng-binding">Hemorrhoids; Lymphedema; Microangiopathy; Premenstrual syndrome; Ulcer</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Diosmin.svg" class="CToWUd" height="85" id="m_9069134610377535087Picture_x0020_5" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16218e68410fdc68&attid=0.5&disp=emb&attbid=ANGjdJ82atHACVp_ABEAOVayyghsEjp1mS0YzH7IUCPBmRwivgvqSsFNStkcMO3SMxuQbu9mIn95AQbIde1JgoHcJVvfcmN7CvFM2ZeRIdp2iYA2hLLgd1oz9h_qfBg&sz=w440-h170&ats=1520935187534&rm=16218e68410fdc68&zw&atsh=1" width="220" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 116.4pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">5<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018041639</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">VILDAGLIPTIN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">UNIV OF BIELEFELD<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_9069134610377535087ng-binding">Non-insulin dependent diabetes</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Skeletal formula" class="CToWUd" height="131" id="m_9069134610377535087Picture_x0020_6" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16218e68410fdc68&attid=0.6&disp=emb&attbid=ANGjdJ_8ngGsdhg6K1I-iKleeW-4AYjfU97_1v0rO4FN8q3w7z3jF52rWshua8vuIT1ctyoEVaewPiblszNoWpBIeTk-DZ8Vwrzr2v6FlbzF6M1EG0lqfzcuc2fS2Y4&sz=w440-h262&ats=1520935187535&rm=16218e68410fdc68&zw&atsh=1" width="220" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 124.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">6<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018045043</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">CENICRIVIROC<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">TOBIRA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_9069134610377535087ng-binding">Fibrosis; Non alcoholic fatty liver disease; Non-alcoholic steatohepatitis</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Cenicriviroc.svg" class="CToWUd a6T" height="172" id="m_9069134610377535087Picture_x0020_7" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=16218e68410fdc68&attid=0.7&disp=emb&attbid=ANGjdJ9Ab1E1Py2-9EAhhzWJUTE0EVEm7KP-nPjJ3WEiRQhXBZ9yt0e73j9XHBNQgW5Z8meCh8KF0dBenVXiBCiJsgz324v6GihNd_PPdYtyVEx3hNMzYS0ve3tvzG0&sz=w630-h344&ats=1520935187536&rm=16218e68410fdc68&zw&atsh=1" style="cursor: pointer; outline: 0px;" tabindex="0" width="315" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 90.6pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
</tbody></table>
</div>
DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com0tag:blogger.com,1999:blog-4738331378048275307.post-72253658468525642282018-03-05T02:42:00.003-08:002018-03-05T02:42:55.376-08:005 TH MARCH NEW PATENTS<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal" style="background-color: white; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">END FEB, start march 2018</span><span style="color: #c00000; font-size: 20pt;"><u></u><u></u></span></div>
<div class="MsoNormal" style="background-color: white; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="color: #ed7d31; font-size: 20pt;">11 new patents,<u></u><u></u></span></div>
<div class="MsoNormal" style="background-color: white; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<table border="0" cellpadding="0" cellspacing="0" class="m_7301375671565438672m_-4087998850896891188MsoNormalTable" style="background-color: white; border-collapse: collapse; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;"><tbody>
<tr style="height: 7.05pt;"><td style="border: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">Sr no<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<span style="color: #1f497d;">Patent number<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #1f497d;">name<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #1f497d;">company<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #1f497d; font-family: "Arial Black", sans-serif;">INDICATION<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #1f497d;">REMARKS, WAIT FOR STR TO APPEAR<u></u><u></u></span></div>
</td></tr>
<tr style="height: 7.05pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">1<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">EP-03287467</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">OBETICHOLIC ACID<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">RATIOPHARM<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Liver disease; Primary biliary cirrhosis</span><i><span style="color: red; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Obeticholic acid.svg" class="CToWUd" height="149" id="m_7301375671565438672m_-4087998850896891188Picture_x0020_2" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161f5c0666ae2dce&attid=0.5&disp=emb&realattid=b34884c7af19a62c_0.2&attbid=ANGjdJ-OJyR3rk4cUUkPPn4NAMDeeFyOeL_V2ES_KseInAWa3FI3OsQwmzh0ZLTpEflfYxqTbD3hUbCWyZiAhN2FZFMfBuWnb7OLVTdLslDdIvt5Va92RdARfnVX3b4&sz=w500-h298&ats=1520246497300&rm=161f5c0666ae2dce&zw&atsh=1" width="250" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">2<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018039521</span></u><span style="color: red;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">CENICRIVIROC<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">CONCERT<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_7301375671565438672m_-4087998850896891188ng-binding">Bladder cancer; HIV infection; Head and neck tumor; Hodgkins disease; Melanoma;</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Cenicriviroc.svg" class="CToWUd a6T" height="172" id="m_7301375671565438672m_-4087998850896891188Picture_x0020_3" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161f5c0666ae2dce&attid=0.6&disp=emb&realattid=b34884c7af19a62c_0.3&attbid=ANGjdJ_oEzwxHrr5lWNozfEL0MU1TEjzfw41CpYxRoNogbrLEbn_4SWkv5af1suD-nAiKcrJRP-avm8HoTZe8HFDNJ--T1ABochy_ZJplbqHK0b31STGimuMB5Jia8o&sz=w630-h344&ats=1520246497303&rm=161f5c0666ae2dce&zw&atsh=1" style="cursor: pointer; outline: 0px;" tabindex="0" width="315" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">3<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018038680</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #ed7d31;">OLAPARIB<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #ed7d31;">SCINOPHARM<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Breast tumor; Fallopian tube cancer; </span><i><span style="color: #ed7d31; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Olaparib.svg" class="CToWUd" height="89" id="m_7301375671565438672m_-4087998850896891188Picture_x0020_4" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161f5c0666ae2dce&attid=0.3&disp=emb&realattid=b34884c7af19a62c_0.4&attbid=ANGjdJ9eqAS1TUCJ4QDRtrpY_IQblqUY0zjpw05n1Hrl9ju1S2m2S3qHagGWDSeX-3dbkGfFWm_YQsQbSErVklNeFXlmxR78A8CQGu1czgA3pa4H52q-0SYZ6D2UUrM&sz=w440-h178&ats=1520246497303&rm=161f5c0666ae2dce&zw&atsh=1" width="220" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 92.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">4<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018038426</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">EDOXABAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">DONG<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Deep vein thrombosis</span><i><span style="color: #7030a0; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Edoxaban.svg" class="CToWUd" height="147" id="m_7301375671565438672m_-4087998850896891188Picture_x0020_5" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161f5c0666ae2dce&attid=0.11&disp=emb&realattid=b34884c7af19a62c_0.5&attbid=ANGjdJ_UnuwxKwIQ56vvBEeUFR4Xf0W6Rv3qLzdI0DfACre9YEHL7cfoAzktM9jOTPfcYNh6bgUiqDkkCwHzJhpLoD4mbPkXABzqPmTzvwV_pIxfoNvNRM2fUVK-tH8&sz=w550-h294&ats=1520246497308&rm=161f5c0666ae2dce&zw&atsh=1" width="275" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 116.4pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">5<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018037423</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">FLUNISOLIDE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">CORAL<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Allergic rhinitis; Inflammatory disease</span><i><span style="color: #00b050; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Flunisolide.png" class="CToWUd" height="185" id="m_7301375671565438672m_-4087998850896891188Picture_x0020_6" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161f5c0666ae2dce&attid=0.8&disp=emb&realattid=b34884c7af19a62c_0.6&attbid=ANGjdJ9_4NiwQ9lG3zNxem4L7M0Fb2zJGrX-CjumCUD1H8udTPdciB01OqXjA7PP3YXBlxeSVkygSx6urDCH4qScy8kvNUh3Ek64XaermumOOPNUOk-8z1kWD2B8qN0&sz=w440-h370&ats=1520246497309&rm=161f5c0666ae2dce&zw&atsh=1" width="220" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 124.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">6<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018037350</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">LUMACAFTOR<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">LAURUS<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_7301375671565438672m_-4087998850896891188ng-binding">Cystic fibrosis</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Lumacaftor skeletal.svg" class="CToWUd" height="65" id="m_7301375671565438672m_-4087998850896891188Picture_x0020_7" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161f5c0666ae2dce&attid=0.1&disp=emb&realattid=b34884c7af19a62c_0.7&attbid=ANGjdJ-YRZLIKx1SC09qdFmSLbWxkxVCTazwASp9wIgL-iaDMcFl5zQsGPCzpJOsEfusyURFZnYh7BvKAptGMdd0EfYyJvXBWpRDB7G7HYBPgq05B7Jq_ojKh96c5pE&sz=w440-h130&ats=1520246497311&rm=161f5c0666ae2dce&zw&atsh=1" width="220" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 90.6pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">7<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018037124</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">AVIBACTAM<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">SANDOZ<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #00b050; font-family: "Arial Black", sans-serif;">ANTIBACTERIAL<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Image result for avibactam sodium" class="CToWUd" height="134" id="m_7301375671565438672m_-4087998850896891188Picture_x0020_8" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161f5c0666ae2dce&attid=0.2&disp=emb&realattid=b34884c7af19a62c_0.8&attbid=ANGjdJ-cbvDikDKGAwXkfNFbFbpP1SCPp4MEvFnZ2aE7O9uhOlSEhGrgelBiridBzlk_alEq2W_n66mFQpL3OMppy3iQTn3kalOXPrZRwQI0OPNuN5flPD0HX93X5pA&sz=w412-h268&ats=1520246497312&rm=161f5c0666ae2dce&zw&atsh=1" width="206" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 85.45pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">8<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018036982</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">URSODEOXYCHOLIC ACID<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">PHARMAZELL<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Cholelithiasis; Hepatitis; </span><i><span style="color: #7030a0; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Ursodeoxycholic acid acsv.svg" class="CToWUd a6T" height="185" id="m_7301375671565438672m_-4087998850896891188Picture_x0020_9" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161f5c0666ae2dce&attid=0.9&disp=emb&realattid=b34884c7af19a62c_0.9&attbid=ANGjdJ8tDEHoQpZL3H63pVvk1BQrwiuO0T88_zmgBLgOV4Ho6ylO0Buwt0cVQttC1wIVOz2byfaOuwqDiGiDZr8_9qrg1zCA73uYJNh6z-Ze0sYGy9PMULbMuu-sdyM&sz=w600-h370&ats=1520246497314&rm=161f5c0666ae2dce&zw&atsh=1" style="cursor: pointer; outline: 0px;" tabindex="0" width="300" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 75.9pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">9<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018036558</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">DAROLUTAMIDE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">CRYSTAL<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_7301375671565438672m_-4087998850896891188ng-binding">Hormone dependent prostate cancer; </span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="ODM-201.svg" class="CToWUd" height="78" id="m_7301375671565438672m_-4087998850896891188Picture_x0020_10" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161f5c0666ae2dce&attid=0.10&disp=emb&realattid=b34884c7af19a62c_0.10&attbid=ANGjdJ_FthayD8eXig6B0_bzPLAz5GTP_4vs0MlA-wEXQBFgZ35CQr3KqKk47M2tqgll6Ir94FvKpL984UhFf6JWVjpe6y1Cmbo9YgOXRwhBMO6CVc4hfHb-uHL2TUM&sz=w500-h156&ats=1520246497317&rm=161f5c0666ae2dce&zw&atsh=1" width="250" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">10<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018036557</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">LENALIDOMIDE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">ZHEJIANG<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Adult T-cell lymphoma; Mantle cell lymphoma; Myelodysplastic syndrome</span><i><span style="color: #00b050; font-family: "Albertus Medium", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Lenalidomide enantiomers.svg" class="CToWUd" height="248" id="m_7301375671565438672m_-4087998850896891188_x0000_i1027" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161f5c0666ae2dce&attid=0.7&disp=emb&realattid=b34884c7af19a62c_0.11&attbid=ANGjdJ_GgYu66WNC4riaEpYySdCmPgqw9SGb05oNtCDXLUikySpikDclqcoT_i50Qk8rad0Na-j8HxxnF2993yKMkujEIzjGT3nIV3n5tsvDxlWj979FPFssqHg4zP8&sz=w400-h496&ats=1520246497317&rm=161f5c0666ae2dce&zw&atsh=1" width="200" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 14pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">11<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018036416</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #ed7d31;">EFINACONAZOLE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #ed7d31;">TROPHARMAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_7301375671565438672m_-4087998850896891188ng-binding">Fungal infection; Onychomycosis</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Efinaconazole.svg" class="CToWUd" height="162" id="m_7301375671565438672m_-4087998850896891188Picture_x0020_12" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161f5c0666ae2dce&attid=0.4&disp=emb&realattid=b34884c7af19a62c_0.12&attbid=ANGjdJ_9vcnSqlffqJQTztcet95X7I-gynMhaYQNxT1QyfTDkmIh2RjFJkp1hF3-LjX44MmphczdlcrjdjbeT6-5wN8r9iSz8mfHo2RGk1eaKMG3N-WyfPypfkqT0M8&sz=w440-h324&ats=1520246497319&rm=161f5c0666ae2dce&zw&atsh=1" width="220" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 14pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"></td></tr>
<tr style="height: 12pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
</tbody></table>
<div class="MsoNormal" style="background-color: white; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<div class="MsoNormal" style="background-color: white; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
</div>
DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com0tag:blogger.com,1999:blog-4738331378048275307.post-35846349483903316952018-02-27T02:50:00.001-08:002018-02-27T02:50:39.445-08:00NEW PATENTS FEB 2018<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="color: #ed7d31; font-size: 20pt;">New patents,<u></u><u></u></span></div>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<table border="0" cellpadding="0" cellspacing="0" class="m_4818582107226301650MsoNormalTable" style="background-color: white; border-collapse: collapse; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;"><tbody>
<tr style="height: 7.05pt;"><td style="border: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">Sr no<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<span style="color: #1f497d;">Patent number<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #1f497d;">name<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #1f497d;">company<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #1f497d; font-family: "Arial Black", sans-serif;">INDICATION<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #1f497d;">REMARKS, WAIT FOR STR TO APPEAR<u></u><u></u></span></div>
</td></tr>
<tr style="height: 7.05pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">1<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018033631</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">MARIZOMIB<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">CELGENE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: red; font-family: "Arial Black", sans-serif;">CANCER<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Image result for MARIZOMIB" class="CToWUd" height="161" id="m_4818582107226301650Picture_x0020_3" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161d5708976357a7&attid=0.7&disp=emb&attbid=ANGjdJ_S3Qr41-AYHWR0d7yTPAZHwcajIFg2pwHK5xBDNoCNxwP1IDFRTkIPUxS43tDPNeKP_E4Gut8htrbzYsFhPsHIE1muK5uCdgIP5JEUsiXA-4rMnrmo6kftDGA&sz=w236-h322&ats=1519728341226&rm=161d5708976357a7&zw&atsh=1" width="118" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">2<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018034901</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">ELAMIPRETIDE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">STEALTH<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Barth syndrome; Mitochondrial myopathy</span><i><span style="color: red; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Elamipretide structure.svg" class="CToWUd" height="134" id="m_4818582107226301650Picture_x0020_4" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161d5708976357a7&attid=0.2&disp=emb&attbid=ANGjdJ_ZwYyTA-2ZFiYB4VZyhPWcQCxsUEv8pcPQ4k2xBrmL8ABlscpy4ooWOoT_uaVFG2etZdZxvJo4nOmJqe38qeNkByM3FIrYHEZP568mBmdExil3c83AzdyxCy8&sz=w440-h268&ats=1519728341228&rm=161d5708976357a7&zw&atsh=1" width="220" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">3<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018033866</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #ed7d31;">SACUBITRIL, VALSARTAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #ed7d31;">NOVARTIS<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #ed7d31; font-family: "Arial Black", sans-serif;">CARDIAC FAILURE, HYPERTENSION<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Image result for sacubitril and valsartan" class="CToWUd" height="267" id="m_4818582107226301650Picture_x0020_5" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161d5708976357a7&attid=0.8&disp=emb&attbid=ANGjdJ_mJ4UuknXqkzgnuVXHMGf6uzU5luTi5b01CRX5ucTEvKRRGBcgq6iRWxv9s5eGaDTUZB0qRLTK00zLTLtcV3ET7l14q-MkMebrTI-OiYGHXwKk2uQvJ-4YQF0&sz=w370-h534&ats=1519728341229&rm=161d5708976357a7&zw&atsh=1" width="185" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 92.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">4<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018033149</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">OZANIMOD<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">CRYSTAL<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Multiple sclerosis; Ulcerative colitis</span><i><span style="color: #7030a0; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Ozanimod.svg" class="CToWUd" height="139" id="m_4818582107226301650Picture_x0020_6" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161d5708976357a7&attid=0.3&disp=emb&attbid=ANGjdJ9Us4PtV7ObkbBG2hnfL-kr5bRk8JzSeZf-J8rkemNI1LHH-XvR1bgWdswNA00goJcvB4W6rW6yZufFTCSlXpvS10vJZdlLdAdGvoJ3tbqx7XfLO91ukRL_OG8&sz=w570-h278&ats=1519728341232&rm=161d5708976357a7&zw&atsh=1" width="285" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 116.4pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">5<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018033139</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">SOFOSBUVIR<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">CHIA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Hepatitis C virus infection</span><i><span style="color: #00b050; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Sofosbuvir.svg" class="CToWUd" height="171" id="m_4818582107226301650Picture_x0020_7" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161d5708976357a7&attid=0.4&disp=emb&attbid=ANGjdJ8VkAMAyeSBMo2UMj-wt0M_e1_oBXdxH-AsnYWmyQiIm-_aBWAMvANgt6XZ_fJc8uF66m_asG6HSRChvmkDjvhA41g1DQZ8AGSWDrCyWyYL4Ee5oFo6FKE__m4&sz=w440-h342&ats=1519728341235&rm=161d5708976357a7&zw&atsh=1" width="220" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 124.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">6<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018032521</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">LIRAGLUTIDE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">SHENZEN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_4818582107226301650ng-binding">Non-insulin dependent diabetes; Obesity</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Liraglutide.png" class="CToWUd" height="132" id="m_4818582107226301650Picture_x0020_8" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161d5708976357a7&attid=0.5&disp=emb&attbid=ANGjdJ9YD7cibN6TOoXBi4AIJIXnIkKViRhVjtiVBRi0ATNc0OBud1oeYZAt7DHIB1CMe6xGTxmRzHN5XbZJEVFKO4cyxzb-RhCcc7R2NG1D0SiRDva53FFRqYzcvjg&sz=w440-h264&ats=1519728341238&rm=161d5708976357a7&zw&atsh=1" width="220" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 90.6pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">7<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018032356</span></u><span style="color: #00b050;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">SOFOSBUVIR<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">PHARMARESOURCES<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Hepatitis C virus infection</span><i><span style="color: #00b050; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Sofosbuvir.svg" class="CToWUd" height="171" id="m_4818582107226301650Picture_x0020_9" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161d5708976357a7&attid=0.4&disp=emb&attbid=ANGjdJ_FWdKZ3GbvtOa_u9KxbDkXp7eLNxl4hrMcMxsyqvlnp87O9Vm36ysjDPrM1UstXeKpa-EqdPgTDIMcoiGr9li3gz4m_57um1qXMa7C2sQ281pU6ZsQnRFwDDc&sz=w440-h342&ats=1519728341239&rm=161d5708976357a7&zw&atsh=1" width="220" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 85.45pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">8<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018032796</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">SITAFLOXACIN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">CHEN-STONE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Bacterial infection</span><i><span style="color: #7030a0; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Sitafloxacin.png" class="CToWUd" height="139" id="m_4818582107226301650Picture_x0020_10" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161d5708976357a7&attid=0.6&disp=emb&attbid=ANGjdJ-2_A8Z6hRZTDR1_TwrD6Hms3zdCZWB9xw7yHKtRw05ogE0xq4qeZN7ZZsvS0v9FNjXdKhKNH36XFOqyi4-7Rs3YuwYf0GG2XWJjXLhD7gQSXk7BzN0ERXbNS8&sz=w440-h278&ats=1519728341242&rm=161d5708976357a7&zw&atsh=1" width="220" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 75.9pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">9<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018033939</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">BUDESONIDE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">ANANTCO<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Allergic rhinitis; Inflammatory bowel disease; Irritable bowel syndrome</span><i><span style="color: #00b050; font-family: "Albertus Medium", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Budesonid Grundstruktur V4.svg" class="CToWUd" height="154" id="m_4818582107226301650Picture_x0020_11" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161d5708976357a7&attid=0.9&disp=emb&attbid=ANGjdJ93HikNwCVfVBRX0ag1etM0e-yJlUze2IjlDXILUAZemrZsqERykeM89VubeG4pknNT2RVpHpzZWOr-mNDffW0GkxmgPQo21x8LDe4OEa5IIKjxcS6M9LsktuU&sz=w500-h308&ats=1519728341244&rm=161d5708976357a7&zw&atsh=1" width="250" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"></td></tr>
</tbody></table>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="color: #1f497d; font-size: 24pt;"><u></u> <u></u></span><span style="color: #ed7d31; font-size: 20pt;">new patents,</span></div>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<table border="0" cellpadding="0" cellspacing="0" class="m_-1661263229472325810MsoNormalTable" style="background-color: white; border-collapse: collapse; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;"><tbody>
<tr style="height: 7.05pt;"><td style="border: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">Sr no<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<span style="color: #1f497d;">Patent number<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #1f497d;">name<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #1f497d;">company<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #1f497d; font-family: "Arial Black", sans-serif;">INDICATION<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #1f497d;">REMARKS, WAIT FOR STR TO APPEAR<u></u><u></u></span></div>
</td></tr>
<tr style="height: 7.05pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">1<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">EP-03281941</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">LESINURAD<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">ZENTIVA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_-1661263229472325810ng-binding">Gout; Hyperuricemia</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Image result for LESINURAD" class="CToWUd" height="161" id="m_-1661263229472325810Picture_x0020_2" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161ac4bdd29419be&attid=0.5&disp=emb&attbid=ANGjdJ961r1XN5b1KJ7mQLUWMfdZ5bbm61jnC_hYGqQ1SMC9p4EhC7uLdUegMLr6spzq9bIkcKZx_TyQAvthk9u1SV-1Kc7ZLeGuCm0mgS3yjWtTDJWRZgxjYrttEQQ&sz=w312-h322&ats=1519728603639&rm=161ac4bdd29419be&zw&atsh=1" width="156" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">2<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018029711</span></u><span style="color: red;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">VENETOCLAX<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">MYLAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Chronic lymphocytic leukemia</span><i><span style="color: red; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Venetoclax.svg" class="CToWUd" height="138" id="m_-1661263229472325810Picture_x0020_3" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161ac4bdd29419be&attid=0.2&disp=emb&attbid=ANGjdJ996kVbvB6UfpsWIgUpYTtBRyM-WIbWzYRxMzkHvlmFG93iNg4VqdSy8lEmSl49IM-Xy6M1rSjISVos8VJzkqErO3LS5OeyjBbVnFTRV2dfW9dfY958W--EVuE&sz=w550-h276&ats=1519728603641&rm=161ac4bdd29419be&zw&atsh=1" width="275" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">3<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018029699</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #ed7d31;">BELINIOSTAT<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #ed7d31;">MSN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Hematological neoplasm; Solid tumor</span><i><span style="color: #ed7d31; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Belinostat.svg" class="CToWUd" height="76" id="m_-1661263229472325810Picture_x0020_4" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161ac4bdd29419be&attid=0.3&disp=emb&attbid=ANGjdJ-2pZDxA5Qytk5bGnIBUq2O4NjE7NuU9Q7sT_z6SAALcgB9HK-cKpLlVKE5PGYNFglUn5DINJ5ZoK2hzz1CsTdgvJfdcil-T0IJgEeYkvUzuEZvD3NDVKtlJNM&sz=w440-h152&ats=1519728603641&rm=161ac4bdd29419be&zw&atsh=1" width="220" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 92.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">4<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018029264</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">DAPAGLIFLOZIN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">AMNEAL<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_-1661263229472325810ng-binding">Non-insulin dependent diabetes</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Image result for DAPAGLIFLOZIN" class="CToWUd" height="142" id="m_-1661263229472325810_x0000_i1032" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161ac4bdd29419be&attid=0.6&disp=emb&attbid=ANGjdJ_oVI1fBgBGkudGsd3QvXV2c09mXoIVhBO0RKoL53k1FAisE682j7fWoTcomAhSTug49D3bTumUon46JB438NT8XNYjWITyNu5ZrQlLR26gafJC7E5qCgZJZqc&sz=w448-h284&ats=1519728603644&rm=161ac4bdd29419be&zw&atsh=1" width="224" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 116.4pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">5<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018029223</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">GALETERONE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">INDUSTRIALE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #00b050; font-family: "Arial Black", sans-serif;">PROSTRATE TUMOR<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Galeterone.svg" class="CToWUd" height="148" id="m_-1661263229472325810Picture_x0020_6" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161ac4bdd29419be&attid=0.4&disp=emb&attbid=ANGjdJ_cJ8JBzL_q2amfi3wXBmjRupoheVMNSoazdTz4twFxf10KJO_gbDe7GGdE8bs1UNbScdX2oo3GOhhnyEXZ04cma9-bh3kWzNx5VMoqLXKtfUUAkkPIQa6y9ko&sz=w440-h296&ats=1519728603646&rm=161ac4bdd29419be&zw&atsh=1" width="220" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 124.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">6<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;"><br />WO-2018028508</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">PIRFENIDONE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">IND<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_-1661263229472325810ng-binding">Idiopathic pulmonary fibrosis</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 124.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Pirfenidone2DACS.svg" class="CToWUd" height="173" id="m_-1661263229472325810Picture_x0020_7" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161ac4bdd29419be&attid=0.7&disp=emb&attbid=ANGjdJ82ngiFbV61mIRHLauKrI6oeo5kYcFEgua7KNHx5Ep8KJ6cJFxaqilEfgPCDWGYzGvMmByLCmwcZIB76FQU3GI3ay3k913J4zx0ma1TM2Upwui3TGC55YL_UaA&sz=w352-h346&ats=1519728603647&rm=161ac4bdd29419be&zw&atsh=1" width="176" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 90.6pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">7<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;"><br /></span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018028506</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">PIRFENIDONE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">IND<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_-1661263229472325810ng-binding">Idiopathic pulmonary fibrosis</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Pirfenidone2DACS.svg" class="CToWUd" height="173" id="m_-1661263229472325810Picture_x0020_8" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161ac4bdd29419be&attid=0.7&disp=emb&attbid=ANGjdJ-kNqlOzTQrduLIPgKYr9BTg36Oma6W34zQezJeWlGrnsdfOouVDdH5KxtTQA4mORb0cX0mZMkgEC0E9q8uwrehOXU8hlWuk8KQTpcdS-xwMbaVGT0UcrmAs24&sz=w352-h346&ats=1519728603649&rm=161ac4bdd29419be&zw&atsh=1" width="176" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 85.45pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">8<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018029611</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">DAPAGLIFLOZIN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">LAURUS<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_-1661263229472325810ng-binding">Non-insulin dependent diabetes</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Image result for DAPAGLIFLOZIN" class="CToWUd" height="142" id="m_-1661263229472325810Picture_x0020_5" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161ac4bdd29419be&attid=0.8&disp=emb&attbid=ANGjdJ_uaQ2b-szV4ok0dy81sZJIBBWRhSasPt7VomPwPMK5FtcrcrjHpaBSlAEFdRVBPVt6sg4smpYnmLgKqfsGSHo2K6NRWaS5PmnHmxx5i_Qd_M5KBLytiITLdVs&sz=w448-h284&ats=1519728603650&rm=161ac4bdd29419be&zw&atsh=1" width="224" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 75.9pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">9<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018028420</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">PLINABULIN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">QUINGDAO<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #00b050; font-family: "Albertus Medium", sans-serif;">CANCER<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Plinabulin.svg" class="CToWUd" height="112" id="m_-1661263229472325810Picture_x0020_10" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161ac4bdd29419be&attid=0.9&disp=emb&attbid=ANGjdJ_tzgW5Z6NLTPvbp-c74C5-GVuCF53n6Gf0HpBgNnboDf3QNcyM5-YnQCJeyjjSEfabQtp3dQdVmlNPllMnq63KOzkD8x9nJXq123ZNNsnXHLkc0bTDXWcExs8&sz=w400-h224&ats=1519728603652&rm=161ac4bdd29419be&zw&atsh=1" width="200" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">10<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018028679</span></u><span style="color: #00b050;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">MIRABEGRON<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">ZHEJIANG<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_-1661263229472325810ng-binding">Overactive bladder</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Mirabegron.svg" class="CToWUd" height="85" id="m_-1661263229472325810Picture_x0020_11" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161ac4bdd29419be&attid=0.10&disp=emb&attbid=ANGjdJ_EMChzpPbokgM2W_xhzuZa2-cXhojj7RHF_heamk22lFjhmUWrLZPVmlHUu941J5BW6IXQapkpflfnipQ7TorbKP4VLXSi3sHX4EGThk-IUi6OzRwB-vZHUQI&sz=w600-h170&ats=1519728603652&rm=161ac4bdd29419be&zw&atsh=1" width="300" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 14pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
</div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"></td></tr>
<tr style="height: 12pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
</tbody></table>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
</div>
DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com0tag:blogger.com,1999:blog-4738331378048275307.post-45694880260151120972018-02-05T02:39:00.000-08:002018-02-05T02:39:08.849-08:00FEB 05 2018, NEW PATENTS<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal" style="background-color: white; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">FEB 052018</span><span style="color: #c00000; font-size: 20pt;"><u></u><u></u></span></div>
<div class="MsoNormal" style="background-color: white; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="color: #ed7d31; font-size: 20pt;">12 new patents,<u></u><u></u></span></div>
<div class="MsoNormal" style="background-color: white; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<table border="0" cellpadding="0" cellspacing="0" class="m_4859889627246036064m_-807724906811556290MsoNormalTable" style="background-color: white; border-collapse: collapse; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;"><tbody>
<tr style="height: 7.05pt;"><td style="border: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">Sr no<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<span style="color: #1f497d;">Patent number<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #1f497d;">name<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #1f497d;">company<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #1f497d; font-family: "Arial Black", sans-serif;">INDICATION<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #1f497d;">REMARKS, WAIT FOR STR TO APPEAR<u></u><u></u></span></div>
</td></tr>
<tr style="height: 7.05pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">1<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018023009</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">LURASIDONE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">CONCERT<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Bipolar I disorder; Schizophrenia</span><i><span style="color: red; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Lurasidone.svg" class="CToWUd" height="168" id="m_4859889627246036064m_-807724906811556290Picture_x0020_2" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161658598eec9d2a&attid=0.0.7&disp=emb&realattid=616706615e7ccba5_0.2&attbid=ANGjdJ8oj3VdmoHz1UIjLGXME39PO1WJjzb1GzmiAigK-HS3a7_v4HZZQNpkpnTtByY1-94mFck6mMJqqVXXm0UbzCjatP_PhQzVXH6PsME-28GXudiSm5Xqx9xcHO4&sz=w540-h336&ats=1517826713668&rm=161658598eec9d2a&zw&atsh=1" width="270" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">2<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018022704</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">SELEXIPAG<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">TEVA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_4859889627246036064m_-807724906811556290ng-binding">Pulmonary artery hypertension</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Selexipag.svg" class="CToWUd" height="94" id="m_4859889627246036064m_-807724906811556290Picture_x0020_3" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161658598eec9d2a&attid=0.0.1&disp=emb&realattid=616706615e7ccba5_0.3&attbid=ANGjdJ9DSpbmccI7Cwe-f65rq542EsTdk404s6t0xytQF31LpubqSn2CqHtHljeXINm4QmUic_1p77iNpu2yFEnUUsB74QnsVsk84GFhydrD_6PA4bcgJco8pg9OEno&sz=w500-h188&ats=1517826713670&rm=161658598eec9d2a&zw&atsh=1" width="250" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">3<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018021818</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #ed7d31;">FEBUXOSTAT<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #ed7d31;">HANMI<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Gout; Hyperuricemia; Tumor lysis syndrome</span><i><span style="color: #ed7d31; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Image result for febuxostat" class="CToWUd" height="95" id="m_4859889627246036064m_-807724906811556290Picture_x0020_4" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161658598eec9d2a&attid=0.0.10&disp=emb&realattid=616706615e7ccba5_0.11&attbid=ANGjdJ-GmiMFxhVi31AidTERqpEP6fZuC65xtd-RasIxlFfI3pZQqT4Gl7IaYNXENtWPwUMNDt8UR7BMXY42bIUpOjg5Ky05yKo_XxPDx-r15SAvEVS1jboE7jqw75k&sz=w384-h190&ats=1517826713670&rm=161658598eec9d2a&zw&atsh=1" width="192" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 92.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">4<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018021517</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">AMISELIMOD<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">MITSUBISHI<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Autoimmune disease; Crohns disease; Inflammatory bowel disease; Multiple sclerosis; Psoriasis</span><i><span style="color: #7030a0; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Image result for AMISELIMOD" class="CToWUd" height="250" id="m_4859889627246036064m_-807724906811556290Picture_x0020_5" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161658598eec9d2a&attid=0.0.8&disp=emb&realattid=616706615e7ccba5_0.4&attbid=ANGjdJ92Tc6GtXLNSOOvB2cJJiO_X8ll8rw4SE5jQS9xSXnFvXan8yk9Y9DGDO82-uSHLEDGeLzsWR0sj0Byku5MF-EuEuJ4IDTXM2bzxJvHjtAJXeznk27yHEh1HCs&sz=w500-h500&ats=1517826713675&rm=161658598eec9d2a&zw&atsh=1" width="250" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 116.4pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">5<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;"><br />WO-2018020506</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">CANAGLIFLOZIN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">NATCO<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Non-insulin dependent diabetes</span><i><span style="color: #00b050; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Canagliflozin structure.svg" class="CToWUd" height="65" id="m_4859889627246036064m_-807724906811556290Picture_x0020_6" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161658598eec9d2a&attid=0.0.3&disp=emb&realattid=616706615e7ccba5_0.5&attbid=ANGjdJ9b7V3bF5X3WFpnnoS6GX9At4wgglpieRgpdldIH9QLXISM06_CE9xHnBd2Uf4sytvfvewa1vRVnhJEmfCU5k-agCwfJJvqAkc48BAccKeT6v_kAsqii5nyou8&sz=w400-h130&ats=1517826713678&rm=161658598eec9d2a&zw&atsh=1" width="200" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 236.15pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 236.15pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">6<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 236.15pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018020450</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 236.15pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">ELUXADOLINE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 236.15pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">LUPIN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 236.15pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_4859889627246036064m_-807724906811556290ng-binding">Diarrhea predominant irritable bowel syndrome</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 236.15pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Eluxadoline.svg" class="CToWUd" height="178" id="m_4859889627246036064m_-807724906811556290Picture_x0020_7" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161658598eec9d2a&attid=0.0.4&disp=emb&realattid=616706615e7ccba5_0.6&attbid=ANGjdJ__fPoGPQ8fCyJhu5YxR0DddyRr9xbtsdp6-a6Y43v3ghjNpe0OnKxWCEkBb70mz2iZ536sl0Esmef8jU01GkkpW5n3-SbwI97UyeF6oJcrim7ZNBU468e9I9I&sz=w510-h356&ats=1517826713680&rm=161658598eec9d2a&zw&atsh=1" width="255" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 90.6pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">7<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018020406</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #bf9000;">BELINOSTAT<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #bf9000;">FRASENIUS<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #bf9000; font-family: "Arial Black", sans-serif;">CANCER<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<b><span style="color: #bf9000;"><img alt="Belinostat.svg" class="CToWUd" height="76" id="m_4859889627246036064m_-807724906811556290Picture_x0020_8" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161658598eec9d2a&attid=0.0.2&disp=emb&realattid=616706615e7ccba5_0.7&attbid=ANGjdJ-F7ZarzHvqdHi8GxDWlYYWsFxL3Z6naUTl3unj7L4z1etCQAglnbnjkIr9ngvyGOygUVXlCXO-km8zw3-JJolM2Bl5jveE4ECyNhcNc7onDMja0Drdgb4AD_k&sz=w440-h152&ats=1517826713682&rm=161658598eec9d2a&zw&atsh=1" width="220" /></span><span style="color: #bf9000;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 85.45pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">8<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018020380</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">DOLUTEGRAVIR<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">LUPIN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">HIV infection</span><span style="color: red; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: red;"><img alt="Dolutegravir.svg" class="CToWUd" height="102" id="m_4859889627246036064m_-807724906811556290Picture_x0020_9" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161658598eec9d2a&attid=0.0.12&disp=emb&realattid=616706615e7ccba5_0.8&attbid=ANGjdJ_i75zGR1M2pFbv5eNamr3iiofWs6zV0qOGNHuqADufBXD5kvYWMnuqg6tDc5uspCEWeyyyJCmeFgYoke6FBXijTPFA2FhE0Z6wMWbeMG8shIGWj-3FS1iJTEo&sz=w500-h204&ats=1517826713684&rm=161658598eec9d2a&zw&atsh=1" width="250" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 75.9pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">9<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;"><br />WO-2018020366</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #0070c0;">TRANYLCYPROMINE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #0070c0;">GSK<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Depression; Parkinsons disease</span><span style="color: #0070c0; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #0070c0;"><img alt="Tranylcypromine.svg" class="CToWUd" height="198" id="m_4859889627246036064m_-807724906811556290Picture_x0020_10" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161658598eec9d2a&attid=0.0.5&disp=emb&realattid=616706615e7ccba5_0.9&attbid=ANGjdJ_Snr6aZ06SmDjOkK-LNrH5e7KwTmGDmmF4gLU97LMN2uEWBqsK87qwCNRgu4dVE6nh62WBhy7C53IRDjd7RG4PwlVmVR8GG6jyWv5TdTySSYbQ-rpXvjH33IQ&sz=w350-h396&ats=1517826713686&rm=161658598eec9d2a&zw&atsh=1" width="175" /></span><span style="color: #0070c0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">10<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018019549</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #ed7d31;">OMACETAXINE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #ed7d31;">INDENA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_4859889627246036064m_-807724906811556290ng-binding">Chronic myelocytic leukemia</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Omacetaxine mepesuccinate.svg" class="CToWUd" height="209" id="m_4859889627246036064m_-807724906811556290Picture_x0020_11" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161658598eec9d2a&attid=0.0.6&disp=emb&realattid=616706615e7ccba5_0.10&attbid=ANGjdJ8BhE_QqZ3xc3HbrsUw6moAbRONrdRYUqoxp7C7Id039H1l5R4pUzNfmtjr3cvH2SIR3GFX-LJPROi0lvzJFmFFmBdtrpNtXZMfFYlMfEoHipd-s6HvThflZso&sz=w440-h418&ats=1517826713686&rm=161658598eec9d2a&zw&atsh=1" width="220" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 14pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">11<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018019196</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #ed7d31;">IXAZOMIB<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #ed7d31;">SHENZEN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="color: #ed7d31; font-family: "Arial Black", sans-serif;">CANCER<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Ixazomib.svg" class="CToWUd" height="110" id="m_4859889627246036064m_-807724906811556290Picture_x0020_12" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161658598eec9d2a&attid=0.0.11&disp=emb&realattid=616706615e7ccba5_0.12&attbid=ANGjdJ9pOEOkOuHY-79Rri9XVkhga5CrjgKsD-nyC2mlwOiJurmKrt70o-N8qx5J2q8aAUm0kw_Rc6HpIgS_W8zbcCeyyP2OmQ6GFTr2m2yg1N4C8vSUGJq_FOU03Wc&sz=w440-h220&ats=1517826713688&rm=161658598eec9d2a&zw&atsh=1" width="220" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 14pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">12<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;"><br />WO-2018018986</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #ed7d31;">CERITINIB<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #ed7d31;">ARROMAX<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Cardiovascular disease; Infectious disease; Inflammatory disease; Metabolic disorder; Viral infection</span><span style="color: #ed7d31; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Ceritinib structure.svg" class="CToWUd" height="135" id="m_4859889627246036064m_-807724906811556290Picture_x0020_13" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161658598eec9d2a&attid=0.0.9&disp=emb&realattid=616706615e7ccba5_0.13&attbid=ANGjdJ-2fMQ-S9R1yWbF8MfIuTcwhBeOLaIDT56e62TU5jbBtjG9PBvCz-JE_9v2YScsouwvhYgx3pANqZ6Xq6o9NVZeq_YUFY5hfyM3ONQ_x7XmuAvJbp3P0IczqFs&sz=w550-h270&ats=1517826713688&rm=161658598eec9d2a&zw&atsh=1" width="275" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">13<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">14<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 25.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 25.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">15<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 25.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 25.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 25.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 25.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 25.75pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 13.5pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.5pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">16<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.5pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.5pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.5pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.5pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.5pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 12pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 229.5pt;" valign="top" width="306"><div class="MsoNormal">
<br /></div>
</td></tr>
</tbody></table>
<div class="MsoNormal" style="background-color: white; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<div class="MsoNormal" style="background-color: white; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
</div>
DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com0tag:blogger.com,1999:blog-4738331378048275307.post-50947104156367302582018-02-01T04:22:00.002-08:002018-02-01T04:22:24.195-08:00Feb 01 NEW PATENTS<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal" style="background-color: white; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="color: #ed7d31; font-size: 20pt;">new patents,<u></u><u></u></span></div>
<div class="MsoNormal" style="background-color: white; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<table border="0" cellpadding="0" cellspacing="0" class="m_1258769223932238611m_2677116949983763778MsoNormalTable" style="background-color: white; border-collapse: collapse; color: #500050; font-family: arial, sans-serif; font-size: 12.8px;"><tbody>
<tr style="height: 7.05pt;"><td style="border: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">Sr no<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<span style="color: #1f497d;">Patent number<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #1f497d;">name<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #1f497d;">company<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<i><span style="color: #1f497d; font-family: "Arial Black", sans-serif;">INDICATION<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 261.35pt;" valign="top" width="348"><div class="MsoNormal">
<span style="color: #1f497d;">REMARKS, WAIT FOR STR TO APPEAR<u></u><u></u></span></div>
</td></tr>
<tr style="height: 7.05pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">1<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #75b2d5; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018015821</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">SOFOSBUVIR<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">OPTIMUS<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_1258769223932238611m_2677116949983763778ng-binding">Hepatitis C virus infection</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 261.35pt;" valign="top" width="348"><div class="MsoNormal">
<span style="color: red;"><img alt="Sofosbuvir.svg" class="CToWUd" height="171" id="m_1258769223932238611m_2677116949983763778Picture_x0020_2" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161514ff6f4ea8b7&attid=0.0.7&disp=emb&realattid=e87fbcc8a73b7fb1_0.2&attbid=ANGjdJ-SYRU7oQxZ8qTzIASVdVK3vZnAAoHiw74tAUdKo9XHsmFUsFkwtdvxEBM01pQpadVup9_0OqLmLgTVwGeC09dm_UCq0DfJFAmPP2kymEr8M2ekECzIt8pUfjw&sz=w440-h342&ats=1517487651709&rm=161514ff6f4ea8b7&zw&atsh=1" width="220" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">2<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018015974</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">SELEXIPAG<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">MYLAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Pulmonary artery hypertension</span><i><span style="color: red; font-family: "Albertus Extra Bold", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 261.35pt;" valign="top" width="348"><div class="MsoNormal">
<span style="color: red;"><img alt="Selexipag.svg" class="CToWUd" height="94" id="m_1258769223932238611m_2677116949983763778Picture_x0020_3" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161514ff6f4ea8b7&attid=0.0.1&disp=emb&realattid=e87fbcc8a73b7fb1_0.3&attbid=ANGjdJ8_1onNWbnuK_Zx21nvfLKq-U-8CtRf3YVDThUZZh9lgQGEK1H8O8juvXfX0IpJFCU_sCg3yGxbDiD3kA0Z3AWx23LYD367S-4Fj03357b9cSlHe6xv9GqRMdA&sz=w500-h188&ats=1517487651711&rm=161514ff6f4ea8b7&zw&atsh=1" width="250" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">3<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018017153</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #ed7d31;">VECABRUTINIB<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #ed7d31;">BIOGEN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Autoimmune disease; Cancer; Inflammatory disease</span><i><span style="color: #ed7d31; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 261.35pt;" valign="top" width="348"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="img" class="CToWUd a6T" height="175" id="m_1258769223932238611m_2677116949983763778Picture_x0020_4" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161514ff6f4ea8b7&attid=0.0.2&disp=emb&realattid=e87fbcc8a73b7fb1_0.4&attbid=ANGjdJ-F6rhP-T01XNaDWhdewZnqNMGpl-jpp-qWiLhpDQkgzjow9xM2r3m8gtr2vnyp9TCTchqBI8JikdKI8crvEUVgKiGqvIumvfyhXxRspGXReuoiTl46KFU9ZRQ&sz=w624-h350&ats=1517487651711&rm=161514ff6f4ea8b7&zw&atsh=1" style="cursor: pointer; outline: 0px;" tabindex="0" width="312" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 261.35pt;" valign="top" width="348"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 92.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">4<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #75b2d5; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018016795</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #7030a0;">BESIFOVIR<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #7030a0;">IL DONG<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_1258769223932238611m_2677116949983763778ng-binding">Hepatitis B virus infection</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 261.35pt;" valign="top" width="348"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Besifovir.svg" class="CToWUd" height="101" id="m_1258769223932238611m_2677116949983763778Picture_x0020_5" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161514ff6f4ea8b7&attid=0.0.8&disp=emb&realattid=e87fbcc8a73b7fb1_0.5&attbid=ANGjdJ-aaj2XS9JlqFHTTzleTnhQdYt9tzSK8jHrgsa8SXEK_C1CyCMVQ39NzUlNjiKq12x8Rgr_qLIeNWS9SZI8kK5olZrQeYjXOmNp8f289_ay_rI9K7wyzNCLVPA&sz=w440-h202&ats=1517487651715&rm=161514ff6f4ea8b7&zw&atsh=1" width="220" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 116.4pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">5<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018015929</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">DARUNAVIR<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">GRANULES<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_1258769223932238611m_2677116949983763778ng-binding">HIV-1 infection</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 261.35pt;" valign="top" width="348"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Darunavir structure.svg" class="CToWUd" height="252" id="m_1258769223932238611m_2677116949983763778Picture_x0020_6" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161514ff6f4ea8b7&attid=0.0.4&disp=emb&realattid=e87fbcc8a73b7fb1_0.6&attbid=ANGjdJ-IJRaekbruOkiRbwzmZJmx1G6vi58BT5-PpngVGUuz50K_fDiWoZJZvGDjV8LYOPLes4BeucvjCugT7Pc7Sht3ksdIxd7BAeQ9ulYGp2a7QmR-pmJGJxaBj84&sz=w400-h504&ats=1517487651717&rm=161514ff6f4ea8b7&zw&atsh=1" width="200" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 236.15pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 236.15pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">6<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 236.15pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018015847</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 236.15pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #00b050;">DACLATASVIR<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 236.15pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #00b050;">GLENMARK<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 236.15pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_1258769223932238611m_2677116949983763778ng-binding">Hepatitis C virus infection</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 236.15pt; margin: 0px; padding: 0in 5.4pt; width: 261.35pt;" valign="top" width="348"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Daclatasvir.svg" class="CToWUd" height="92" id="m_1258769223932238611m_2677116949983763778Picture_x0020_7" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161514ff6f4ea8b7&attid=0.0.6&disp=emb&realattid=e87fbcc8a73b7fb1_0.7&attbid=ANGjdJ8alGSRuvrKoVXtNhoqbw4XUjgHyfpxgTwU9ZnvbqVEHW2YR9yC1xkRuwLge-4d1ZA9LaSjujMAub7Y2uy0nh0YgGlS7gyehlBRMBmcL9Mvxl7i_9HxRfct7Z4&sz=w550-h184&ats=1517487651718&rm=161514ff6f4ea8b7&zw&atsh=1" width="275" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 90.6pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">7<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018015354</span></u><span style="color: #bf9000;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #bf9000;">BREXPIPRAZOLE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #bf9000;">ADAMED<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_1258769223932238611m_2677116949983763778ng-binding">Major depressive disorder; Schizophrenia</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 261.35pt;" valign="top" width="348"><div class="MsoNormal">
<b><span style="color: #bf9000;"><img alt="Brexpiprazole.svg" class="CToWUd" height="181" id="m_1258769223932238611m_2677116949983763778Picture_x0020_8" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161514ff6f4ea8b7&attid=0.0.5&disp=emb&realattid=e87fbcc8a73b7fb1_0.8&attbid=ANGjdJ-ysP9nu3b2WBwL7B67-19AkQPx7G_mafRZ9Igxt_uEGmegO17e2JrHeESVKyC4eXh5qMIRN4FkMSzccAdLahX4mEt2fOcpXFWsi2QBP_PcOKUfSH7Xn3QFxoM&sz=w350-h362&ats=1517487651720&rm=161514ff6f4ea8b7&zw&atsh=1" width="175" /></span><span style="color: #bf9000;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 85.45pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">8<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018014880</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: red;">VORTIOXETINE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: red;">IND<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_1258769223932238611m_2677116949983763778ng-binding">Major depressive disorder</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 261.35pt;" valign="top" width="348"><div class="MsoNormal">
<span style="color: red;"><img alt="Vortioxetine.svg" class="CToWUd" height="143" id="m_1258769223932238611m_2677116949983763778Picture_x0020_9" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161514ff6f4ea8b7&attid=0.0.9&disp=emb&realattid=e87fbcc8a73b7fb1_0.9&attbid=ANGjdJ-U6Mrl76egp4MGJjekij8wQ0qRNPY8sCQsq238EqYAZQbYYcOrh80ZRTdGPcNtJ1TGUwqv329kncgD0yR96UyYy9k8Tef6B38UDeYrpV9O_efOFIMNbImn8IM&sz=w300-h286&ats=1517487651721&rm=161514ff6f4ea8b7&zw&atsh=1" width="150" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 75.9pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">9<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018014866</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 101.55pt;" valign="top" width="135"><div class="MsoNormal">
<span style="color: #0070c0;">DAPAGLIFLOZIN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 77.75pt;" valign="top" width="104"><div class="MsoNormal">
<span style="color: #0070c0;">JIANGSU<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 115.75pt;" valign="top" width="154"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">Non-insulin dependent diabetes</span><span style="color: #0070c0; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 261.35pt;" valign="top" width="348"><div class="MsoNormal">
<span style="color: #0070c0;"><img alt="Haworth projection of dapagliflozin.svg" class="CToWUd" height="142" id="m_1258769223932238611m_2677116949983763778Picture_x0020_10" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=161514ff6f4ea8b7&attid=0.0.3&disp=emb&realattid=e87fbcc8a73b7fb1_0.10&attbid=ANGjdJ8TXM0e_oVyS9BWG9nEcESusKOrpCcjF5dRn_YRz9PzDCU6H9Dq_cX19S9x1DJaOutmgAOrJ1dkNzV8SHIPPxdI5hOl5kA1KgHi0H_Wiyd3WqnySMNjPoGkRqs&sz=w450-h284&ats=1517487651723&rm=161514ff6f4ea8b7&zw&atsh=1" width="225" /></span></div>
</td></tr>
</tbody></table>
</div>
DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com0tag:blogger.com,1999:blog-4738331378048275307.post-19334694527763428982018-01-22T20:54:00.000-08:002018-01-22T20:54:55.419-08:0022 Jan 2018 New patents<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;">JAN 2018</span><span style="color: #c00000; font-size: 20pt;"><u></u><u></u></span></div>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<span style="color: #ed7d31; font-size: 20pt;">11new patents,<u></u><u></u></span></div>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<table border="0" cellpadding="0" cellspacing="0" class="m_-6681987249293985003MsoNormalTable" style="background-color: white; border-collapse: collapse; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;"><tbody>
<tr style="height: 7.05pt;"><td style="border: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">Sr no<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<span style="color: #1f497d;">Patent number<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 91.05pt;" valign="top" width="121"><div class="MsoNormal">
<span style="color: #1f497d;">name<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 88.25pt;" valign="top" width="118"><div class="MsoNormal">
<span style="color: #1f497d;">company<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 103.8pt;" valign="top" width="138"><div class="MsoNormal">
<i><span style="color: #1f497d; font-family: "Arial Black", sans-serif;">INDICATION<u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: none; border-right: 1pt solid windowtext; border-top: 1pt solid windowtext; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 273.3pt;" valign="top" width="364"><div class="MsoNormal">
<span style="color: #1f497d;">REMARKS, WAIT FOR STR TO APPEAR<u></u><u></u></span></div>
</td></tr>
<tr style="height: 7.05pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">1<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018013686</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 91.05pt;" valign="top" width="121"><div class="MsoNormal">
<span style="color: red;">idalopirdine<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 88.25pt;" valign="top" width="118"><div class="MsoNormal">
<span style="color: red;">CONCERT<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 103.8pt;" valign="top" width="138"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><i><b>Alzheimers disease; Cognitive disorder</b></i></span><i><span style="color: red; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 7.05pt; margin: 0px; padding: 0in 5.4pt; width: 273.3pt;" valign="top" width="364"><div class="MsoNormal">
<span style="color: red;"><img alt="Lu-AE58054.svg" class="CToWUd" height="68" id="m_-6681987249293985003Picture_x0020_2" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1611ca81769db5d0&attid=0.2&disp=emb&attbid=ANGjdJ-0grT4HxCdyp2dZBSENWmswVhLq8yXvlI_bDix51emIIwWGyVwCNBZq7Qy3HsQd32fm-Kajvtdp_fRU7hmkbzsnVk6RVGlqef95nk1pXLXZIwzhd67NP18e9w&sz=w440-h136&ats=1516682716364&rm=1611ca81769db5d0&zw&atsh=1" width="220" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">2<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018011823</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 91.05pt;" valign="top" width="121"><div class="MsoNormal">
<span style="color: red;">EDOXABAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 88.25pt;" valign="top" width="118"><div class="MsoNormal">
<span style="color: red;">MYLAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 103.8pt;" valign="top" width="138"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><i><b><br /><span class="m_-6681987249293985003ng-binding">Deep vein thrombosis; Lung embolism; Thromboembolism</span></b></i></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 273.3pt;" valign="top" width="364"><div class="MsoNormal">
<span style="color: red;"><img alt="Edoxaban.svg" class="CToWUd" height="147" id="m_-6681987249293985003Picture_x0020_3" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1611ca81769db5d0&attid=0.3&disp=emb&attbid=ANGjdJ9pDMsttbRkI1yXwWq2CiLU86GXh4QWNZ6AY-QfCjLW7ScLDCHGlp9EzF8NlVN0Lc3BlPaEE4qKjmm4CbTIfH47hlT-wAcdY7I9mOC8_Glfnv87jxsJzf26-2o&sz=w550-h294&ats=1516682716367&rm=1611ca81769db5d0&zw&atsh=1" width="275" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 140.75pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">3<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018011721</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 91.05pt;" valign="top" width="121"><div class="MsoNormal">
<span style="color: #ed7d31;">ERTUGLIFLOZIN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 88.25pt;" valign="top" width="118"><div class="MsoNormal">
<span style="color: #ed7d31;">GRANULES<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 103.8pt;" valign="top" width="138"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><i><b>Non-insulin dependent diabetes</b></i></span><i><span style="color: #ed7d31; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 140.75pt; margin: 0px; padding: 0in 5.4pt; width: 273.3pt;" valign="top" width="364"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Ertugliflozin.svg" class="CToWUd" height="74" id="m_-6681987249293985003Picture_x0020_4" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1611ca81769db5d0&attid=0.4&disp=emb&attbid=ANGjdJ_5j6qaqe2PPi3VHcL7pG0dGT_zzXREq66JxiJ7EhkDz7iLhKS7pgX1d4z3b4ni86-9BL6xtytz68jkd-OysN6rPGH4ctEhqdxqmCySUyT8W3D64CCHnVT6DJ8&sz=w440-h148&ats=1516682716367&rm=1611ca81769db5d0&zw&atsh=1" width="220" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 91.05pt;" valign="top" width="121"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 88.25pt;" valign="top" width="118"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 103.8pt;" valign="top" width="138"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 273.3pt;" valign="top" width="364"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 92.1pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">4<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018011676</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 91.05pt;" valign="top" width="121"><div class="MsoNormal">
<span style="color: #7030a0;">CETILISTAT<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 88.25pt;" valign="top" width="118"><div class="MsoNormal">
<span style="color: #7030a0;">SYMED<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 103.8pt;" valign="top" width="138"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_-6681987249293985003ng-binding"><i><b>Hyperlipidemia; Obesity</b></i></span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><i><b><u></u><u></u></b></i></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 92.1pt; margin: 0px; padding: 0in 5.4pt; width: 273.3pt;" valign="top" width="364"><div class="MsoNormal">
<span style="color: #7030a0;"><img alt="Cetilistat.svg" class="CToWUd" height="94" id="m_-6681987249293985003Picture_x0020_5" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1611ca81769db5d0&attid=0.5&disp=emb&attbid=ANGjdJ9lcFaFmyfo6AfaGZ61MA7pNjMlaz5osh_N-1a_QXiA2Ih1CbA-VLLruTLC6YAKlTUNWkFnBVsDbIsgSwzY0KziqC4idnfqTE4BIOdEl7qmDqkg5NJg21sZjCw&sz=w700-h188&ats=1516682716371&rm=1611ca81769db5d0&zw&atsh=1" width="350" /></span><span style="color: #7030a0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 116.4pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">5<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018010651</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 91.05pt;" valign="top" width="121"><div class="MsoNormal">
<span style="color: #00b050;">OBETICHOLIC ACID<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 88.25pt;" valign="top" width="118"><div class="MsoNormal">
<span style="color: #00b050;">JIANGSU<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 103.8pt;" valign="top" width="138"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><i><b>Primary biliary cirrhosis</b></i></span><i><span style="color: #00b050; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></i></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 116.4pt; margin: 0px; padding: 0in 5.4pt; width: 273.3pt;" valign="top" width="364"><div class="MsoNormal">
<span style="color: #00b050;"><img alt="Obeticholic acid.svg" class="CToWUd" height="149" id="m_-6681987249293985003Picture_x0020_6" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1611ca81769db5d0&attid=0.6&disp=emb&attbid=ANGjdJ8PCI5-s93ejkZl9dqqT_aC1kiMv76Sxe7m-6ursacRA_06lbFwdfa9G8bCqy5_afSB56Owh8Ty7k3vgV0lQz0dTLlKxPkFuf2WmIQrMxkWaOEHr4ORnwyruHg&sz=w500-h298&ats=1516682716373&rm=1611ca81769db5d0&zw&atsh=1" width="250" /></span><span style="color: #00b050;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 236.15pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 236.15pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">6<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 236.15pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018010345</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 236.15pt; margin: 0px; padding: 0in 5.4pt; width: 91.05pt;" valign="top" width="121"><div class="MsoNormal">
<span style="color: #00b050;">LASMIDITAN<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 236.15pt; margin: 0px; padding: 0in 5.4pt; width: 88.25pt;" valign="top" width="118"><div class="MsoNormal">
<span style="color: #00b050;">SOLIPHARMA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 236.15pt; margin: 0px; padding: 0in 5.4pt; width: 103.8pt;" valign="top" width="138"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><i><b>Anxiety disorder; Attention deficit hyperactivity disorder; Depression; Epilepsy; Fatigue; </b></i></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 236.15pt; margin: 0px; padding: 0in 5.4pt; width: 273.3pt;" valign="top" width="364"><div class="MsoNormal">
<b><span style="color: #00b050;"><img alt="Lasmiditan skeletal.svg" class="CToWUd" height="84" id="m_-6681987249293985003Picture_x0020_7" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1611ca81769db5d0&attid=0.7&disp=emb&attbid=ANGjdJ_5TP6DcDgiZR2t-OSBGahfEtEgyZYbPU8n1QMHtXGb9keKeaF_fgjuX9ksrDFOxXtqGTWec-zvVXBRE2LXfNu2c5TYh2BrAeB9ToejBkqBK44pnoop3SB05kE&sz=w440-h168&ats=1516682716375&rm=1611ca81769db5d0&zw&atsh=1" width="220" /></span><span style="color: #00b050;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 90.6pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">7<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">EP-03266773</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 91.05pt;" valign="top" width="121"><div class="MsoNormal">
<span style="color: #bf9000;">LAPATINIB<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 88.25pt;" valign="top" width="118"><div class="MsoNormal">
<span style="color: #bf9000;">FABBRICA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 103.8pt;" valign="top" width="138"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_-6681987249293985003ng-binding"><i><b>Breast tumor; Solid tumor</b></i></span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><i><b><u></u><u></u></b></i></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 90.6pt; margin: 0px; padding: 0in 5.4pt; width: 273.3pt;" valign="top" width="364"><div class="MsoNormal">
<b><span style="color: #bf9000;"><img alt="Lapatinib.svg" class="CToWUd" height="177" id="m_-6681987249293985003Picture_x0020_8" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1611ca81769db5d0&attid=0.8&disp=emb&attbid=ANGjdJ_-6RVDi9T45yi4Y3vh9EMhcM4boznVovkIsxY0no4kZwvzI2LzO-_2n_j7pvOBX7wfN6fI5X1CDikK-l9SJPPYaCzxdO9gZZm2gAhRMPQJv5YbrMDgKXZAH5o&sz=w550-h354&ats=1516682716378&rm=1611ca81769db5d0&zw&atsh=1" width="275" /></span><span style="color: #bf9000;"><u></u><u></u></span></b></div>
</td></tr>
<tr style="height: 85.45pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">8<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">EP-03266767</span></u><span style="color: red;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 91.05pt;" valign="top" width="121"><div class="MsoNormal">
<span style="color: red;">PIRFENIDONE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 88.25pt;" valign="top" width="118"><div class="MsoNormal">
<span style="color: red;">DIPHARMA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 103.8pt;" valign="top" width="138"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<i><b><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><br /><span class="m_-6681987249293985003ng-binding">Idiopathic pulmonary fibrosis</span></span><span style="color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><u></u><u></u></span></b></i></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 85.45pt; margin: 0px; padding: 0in 5.4pt; width: 273.3pt;" valign="top" width="364"><div class="MsoNormal">
<span style="color: red;"><img alt="Pirfenidone2DACS.svg" class="CToWUd" height="147" id="m_-6681987249293985003Picture_x0020_9" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1611ca81769db5d0&attid=0.9&disp=emb&attbid=ANGjdJ8GcWFsPq3h3izRvd6qVCxSBXHZucJLjNee-nyVq5gnlVzit7g55gA-EufuDgczJG8T2-nvpanaN-Lpv3CQyeK3cKCwX70bcSYDhRUCLIntfLfMpm_NIHE30X4&sz=w300-h294&ats=1516682716380&rm=1611ca81769db5d0&zw&atsh=1" width="150" /></span><span style="color: red;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 75.9pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">9<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #75b2d5; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018013655</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 91.05pt;" valign="top" width="121"><div class="MsoNormal">
<span style="color: #0070c0;">CRISABOROLE<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 88.25pt;" valign="top" width="118"><div class="MsoNormal">
<span style="color: #0070c0;">PLIVA<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 103.8pt;" valign="top" width="138"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><i><b>Atopic dermatitis</b></i></span><span style="color: #0070c0; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 75.9pt; margin: 0px; padding: 0in 5.4pt; width: 273.3pt;" valign="top" width="364"><div class="MsoNormal">
<span style="color: #0070c0;"><img alt="Crisaborole.svg" class="CToWUd" height="87" id="m_-6681987249293985003Picture_x0020_10" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1611ca81769db5d0&attid=0.10&disp=emb&attbid=ANGjdJ8ctj6qaSAC4hbYQuR4mhVXVr7nhJHzJUFY3KFoH7lZK6RWigY6oWh3CmgUhsIqnXC6rusmYRUqvvSvWecGwOCTFzzBOT9fNUImPeQctTUnRA8t6cna4vQRxFM&sz=w440-h174&ats=1516682716382&rm=1611ca81769db5d0&zw&atsh=1" width="220" /></span><span style="color: #0070c0;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 13.25pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">10<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018011579</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 91.05pt;" valign="top" width="121"><div class="MsoNormal">
<span style="color: #ed7d31;">ACUMAPIMOD<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 88.25pt;" valign="top" width="118"><div class="MsoNormal">
<span style="color: #ed7d31;">MEREO<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 103.8pt;" valign="top" width="138"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><i><b>Chronic obstructive pulmonary disease</b></i></span><span style="color: #ed7d31; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.25pt; margin: 0px; padding: 0in 5.4pt; width: 273.3pt;" valign="top" width="364"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Acumapimod.png" class="CToWUd a6T" height="300" id="m_-6681987249293985003Picture_x0020_11" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1611ca81769db5d0&attid=0.11&disp=emb&attbid=ANGjdJ_Ixojc35z1_wx-Z7F7whP4E20_mPO0Fj2MFjLLlRgxuedMwMO6GLUnRnOyWh1GTP2SLgZhwl9ylV3_HJO9aDyeRnK8xl-Z00FrdNYTrUCa7qkBZn9BMToBgv4&sz=w600-h600&ats=1516682716382&rm=1611ca81769db5d0&zw&atsh=1" style="cursor: pointer; outline: 0px;" tabindex="0" width="300" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 14pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<span style="color: #1f497d;">11<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<u><span style="color: #0078ae; font-family: sourceSansProRegular; font-size: 10.5pt;">WO-2018011578</span></u><span style="font-family: "Times New Roman", serif; font-size: 12pt;"><u></u><u></u></span></div>
<div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 91.05pt;" valign="top" width="121"><div class="MsoNormal">
<span style="color: #ed7d31;">ACUMAPIMOD<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 88.25pt;" valign="top" width="118"><div class="MsoNormal">
<span style="color: #ed7d31;">MEREO<u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 103.8pt;" valign="top" width="138"><div class="MsoNormal">
<span style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial; background-repeat: initial; background-size: initial; color: #505050; font-family: sourceSansProRegular; font-size: 9pt;"><i><b>Chronic obstructive pulmonary disease</b></i></span><span style="color: #ed7d31; font-family: "Arial Black", sans-serif;"><u></u><u></u></span></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 273.3pt;" valign="top" width="364"><div class="MsoNormal">
<span style="color: #ed7d31;"><img alt="Acumapimod.png" class="CToWUd a6T" height="300" id="m_-6681987249293985003Picture_x0020_12" src="https://mail.google.com/mail/u/0/?ui=2&ik=ea058c9211&view=fimg&th=1611ca81769db5d0&attid=0.11&disp=emb&attbid=ANGjdJ8bk3AAUdy5Uf71UkJ7Ea_GtDIpbBrsTWUykphVw88lEvELGOVL324zc_1rV1gdRNt7q7BdKBRHBCAcA8ehzwlEXOK516S7Q9h19c0LHcYMwQ3G--8gsKrAdDU&sz=w600-h600&ats=1516682716384&rm=1611ca81769db5d0&zw&atsh=1" style="cursor: pointer; outline: 0px;" tabindex="0" width="300" /></span><span style="color: #ed7d31;"><u></u><u></u></span></div>
</td></tr>
<tr style="height: 14pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
</div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 91.05pt;" valign="top" width="121"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 88.25pt;" valign="top" width="118"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 103.8pt;" valign="top" width="138"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 14pt; margin: 0px; padding: 0in 5.4pt; width: 273.3pt;" valign="top" width="364"></td></tr>
<tr style="height: 13.5pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 13.5pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"></td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.5pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.5pt; margin: 0px; padding: 0in 5.4pt; width: 91.05pt;" valign="top" width="121"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.5pt; margin: 0px; padding: 0in 5.4pt; width: 88.25pt;" valign="top" width="118"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.5pt; margin: 0px; padding: 0in 5.4pt; width: 103.8pt;" valign="top" width="138"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 13.5pt; margin: 0px; padding: 0in 5.4pt; width: 273.3pt;" valign="top" width="364"><div class="MsoNormal">
<br /></div>
</td></tr>
<tr style="height: 12pt;"><td style="border-bottom: 1pt solid windowtext; border-image: initial; border-left: 1pt solid windowtext; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 46.35pt;" valign="top" width="62"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 148.7pt;" valign="top" width="198"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 91.05pt;" valign="top" width="121"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 88.25pt;" valign="top" width="118"><div class="MsoNormal">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 103.8pt;" valign="top" width="138"><div class="MsoNormal" style="margin-bottom: 7.5pt; margin-left: 0in; margin-right: 0in;">
<br /></div>
</td><td style="border-bottom: 1pt solid windowtext; border-left: none; border-right: 1pt solid windowtext; border-top: none; height: 12pt; margin: 0px; padding: 0in 5.4pt; width: 273.3pt;" valign="top" width="364"><div class="MsoNormal">
<br /></div>
</td></tr>
</tbody></table>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
<div class="MsoNormal" style="background-color: white; color: #222222; font-family: arial, sans-serif; font-size: 12.8px;">
<br /></div>
</div>
DRUG PATENTS INTERNATIONALhttp://www.blogger.com/profile/12652768774396889936noreply@blogger.com0